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 Zusammenfassung 
Leberfibrose, d.h. der Verlust funktionellen Lebergewebes und die Vernarbung des Gewe-
bes, ist eine typische Folge chronischer Leberschädigungen. Die Fibrogenese hängt eng 
mit inflammatorischen Prozessen und der Aktivierung hepatischer Sternzellen (HSCs) zu-
sammen. Diese transdifferenzieren zu Myofibroblasten und tragen maßgeblich zu Kolla-
genablagerungen und dem Umbau der existierenden extrazellularen Matrix bei. Das Zyto-
kin macrophage migration inhibitory factor (MIF), ein pleiotropes pro-inflammatorisches 
Chemokin, zeigte einen unerwarteten protektiven Effekt in der experimentellen Hepato-
toxin-induzierten Leberfibrose, einhergehend mit der verstärkten Expression HSC-assozi-
ierter Gene. Die molekularen Mechanismen, die diesen schützenden Eigenschaften zu-
grunde liegen, sind bisher noch nicht untersucht worden. 
Im Rahmen dieser Arbeit wurden immortalisierte und primäre Hepatozyten, Kupffer-Zel-
len sowie HSCs als mögliche Produzenten hepatischen MIFs und MIF-Zielzellen charakte-
risiert. Hepatozyten setzen MIF nach Stimulation mit apoptischen oder toxischen Stimuli 
frei, während oxidativer Stress zur Sekretion von MIF sowohl aus Hepatozyten als auch 
aus Kupffer-Zellen führt. Bei HSCs dagegen ist gemäß der durchgeführten in vitro-Studien 
die MIF-Sekretion in Abhängigkeit verschiedener Zytokine und je nach Aktivierungs-
zustand der Zellen unterschiedlich reguliert. Hepatozyten, Kupffer-Zellen und HSCs ex-
primieren die MIF-Rezeptoren CD74 und CXCR4. Ihre Exposition an der Zelloberfläche 
ist jedoch nicht in allen Zellen nachweisbar. Die beschriebenen drei Zelltypen können also 
zur Regulation hepatischer MIF-Level beitragen sowie als potenzielle MIF-Zielzellen da-
rauf reagieren. Die schützende Wirkung therapeutisch eingesetzten MIFs in Mäusen mit 
CCl4-induzierter Leberschädigung stützt die Annahme eines anti-fibrotischen Profils von 
MIF in der Leberfibrose. Weiterhin unterstreichen Daten dieses Experimentes die Rolle, 
die HSCs in diesem regulatorischen Prozess zu spielen scheinen. Als relevanter Signalweg, 
der die anti-fibrotischen Eigenschaften von MIF vermittelt, wurde die MIF/AMPK-Achse 
identifiziert, die die PDGF-induzierte Proliferation und Migration Myofibroblasten-ähnli-
cher HSCs inhibiert. Weiterhin wurde eine Aktivierung des JNK-Signalweges in ruhenden 
und aktivierten Sternzellen gezeigt, der möglicherweise ebenfalls an der Regulation HSC-
typischer Eigenschaften beteiligt ist. Durch eine Microarray-basierte Genexpressions-
analyse wurden im Rahmen dieser Arbeit eine Reihe potenzieller MIF-regulierter Zielgene 
identifiziert, die in MIF-stimulierten HSCs differenziell exprimiert sind. Einige dieser 
Gene könnten funktionell in die MIF-vermittelte Regulierung der HSC-Transdifferenzie-
rung und der fibrotischen Aktivität dieser Zellen involviert sein. Das vielversprechendste 
dieser Gene kodiert einen bislang uncharakterisierten G-Protein-gekoppelten Rezeptor. 
Zusammenfassend gibt die vorliegende Arbeit einen ersten Einblick in die komplexen re-
gulatorischen Mechanismen, durch die MIF fibrotische Prozesse in Hepatotoxin-geschä-
digten Mäusen abmildert. Ein tiefgehendes Verständnis dieser Mechanismen ist wesentlich 
für die Entwicklung therapeutischer Maßnahmen, die auf dem Einsatz von MIF zur anti-
fibrotischen Behandlung beruhen könnten. 
 Abstract 
Liver fibrosis, which is the replacement of functional liver tissue with scar tissue, is the 
characteristic result of all chronic liver diseases. Fibrogenesis is accompanied by inflam-
mation and the activation of hepatic stellate cells (HSCs). These transdifferentiate into 
myofibroblasts and crucially contribute to the deposition of extracellular matrix and the 
remodeling of the existing matrix. Unexpectedly, macrophage migration inhibitory factor 
(MIF), a pleiotropic pro-inflammatory chemokine, attenuated hepatotoxin-induced liver 
fibrosis in mice. MIF-treated mice showed increases in HSC gene levels, suggesting 
increased myofibroblast activity following treatment. Leukocyte infiltrates, in contrast, 
were not affected by MIF treatment. While these data suggest that HSCs mediate MIF-
induced protection, the molecular mechanisms underlying its effects have not yet been 
elucidated. 
In this work, hepatic cells, including immortalized and primary hepatocytes, Kupffer cells, 
and HSCs, were characterized as potential cellular sources of hepatic MIF and targets for 
MIF activity. Hepatocytes release MIF in response to apoptotic and toxic stimuli, while 
both hepatocytes and Kupffer cells release MIF following oxidative stress. HSCs, however, 
display a distinct secretion pattern that varies depending on the stimulating pro- or anti-
fibrotic cytokine and on the activation status of the cells. Hepatocytes, Kupffer cells, and 
HSCs express the MIF receptors CD74 and CXCR4 that can localize to the membrane or 
cytosol depending on the context. These three cell types therefore can provide MIF in 
response to damage and take part in the reaction to this damage as MIF target cells. 
Therapeutic application of recombinant MIF in CCl4-induced liver fibrosis reduced the 
fibrotic response in mice. This further supports the assumption of anti-fibrotic properties of 
MIF in liver fibrogenesis and emphasizes a role for HSCs in this regulatory mechanism. 
The MIF/AMPK axis was identified as a relevant signaling pathway mediating anti-fibrotic 
activity of MIF in myofibroblastic HSCs by inhibiting PDGF-induced proliferation and 
migration of these cells. Furthermore, the JNK signaling pathway may be involved in the 
control of HSC behavior by MIF, as it is rapidly activated by MIF in quiescent and acti-
vated HSCs. By microarray-based gene expression analysis, this work identified several 
candidate genes that are differentially regulated in MIF-stimulated HSCs. Some of these 
may have a functional role in controlling MIF-regulated HSC transdifferentiation and fi-
brotic activity. The most promising of these candidate genes encodes a so far uncharac-
terized G protein-coupled receptor. 
Taken together, this work provides the first insight into the complex regulatory mecha-
nisms by which MIF diminishes the fibrotic response in hepatotoxin-treated mice. A pro-
found understanding of these mechanisms will be fundamental for further approaches that 
could apply MIF activity in anti-fibrotic therapy. 
 1 Introduction 
1.1 Liver fibrosis 
The liver has a unique role in the body, as it is the central organ for metabolism (e.g. of 
lipids, carbohydrates, amino acids and lipoproteins), for biosynthesis of serum proteins and 
coagulation factors and for storage of glycogen, triglycerides, and vitamins. The liver also 
is the largest secretory gland of the body, producing bile that is secreted into the bile ducts. 
Furthermore, through production and degradation of hormones, the liver is part of the en-
docrine system [1]. The liver is the first organ to be reached by the blood from the intes-
tines. This portal blood is enriched with nutrients but also contains pathogens and toxins. 
Therefore, the liver exerts important functions of the innate and adaptive immune system 
and is responsible for detoxification [2]. 
1.1.1 Causes and clinical implications 
Liver fibrosis is the pathophysiological consequence of liver injury and the hallmark of 
chronic liver diseases. It is characterized by the progressive replacement of functional liver 
tissue with connective tissue, which results in liver scarring [3]. The end-stage of liver 
fibrosis is cirrhosis, which is characterized by detrimentally changed liver parenchyma and 
vascular architecture. While liver fibrosis usually is asymptomatic, cirrhosis is accompa-
nied by complications such as portal hypertension, ascites, renal failure, encephalopathy, 
and liver failure. Patients with cirrhosis bear an increased risk of developing hepatocellular 
carcinoma (HCC). To date, the only curative treatment for end-stage cirrhosis is liver 
transplantation [4, 5].  
Major etiologies of liver fibrosis are viral hepatitis, non-alcoholic fatty liver disease 
(NAFLD) and alcoholic liver disease (ALD) [6]. Viral infections, predominantly with 
hepatitis B and C virus (HBV and HCV), have been the leading cause of the development 
of liver fibrosis for many years. Along with increasing rates of obesity in the industrialized 
countries, NAFLD and its progressive inflammatory form non-alcoholic steatohepatitis 
(NASH) have become increasingly relevant. These often are related to insulin resistance 
and the metabolic syndrome. Alcohol-induced liver damage results in liver diseases with 
differing severity, including simple steatosis, alcoholic steatohepatitis (ASH) and chronic 
hepatitis. ALD predisposes to liver fibrosis and cirrhosis. Further causes for liver fibrosis 
include drug abuse, autoimmune diseases, metabolic disorders, and cholestatic disorders 
[1, 5, 7]. 
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1.1.2 Microanatomy of the liver 
Functionally, the liver is organized in liver lobules, each comprising all hepatic cell types. 
These are hepatocytes, which are the hepatic epithelial cells, endothelial cells, and resident 
non-parenchymal cells including hepatic stellate cells (HSCs) and Kupffer cells (KCs). 
Hepatocytes, representing the major cell type in the liver, are responsible for metabolism 
and detoxification. They are provided with oxygen, nutrients, toxins and the body’s own 
waste products by a dual blood supply system. The hepatic artery supplies the cells with 
oxygenated blood whereas nutrient-rich blood from the intestines is delivered by the portal 
vein. The blood passes through the widely branched sinusoids, which are the microvascular 
units of the liver. This guarantees a maximum exchange with the parenchymal cells before 
the blood enters the central vein to finally return to the circulation through the hepatic vein 
[2]. Biles produced by hepatocytes are removed through the bile ducts. Figure 1-1 
schematically illustrates the architecture of a liver lobule. 
 
Figure 1-1: Liver lobule structure with the dual blood supply system. Nutrient rich blood is delivered through 
the portal vein, oxygen rich blood through the hepatic artery. The blood percolates through the sinusoids that 
are surrounded by plates of hepatocytes. The sinusoids are lined by fenestrated endothelial cells. Kupffer 
cells are resident in the lumen, stellate cells and dendritic cells in the space of Disse. Blood from the 
sinusoids is collected by the central vein that removes it through the hepatic vein [8]. 
The sinusoids are lined by a discontinuous layer of liver sinusoidal endothelial cells 
(LSECs). These are fenestrated with pores, which are grouped in sieve plates. These fe-
nestrae occupy 6-8% of the surface and serve to sieve the fluids that are exchanged be-
tween the lumen of the sinusoids and the perisinusoidal space [4, 9]. The lumen of the 
sinusoids accommodates Kupffer cells, which are resident macrophages, and Pit cells, 
which are liver-specific natural killer cells [9]. The sinusoids lack a basement membrane 
underlying the epithelial layer. This allows for effective exchange of fluid between 
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sinusoids and the surrounding cells. However, the space underlying the epithelial cells 
contains a basement membrane-like matrix with low density. This perisinusoidal space is 
called the space of Disse. The space of Disse contains HSCs, which comprise 15% of the 
resident cells of the healthy liver [10]. The ratio between HSCs and hepatocytes is about 
1:20 [11]. HSCs are named according to their star-like appearance. In the healthy liver, 
they express a quiescent phenotype and represent the body’s largest reservoir of vitamin A 
(about 80%), which they take up by receptor-mediated endocytosis and store it as retinyl 
esters in large perinuclear lipid droplets [12]. HSCs furthermore maintain the steady-state 
of the membrane-like matrix in the healthy liver while substantially contributing to excess 
matrix deposition in liver fibrosis [11]. 
1.1.3 Cellular and molecular pathogenesis of liver fibrosis 
Initiated as a wound-healing response, liver fibrosis is characterized by a highly dynamic 
remodeling of the normal extracellular matrix (ECM), resulting in the excessive accumula-
tion of extracellular matrix proteins in the case of persisting injury [6]. The cellular 
changes, which are characteristic for fibrogenesis, are visualized in Figure 1-2.  
 
Figure 1-2: Cellular and structural changes during liver fibrosis. The normal liver architecture (A) is dramati-
cally changed as hepatocytes undergo apoptosis, immune cells are recruited, HSCs and KCs get activated and 
excess production of ECM results in liver scarring (B) [6]. 
Usually, the onset of fibrosis is mediated by hepatocyte damage and apoptosis due to 
hepatotoxins, alcohol or bile acids. Necrosis of hepatocytes creates a highly inflammatory 
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milieu and hepatocyte apoptosis drives fibrosis as apoptotic bodies are engulfed by KCs 
and HSCs, resulting in their activation. Damaged hepatocytes and activated KCs release 
reactive oxygen species (ROS), chemokines and inflammatory cytokines, which trigger 
immune cell infiltration and HSC activation [5, 6]. 
HSC activation is a crucial process in liver fibrosis as HSCs are considered the main ECM-
producing cells. HSC activation comprises two major phases. The initiation phase is pro-
voked by paracrine signals from damaged hepatocytes, activated KCs and infiltrating im-
mune cells. Key mediators in this phase are transforming growth factor-β1 (TGF-β11), 
platelet-derived growth factor (PDGF) and ROS. TGF-β1 is mainly released from activated 
KCs and endothelial cells and is considered the most potent fibrogenic cytokine. PDGF is 
mainly derived from KCs and acts as the most prominent mitogen for HSCs. During the 
initiation phase, HSCs become more responsive to growth factors and chemokines that 
further drive the activation process. The perpetuation phase includes both autocrine and 
paracrine signaling and further amplifies HSC activation. The activation process of HSCs, 
which is summarized in Figure 1-3, is accompanied by the loss of lipid droplets and the 
transdifferentiation into myofibroblast-like cells expressing α-smooth muscle actin 
(α-SMA). The cells gain contractility, increase proliferation and migration to the site of 
tissue damage and produce large amounts of collagen and other matrix proteins. HSCs 
furthermore increase secretion of cytokines that either, in an autocrine manner, serve to 
further perpetuate HSC activation, or amplify inflammation by attracting immune cells. 
Additionally, by secreting matrix metalloproteinases (MMPs) and tissue inhibitors of 
metalloproteinases (TIMPs), HSCs regulate degradation and remodeling of the existing 
matrix [6, 10, 13]. HSCs are widely considered the major source of myofibroblasts and 
thus are the predominant cells involved in the accumulation of ECM. However, myofibro-
blasts may also be derived from portal fibroblasts, bone marrow-derived cells and circu-
lating fibrocytes. The conversion of hepatic epithelial cells to myofibroblasts through 
epithelial-mesenchymal transition has been observed as well [4, 12]. 
In healthy liver tissue, the ECM in the perisinusoidal space is mainly composed of collagen 
IV and VI. In fibrosis, it comprises more fibrillar collagens, mainly collagen I and III as 
well as network-forming collagen IV, fibronectin, undulin, elastin, laminin, hyaluronan 
and proteoglycans. In acute injury, ECM remodeling represents a wound-healing response 
that resolves rather fast. In chronic situations, however, the inflammatory and fibrogenic 
processes persist and intensify, and scar tissue progressively replaces the functional tissue. 
In advanced fibrosis, the amount of ECM can increase to 6-fold compared to the normal 
situation [5, 6]. Excess fibril-forming collagen in turn contributes to HSC activation as 
well as to the loss of hepatocyte microvilli and endothelial cell fenestration. This impairs 
hepatic metabolism and increases resistance to blood flow in the sinusoids which can result 
in portal hypertension [10]. 
                                                 
1
 For the sake of clarity, especially in the results section, it is not distinguished between human and murine 
protein abbreviations by the use of upper and lower case letters. 
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Figure 1-3: Features of HSC activation. The activation process comprises an initiation phase, characterized 
by paracrine stimulation of HSCs, and a perpetuation phase, based on autocrine and paracrine signaling 
events. The perpetuation phase is characterized by transdifferentiation into myofibroblast-like cells that show 
enhanced proliferation, contractility and fibrogenic activity [13]. 
1.1.4 Cytokines in liver fibrosis 
Among the broad spectrum of cytokines involved in the regulation of fibrosis, there are 
many that control HSC activation and transdifferentiation. The most important and best 
studied ones are TGF-β1 and PDGF. 
TGF-β1 is the most potent pro-fibrogenic mediator. TGF-β1 secretion by activated KCs, 
HSCs, endothelial cells and infiltrated immune cells stimulates activation and transdiffer-
entiation of HSCs to myofibroblasts (MFBs), enhances matrix gene expression, and de-
creases ECM degradation by regulating MMPs and TIMPs [14]. Although most prominent, 
the pro-fibrotic activity is not restricted to HSCs and may depend on disease stage and 
background [15]. TGF-β1 activates intracellular signaling via Smad proteins, of which 
Smad3 seems to be the main inducer of collagen expression. TGF-β-induced upregulation 
of Smad7 provides a negative feedback loop especially in quiescent HSCs, as Smad7 is an 
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effective inhibitor of TGF-β1 signaling by blocking phosphorylation of Smad2 and Smad3 
[16]. 
PDGF is the most prominent mitogen. Upon liver injury, both secretion of PDGF and ex-
pression of PDGF receptor are increased. Upon PDGF stimulation, the extracellular signal-
regulated kinase (ERK)/MAPK pathway is activated and promotes proliferation and mi-
gration [17]. Furthermore, PI3K activity and the downstream activation of Akt and p70S6 
kinase are required for enhanced HSC proliferation and fibrogenic activity [18, 19]. Fur-
ther mitogenic cytokines that are important in promoting fibrogenesis are tumor necrosis 
factor-α (TNF-α), insulin-like growth factor (IGF), TGF-α, and IL-1. 
A number of pro-inflammatory cytokines trigger fibrogenesis. One of those is TNF-α. 
Mainly produced by macrophages and activated stellate cells, TNF-α triggers early events 
in the HSC activation process while inhibiting some of the advanced fibrotic activities such 
as collagen expression [20]. At the same time, TNF-α induces apoptosis in hepatocytes. In 
contrast, in liver regeneration TNF-α provides pro-proliferative signals to hepatocytes. 
TNF-α signaling results in activation of the transcription factor NF-κB or the JNK pathway 
[21].  
Other pro-inflammatory cytokines have chemotactic properties and recruit immune cells or 
induce HSC chemotaxis to the site of liver damage. Well-known members of this group are 
CCL5 (regulated upon activation, normal T-cell expressed and secreted protein, RANTES) 
and CCL2 (monocyte chemotactic protein-1, MCP-1) [10, 22]. 
Several interleukins play a role in fibrosis, including IL-1, IL-6 and IL-10. The pro-
inflammatory IL-1 promotes activation of stellate cells [23]. IL-6 amplifies collagen 
expression and inflammation and thus has fibrogenic properties. On the other hand, IL-6 
prevents hepatocyte apoptosis and promotes proliferation and regeneration [24, 25]. IL-10 
is one of the anti-fibrotic cytokines [6]. 
Another cytokine with anti-fibrotic properties is interferon-γ (IFN-γ), which acts pro-
apoptotically on HSCs. Effects of IFN-γ are mediated through the Janus kinase (JAK)/ 
signal transducer and activator of transcription (STAT) pathway [4, 26]. Through activa-
tion of STAT1 IFN-γ upregulates Smad7 and decreases Smad2/3 expression and activa-
tion. Thus, IFN-γ impairs TGF-β signaling in HSCs [27]. On the other hand, IFN-γ and 
STAT1 induce hepatocyte apoptosis and chemokine expression in Kupffer cells [28]. 
Cytokines with vasoactive properties have regulatory roles in liver fibrosis. Endothelin-1 
(ET-1) expressed by LSECs and activated HSCs is a powerful vasoconstrictor and pro-
fibrogenic cytokine. A major role among vasoactive cytokines has been assigned to angio-
tensin II, which acts through the renin-angiotensin system. Activation of the renin-angio-
tensin system results in infiltration of inflammatory cells, myofibroblast proliferation, and 
ECM synthesis [29]. 
Moreover, adipokines, mainly derived from adipose tissue and to a lesser extent from 
monocytes and fibroblasts, are relevant in fibrosis regulation. While leptin is pro-
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fibrogenic through activating HSCs, KCs and endothelial cells, adiponectin exerts anti-
fibrogenic properties, which are mediated by the adenosine monophosphate (AMP)-
activated kinase (AMPK) pathway [30, 31]. 
1.2 Selected signaling pathways in liver fibrosis 
A diversity of signaling pathways is involved in regulating the complex cellular interplay 
in liver fibrosis. Cross-talk between different pathways further contributes to complexity. 
Key pathways comprise signaling through Smad2/3, nuclear factor-κB (NF-κB), Toll-like 
receptor 4 (TLR4), JAK/STAT signaling and MAP kinase signaling pathways. Some of 
them have distinct functions in different cell populations of the liver. Below, signaling 
pathways and their role in liver fibrosis are described that are relevant in the context of this 
project. 
1.2.1 AMPK signaling 
AMPK is a pivotal regulator of cellular and systemic energy homeostasis. The functional 
protein is a heterotrimeric complex, comprising an α-, β-, and γ-subunit. The catalytic 
α-subunit is a 63 kDa protein with an N-terminal catalytic domain. Phosphorylation at 
Thr172 is critical for AMPK activation and the degree of phosphorylation directly corre-
lates with kinase activity [32, 33]. The β- and γ-subunits have regulatory functions. Each 
subunit exists in different isoforms (α1, α2, β1, β1, γ1, γ2, γ3). While α1, β1, and γ1 are 
ubiquitously expressed, the other isoforms show higher tissue specificity [34]. At low 
cellular energy charge, being characterized by a high AMP:ATP ratio, AMPK gets acti-
vated. This process is regulated by a complex mechanism that allows a fine-tuned response 
to small changes in energy charge. At high levels, AMP allosterically activates AMPK by 
binding to the γ-subunit, which increases kinase activity by above tenfold. Moreover, 
binding of AMP (or ADP) to the γ-subunit inhibits dephosphorylation and facilitates phos-
phorylation at Thr172, which further increases AMPK activity. Direct activation by phos-
phorylation of Thr172 is performed by the upstream kinases liver kinase B1 (LKB1) and 
calcium/calmodulin-dependent protein kinase kinase (CaMKK). While LKB1 is responsi-
ble for basal AMPK phosphorylation, which is considerably enhanced by AMP, CaMKK-
dependent AMPK phosphorylation is independent of AMP but requires high Ca
2+
 levels 
[34, 35]. Cell culture studies revealed TGF-β-activating kinase 1 (TAK1) as a third up-
stream kinase. In contrast, other recent publications indicate that TAK1 is a downstream 
target of AMPK [36, 37]. 
AMPK is activated in response to cellular pathological stress, such as glucose deprivation, 
hypoxia or oxidative stress, or to physiological stimuli, including exercise and contraction 
in skeletal muscle and adipokines. Furthermore, the anti-diabetic drugs metformin and 
thiazolidinediones and the nucleoside analogue 5-aminoimidazole-4-carboxamide riboside 
(AICAR) activate AMPK [38]. ROS and genotoxic treatments activate AMPK by so far 
unclear mechanisms that are not associated with AMP or Ca
2+
 levels [35]. Activated 
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AMPK switches on catabolic pathways that deliver ATP and switches off anabolic energy 
consuming pathways. Through these pathways, AMPK regulates glucose, lipid and protein 
metabolism, controls cell polarity, cell growth and apoptosis as well as mitochondrial bio-
genesis and autophagy. Figure 1-4 gives an overview over the main effects of AMPK on 
metabolic cellular processes. AMPK regulates not only cellular but also whole-body 
energy homeostasis, partly by mediating effects on the hypothalamus [34, 35]. 
 
Figure 1-4: Overview of the regulation of metabolism by AMPK. The inner wheel shows AMPK substrates 
that mediate activation or inactivation of the depicted pathways in the outer wheel [38]. 
AMPK has beneficial effects in diverse pathological settings. These include obesity and 
the metabolic syndrome, as AMPK regulates fatty acid metabolism, and cardiovascular 
disease and cardiac ischemia/reperfusion injury, which is attenuated by AMPK through the 
upregulation of glucose transporter-4 (GLUT-4) and glucose uptake. AMPK was shown to 
protect cells from mitochondrial oxidative stress and to induce cytoprotective autophagy 
[39, 40]. In cancer, AMPK is thought to be a mediator of the tumor suppressor LKB1 and 
inhibits proliferation and survival of cancer cells. Being highly expressed in the brain, 
functional AMPK furthermore exerts neuroprotective effects [34].  
In the liver, the main function of AMPK is to suppress gluconeogenesis and to control fatty 
acid metabolism. AMPK inhibits Acetyl-CoA carboxylase (ACC)1 and ACC2, thus in-
hibiting fatty acid synthesis and enhancing fatty acid oxidation. Furthermore, AMPK 
downregulates transcription factors that drive expression of enzymes involved in fatty acid 
synthesis, as for example fatty acid synthase (FAS) [41]. Possibly, AMPK is also involved 
in the regulation of the circadian rhythms of AMPK substrates such as ACC in the liver. 
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Upon low blood glucose levels AMPK promotes the release of adrenalin or glucagon that 
increase glucose production in the liver [35]. In hepatic disorders, AMPK has beneficial ef-
fects that can largely be ascribed to its regulatory functions in fat metabolism and to its 
cytoprotective effects. Several AMPK activating chemical compounds impair insulin re-
sistance and processes associated with NAFLD [39]. AMPK activators have furthermore 
been shown to counter-act the development of fatty liver in ethanol-fed rats, indicating a 
role in alcoholic liver disease. AMPK activity and sensitivity to activating agents, how-
ever, are decreased by ethanol, which impairs fatty acid metabolism [42, 43]. Interestingly, 
AMPK counter-regulates fibrogenic activities of HSCs. The reported cellular effects of 
AMPK activation and their proposed underlying molecular mechanisms are summarized in 
Table 1.1.  
Table 1.1: Summary of HSC and myofibroblast activities related to AMPK signaling 
Effect of activated AMPK Underlying mechanism Reference 
PDGF-induced proliferation and 
migration ↓ 
mTor signaling ↓ Caligiuri et al. 2008 [31] 
Akt signaling ↓ 
NADPH oxidase-dependent ROS ↓ 
p27
kip1
 and p21
cip1
 expression ↑ 
Adachi et al. 2008 [44] 
IL-1β-induced release of MCP-1 ↓ NF-κB activation ↓ Caligiuri et al. 2008 [31] 
TGF-β-induced collagen and α-Sma 
expression ↓ 
Association of Smad3 with p300 ↓ 
proteasomal p300 degradation ↑ 
Lim et al. 2012 [45] 
Leptin-stimulated TIMP-1 secretion ↓ 
and MMP-1 activity ↑ 
STAT3 phosphorylation ↓ 
SOCS-3 expression ↓ 
Handy et al. 2010 [46] 
AICAR- but not metformin-induced 
cell death of qHSCs ↓ 
TRAIL expression ↑  
caspase activity ↑ 
Subramaniam et al. 2012 
[47] 
TGF-β-induced transdifferentiation 
of mesangial cell-derived myofibro-
blasts ↓ 
Smad3-dependent transcription ↓ Mishra et al. 2008 [48] 
Genetic deletion of Ampkα1, resulting in considerably diminished AMPK activity, does not 
alter hepatic fibrosis upon CCl4 administration in mice. In vitro activated Ampkα1-deficient 
HSCs show delayed proliferation and comparable levels of collagen and α-SMA expres-
sion. Why low AMPK activity does not enhance fibrosis remains unclear, but this finding 
does not necessarily question the widely accepted view of a beneficial effect of AMPK 
activation in liver fibrosis [49].  
1.2.2 JNK signaling 
JNK, also known as stress-activated protein kinase (SAPK) belongs to the MAP kinase 
family. In the human genome, JNK is encoded by 3 genes, JNK1, JNK2 and JNK3. JNK1 
and JNK2 are ubiquitously expressed, whereas JNK3 is predominantly expressed in brain, 
heart, and testis. Each gene produces different isoforms by alternative splicing, resulting in 
46 kDa and 55 kDa proteins with subtle differences in activity and specificity. It has 
proven difficult, however, to clearly assign specific functions to the different isoforms in 
vivo. [50, 51]. JNK signaling pathways, analogous to other MAPK pathways, comprise a 
kinase cascade including MAP kinase kinase kinases (MAP3Ks or MKKKs), MAP kinase 
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kinases, (MAP2Ks or MKKs) and the JNKs themselves. MAP3Ks encompass 14 different 
kinases that act in a cell type- and stimulus-dependent manner to activate the MAP2Ks 
MKK4 and MKK7. MKK4 and MKK7 activate JNKs by phosphorylation of a conserved 
motif in their activation loop. While MKK4 is the predominant kinase for phosphorylation 
of the tyrosine residue 185 (Tyr185) and activates JNK and p38, MKK7 predominantly 
phosphorylates the threonine residue 183 (Thr183) and specifically activates JNK [50, 52, 
53].  
JNKs are activated by environmental stress, such as ultraviolet (UV) irradiation, pathologi-
cal stress, such as ischemia, ROS, and intra- and extracellular pathogens. A number of cy-
tokines are known to stimulate JNK activation. Among those are TNF-α, IL-1β, TGF-β1, 
PDGF, EGF, and MIF. Cytokine activation is largely mediated by MKK7. Additionally, 
JNK signaling can be induced by G-protein-coupled receptors and the non-canonical Wnt 
pathway [54]. Activated JNK regulates cell proliferation, cell survival, cell death, DNA 
repair and metabolism. Many of the cellular JNK effects are mediated by phosphorylation 
of c-Jun. Phosphorylated c-Jun dimerizes with Fos or other Jun proteins to form the tran-
scription factor AP-1. Besides c-Jun, about 50 JNK substrates have been identified. These 
include transcription factors, apoptosis regulators and other regulatory proteins [50]. 
In the liver, as in other organs, JNK signaling is involved in normal physiology and patho-
genesis. JNK controls proliferation, survival, and apoptosis of hepatocytes. Thus, JNK ac-
tivity mediates cell death in liver injury, e.g. caused by ischemia/reperfusion or by ad-
ministration of hepatotoxic agents. JNK is important for liver regeneration, but attenuates 
regeneration when persistently activated. In liver carcinogenesis, JNK is detrimental by 
promoting apoptosis of hepatocytes and compensatory proliferation and accelerating in-
flammation. Pathological conditions in NAFLD activate JNK, which promotes hepatic 
injury, steatosis, insulin resistance, and obesity, with distinct roles for JNK1 and JNK2 [50, 
55-57]. In Kupffer cells and HSCs, JNK signaling mediates inflammation and fibrosis. 
JNK and c-Jun phosphorylation were shown to be enhanced in bile duct-ligated (BDL) and 
CCl4-treated mice, mainly in collagen-expressing cells in the fibrotic areas. These findings 
were extended to human HCV and NASH livers. In both mouse models, pharmacological 
inhibition of JNK and genetic deletion of Jnk1 result in decreased fibrosis. Jnk2 deletion, 
however, enhances fibrosis in BDL while reducing liver injury [58]. JNK activity promotes 
activation of HSCs. In early stages of HSC activation, JNK increases α-Sma expression. 
Proliferation is promoted independent on the activation status. Interestingly however, JNK 
reduces collagen expression in HSCs, once again showing the complexity of JNK-driven 
regulation of cellular activities [59]. 
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1.3 Macrophage migration inhibitory factor (MIF) 
Macrophage migration inhibitory factor (MIF) is a pleiotropic, pro-inflammatory and non-
classical cytokine with chemokine-like functions. Successful cloning of the MIF cDNA in 
1989 and 1993 and recombinant expression of the protein in Escherichia coli laid the 
foundation for a deeper understanding of the diverse activities of MIF [60-62]. 
1.3.1 Main characteristics 
MIF is a highly conserved, non-glycosylated 12.5 kDa protein [62]. It was one of the first 
cytokines to be described, initially as a T lymphocyte-derived substance, capable of in-
hibiting the random migration of macrophages [63, 64]. Today, it is considered a crucial 
mediator of innate immunity and inflammation by promoting the activation and recruit-
ment of leukocytes [65]. MIF promotes cell migration mediated by the chemokine recep-
tors CXCR2 and CXCR4. Thus, it shares functional properties with classical chemokines. 
There is no sequence homology to other known chemokines, however. Therefore, MIF has 
been classified as a chemokine-like function (CLF) chemokine. The MIF monomer in its 
three-dimensional structure resembles the CXCL8 (IL-8) dimer. Recently, a pseudo-(E)LR 
motif has been identified, which in its architecture is similar to the characteristic N-termi-
nal ELR motif (i.e. glutamate, leucine und arginine residues in sequential neighborhood) of 
CXC chemokines [66]. X-ray structure analysis indicated that MIF exists as a trimer, while 
nuclear magnetic resonance (NMR) spectroscopy revealed the existence of a dimer. Cross-
linking studies, however, indicated a mixture of mono-, di-, and trimeric MIF [67-70]. 
Figure 1-5 shows the crystal structures of the possible oligomerization states. The oligo-
meric state of the bioactive molecule so far remains unclear. 
 
Figure 1-5: Crystal structures of mono-, di-, and trimeric MIF (from left to right) [71]. Illustrated with 
PyMOL [72]. 
Bioactive MIF protein acts in an autocrine or paracrine manner. Target cells include T and 
B lymphocytes, macrophages, granulocytes and other immune cells as well as a diversity 
of parenchymal cells, epithelial and endothelial cells and tumor cells. Similarly, expression 
and secretion of MIF first was described in cells of the immune system, but expression also 
extends to cells in various organs including liver, lung, spleen, kidney, bowel, and skin 
[73-75]. MIF is stored in intracellular pools in many cells and can be rapidly released upon 
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stimulation [61, 73]. The exact mechanism of MIF secretion so far is unknown. MIF lacks 
an N-terminal signal sequence and the contribution of ATPase binding cassette (ABC) 
transporters has been suggested [76]. Rapid release of MIF from cells of the pituitary gland 
in response to stress or inflammatory stimuli suggests an endocrine role. Thus, MIF is a 
mediator between the endocrine and immune systems [61]. In this context, MIF is a unique 
counter-regulator of the immunosuppressive and anti-inflammatory activities of glucocor-
ticoids that functions to control innate and adaptive immune responses [77]. MIF 
comprises two catalytic activities, a tautomerase and an oxidoreductase activity [78, 79]. 
The physiological relevance, however, is not yet fully understood. 
1.3.2 MIF receptors 
To date, three cell surface receptors have been identified. These are CD74 and the chemo-
kine receptors CXCR2 and CXCR4 [65, 80]. 
CD74, also known as invariant chain or Ii, was the first MIF receptor to be identified [80]. 
CD74 is a non-polymorphic type II transmembrane protein that exists in two isoforms. Due 
to alternative splicing of the transcript, a 31 kDa and a 41 kDa protein (p31 and p41) are 
expressed in mice [81]. In humans, four isoforms are known (p33, p35, p41 and p43) that 
result from alternative splicing in combination with an alternative initiation of transcription 
[82]. Murine p41 and human p43 share 77% amino acid identity. Surface expressed CD74 
is frequently posttranslationally modified by chondroitin sulfate, a glycosaminoglycan side 
chain [83]. The most prominent property of CD74 is its role in antigen presenting cells 
(APCs) as a chaperone for major histocompatibility complex (MHC) class II molecules. It 
self-assembles as a trimer, thus building a scaffold for the trimeric assembly of the class II 
MHC molecules [84]. CD74 binds MIF with high affinity and the cell surface expressed 
variant is involved in MIF-induced signaling events. MIF signaling through CD74 involves 
its co-receptor CD44 and/or chemokine receptors [65, 80, 85-88]. Cell surface expression 
of CD74 is low in conventional APCs due to endosomal degradation, but also possible in 
the absence of MHC class II proteins [84]. This extends the accessibility of CD74 for MIF 
to non-classical professional antigen presenting cells. Moreover, a signaling mechanism 
involving the intracellular domain of CD74 (CD74-ICD) has been identified. After intra-
membranal cleavage, CD74-ICD is released and activates the transcription factor NF-κB 
[89]. 
CXCR2 and CXCR4 are G protein-coupled receptors for chemokines of the CXC family. 
They are crucially involved in acute inflammation by mediating leucocyte recruitment and 
have been shown to mediate the chemotactic properties of MIF. CXCR2 is mainly ex-
pressed in neutrophils and monocytes/macrophages. Mice deleted for Cxcr2 display im-
paired neutrophil-mediated inflammation [90]. Besides its most prominent ligand CXCL8, 
CXCR2 binds virtually all chemokine ligands with an ELR motif [91]. The interaction with 
its non-cognate ligand MIF triggers recruitment of immune cells and monocyte arrest in a 
Gαi-dependent manner. Compared to CXCR2, CXCR4 has a broader expression profile. 
CXCR4 is expressed by almost all cells, particularly by stem cells, hematopoietic cells, 
vascular endothelial cells, and most tumor cells [90]. CXCR4 is more selective than 
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CXCR2 and has only two chemokine ligands, namely CXCL12 (stromal-derived factor-1α, 
SDF-1α) and MIF [65, 92]. Additionally, CXCR4 has been shown to act as a co-receptor 
for T-tropic human deficiency virus-1 (HIV-1) strains through association with the princi-
pal HIV-receptor CD4 upon binding of the HIV-1 envelope glycoprotein gp120 [93]. 
CXCR4 is important in the embryonic development of the hematopoietic and nervous sys-
tems. Thus, a homozygous knockout of Cxcr4 in mice is embryonically lethal. In the adult 
organism, CXCR4 together with its ligand SDF-1α is essential in mobilization and re-
cruitment of hematopoietic cells from the bone marrow and homing of endothelial 
progenitor cells. Furthermore, CXCR4 is implicated in tumorigenesis and metastasis [94-
97]. 
Receptor complexes of overexpressed CD74/CXCR2 and endogenous CD74/CXCR4 have 
been demonstrated [65, 88], raising the question whether larger complexes may be formed 
by CXCR2/CD74/CXCR4. Heteromeric complex formation may implement a further level 
of complexity in terms of MIF signaling. 
1.3.3 Signaling pathways 
MIF activities generally are mediated by receptor-dependent intracellular signaling cas-
cades, which include protein kinase signaling pathways. Furthermore, MIF triggers cal-
cium influx and integrin activation via CXCR2, thus mediating monocyte arrest in athero-
genesis [65]. 
MIF controls the activation of mitogen-activated protein kinase (MAPK) pathways. 
Through phosphorylation of the MAP kinase ERK1/2 MIF triggers proliferation of target 
cells. Exogenous MIF rapidly and persistently induces ERK1/2 activation. For sustained 
activation of ERK1/2 the release of endogenous MIF is sufficient. The MIF/ERK1/2 path-
way involves the MIF receptor CD74, Raf-1, the ERK1/2 upstream kinase MEK1/2, and 
the transcription factor Elk-1. Furthermore, MIF-mediated ERK1/2 phosphorylation re-
quires Src kinase activity and is associated with the activation of the cytoplasmic phospho-
lipase A2 (cPLA2) and glucocorticoid overriding [80, 98, 99]. 
The c-Jun N-terminal kinases (JNK), another group of MAP kinases, are important regu-
lators of cell proliferation, cell survival, apoptosis, and cell differentiation [100]. Their role 
is ambivalent in providing survival signals in some cellular contexts and inducing apopto-
sis in others. MIF either activates or inhibits JNK activity, depending on the cellular con-
text. For instance, MIF inhibits JNK signaling during cardiac ischemia/reperfusion, thus 
protecting the heart from injury [101]. In contrast, fibroblasts and resting T cells show 
rapidly increased JNK phosphorylation and activity upon MIF stimulation in vitro [102]. 
Therefore, it is assumed that MIF activates JNK in resting cells, while inactivating JNK in 
pre-stimulated or activated cells. When activating the pathway, MIF triggers the phos-
phorylation of the direct JNK substrate c-Jun, which then is capable of forming 
homodimers or heterodimers with c-Fos to form the activator protein-1 (AP-1) transcrip-
tion factor. MIF-induced JNK signaling is dependent on two MIF receptors, CXCR4 and 
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CD74. It furthermore requires the activity of Src kinase and phosphatidylinositol 3-kinase 
(PI3K) [102]. 
MIF can promote cell survival and control apoptosis through the PI3K/Akt signaling path-
way. Interaction of CD74 with its co-receptor CD44 and the activity of Src kinase are 
necessary to induce Akt activation. Both exogenous MIF and autocrine MIF action con-
tribute to Akt signaling. The latter fact may provide a mechanism that contributes to self-
driven growth of solid tumors, which frequently are associated with enhanced MIF expres-
sion. Autocrine activation of the MIF/Akt pathway is controlled by the MIF binding 
partner c-Jun activation domain binding protein-1 (JAB1), also known as COP9 
signalosome subunit 5 (CSN5), which reduces MIF secretion. Activation of the PI3K/Akt 
pathway by MIF results in the phosphorylation and inactivation of the pro-apoptotic pro-
teins BAD and FOXO3a. Thus, MIF inhibits apoptosis and promotes survival [103].  
MIF signaling is associated with detrimental effects in diverse diseases or inflammatory 
settings (see Chapter 1.3.4). MIF-dependent activation of a further signaling pathway was 
discovered in a context, in which MIF clearly is protective. MIF was shown to activate 
AMPK, a key regulator of cellular and whole body energy homeostasis, in the ischemic 
heart. Subsequent upregulation of GLUT-4 and increased glucose uptake mediated protec-
tion from ischemia/reperfusion injury. As for the activation of the MAPK and PI3K/Akt 
pathways, CD74 is required for AMPK activation by MIF [104]. The precise molecular 
events between MIF/CD74 and AMPK activation, however, are unknown. Besides medi-
ating the beneficial effect of MIF in cardiac ischemia/reperfusion injury, it has been sug-
gested that cardioprotective activity of MIF under type 1 diabetes might also involve 
AMPK activity [105]. Furthermore, a recent study showed that MIF activates AMPK in 
neural stem/progenitor cells (NSPCs), which might promote survival of these cells [106]. 
In non-small cell lung carcinoma cells, however, MIF inhibits AMPK in a redox-dependent 
manner that involves calcium influx and CaMKKβ activity. These findings suggest distinct 
effects of MIF on AMPK signaling, depending on cell type and background [107]. 
Figure 1-6 gives a rough overview about signaling pathways that are activated upon MIF-
receptor interaction and their effects on cellular behavior. 
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Figure 1-6: MIF exerts its diverse functions by inducing receptor-dependent signaling events. CD74 mediates 
regulation of proliferation and survival. CXCR2 and CXCR4 are crucially involved in immune cell recruit-
ment and activation. Receptor complexes may form to fine-tune MIF effects (not shown) [108]. 
1.3.4 MIF in disease 
The unique property of MIF to counter-regulate the anti-inflammatory activity of gluco-
corticoids and the ability to recruit and activate immune cells makes MIF a key mediator in 
various acute and chronic inflammatory diseases and a modulator of innate and adaptive 
immunity. MIF has been discussed as a useful biomarker for inflammation-related dis-
eases, as many of these disorders are mirrored by elevated MIF levels in the circulation 
[109]. This is the case, for example, in endotoxemia and sepsis, where elevated plasma 
levels have been linked to the release from cells of the pituitary gland and from macro-
phages. Systemic administration of MIF together with lipopolysaccharide (LPS) has been 
shown to increase lethality in mice. Based on these findings and a large number of other 
studies, MIF is generally accepted as a crucial mediator of sepsis and infectious diseases 
[61, 110-112]. MIF is furthermore an important mediator in atherosclerosis. MIF expres-
sion is upregulated with progression and is evident through all stages of atherosclerosis. 
MIF drives the progression of atherosclerosis by inducing immune cell recruitment, 
integrin activation, and monocyte arrest [65, 113]. Similarly, there is an implication of MIF 
in inflammatory lung disorders, inflammatory bowel disease [114, 115] and for inflamma-
tory conditions of the liver (Chapter 1.3.5). MIF is implicated in numerous auto-immune 
diseases including systemic lupus erythematodes (SLE), asthma, autoimmune kidney 
diseases, and rheumatoid arthritis [116-118]. In rheumatoid arthritis, MIF protein is 
enhanced in the circulation and inflamed synovial tissue and implicated in angiogenic pro-
cesses [119-121]. Highly elevated MIF levels can also be found in a variety of human tu-
mors, for instance in breast, colon, lung, and liver [122-125]. By regulating invasion, 
proliferation, angiogenesis, and metastasis, MIF promotes all stages of tumorigenesis. 
Moreover, MIF levels often correlate with prognosis [126]. Moreover, MIF is associated 
with metabolic disorders or processes. MIF mediates insulin resistance in white adipose 
tissue [127] and increases glucose uptake in heart muscle during cardiac ische-
mia/reperfusion, thereby reducing injury [104]. Several studies demonstrate a relationship 
between plasma levels of MIF and obesity and link MIF with the dysregulation of glucose 
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metabolism, development of insulin resistance and type 2 diabetes. A causal relationship, 
however, is not yet clear [128]. 
The outcome of inflammatory diseases or the predisposition of patients to develop a certain 
disease might depend on the patient’s MIF allele. The human MIF gene is characterized by 
a microsatellite repeat (−794 CATT) within the 5′ promoter region. The number of repeats 
correlates with MIF expression. Additionally to the diversity of repeat numbers, a single-
nucleotide polymorphism (−173 G/C) is known. High expression MIF alleles are related to 
increased inflammation in several autoimmune diseases [109]. 
1.3.5 MIF in liver disease  
Constitutive hepatic MIF expression at low levels has been detected mainly in hepatocytes 
adjacent to the central vein and weakly in sinusoidal lining cells and biliary epithelial cells 
[73, 129]. MIF has been implicated in diverse hepatic disorders, many of which are 
accompanied by high levels of MIF expression. Increased serum levels of MIF have been 
found in patients with HCC and liver cirrhosis [122] and in patients with alcoholic hepatitis 
and alcoholic cirrhosis. In those patients, hepatic MIF expression could be localized in 
hepatocytes and infiltrated immune cells [130]. Accordingly, ethanol-fed rats express 
enhanced levels of MIF, which are linked to enhanced inflammation and necrosis [131]. In 
NAFLD, MIF levels correlate with fibrosis stage. Increased MIF levels, however, were 
suggested to be secondary to inflammation rather than being causal, as MIF promoter poly-
morphisms were evenly distributed among healthy and NAFLD patients in this study 
[132]. Furthermore, there is a correlation between MIF expression and the severity of 
hepatitis B virus (HBV)-related hepatic necroinflammation [133]. 
Enhanced MIF expression was also found in fibrotic rat livers upon thioacetamide (TAA) 
treatment. High MIF levels, which were associated with enhanced numbers of macro-
phages, were mainly found in degenerated hepatocytes adjacent to the fibrotic areas, 
whereas fibrotic areas displayed low levels of MIF expression [134]. A role for MIF in 
acute liver damage was identified in a mouse model of acute T-cell mediated hepatitis, 
induced by concavalin A (Con A). In this study, Mif 
–/–
 mice were protected in Con A-
induced liver damage. Protection in these mice was not mediated by changes in TNF-α or 
IFN-γ levels but accompanied by lower numbers of activated leukocytes [135]. In line with 
a regulatory role for MIF in ischemia/reperfusion injury in heart, brain and intestine, MIF 
is associated with liver ischemia/reperfusion injury and likely to mediate the inflammatory 
response in this pathological condition. A recent study showed enhanced MIF levels in 
liver and serum of mice and enhanced hepatic expression of CD74 after ische-
mia/reperfusion. Simultaneously, pro-inflammatory mediators were upregulated [129]. 
Taken together, human patient studies as well as rodent disease models clearly depict a 
contribution of MIF to the pathogenesis of liver diseases, largely being associated with the 
progression of inflammation. 
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1.4 Previous findings: MIF in experimental liver fibrosis 
Within the framework of project P07 of the collaborative research center SFB/TRR57, 
preliminary experiments revealed a surprising protective effect of MIF in liver fibrosis 
[136]. Due to its general pro-inflammatory profile (see Chapter 1.3) and its contribution to 
various liver diseases (see Chapter 1.3.5), MIF had been expected to be a driving force in 
hepatic inflammation, and thus to contribute to the progression of liver fibrosis. Unex-
pectedly however, in CCl4-induced liver fibrosis Mif 
–/–
 mice showed a considerably 
stronger fibrotic response than wildtype (WT) control mice. Figure 1-7 documents the 
higher extent of collagen accumulation in Mif-deficient mice as assessed by Sirius red 
staining of fibrotic liver tissue and the computational quantification of the Sirius red-posi-
tive area. Furthermore, hydroxyproline concentration in the liver was significantly in-
creased in Mif 
–/–
 mice. Content of hydroxyproline, an α-amino acid specific for collagen, 
is a prominent marker for the degree of liver scarring. 
 
Figure 1-7: CCl4-induced liver fibrosis in wildtype and Mif-deficient mice. Mice were challenged with CCl4 
for 6 weeks (n = 12 per group). Representative Sirius red stainings of fibrotic liver tissue (upper pictures) 
show the extent of accumulated collagen. For both groups, Sirius red-positive area of stained tissue was 
quantified (lower left) and hydroxyproline concentration was measured (lower right). Bars indicate mean 
values ± SEM (*p < 0.05, **p < 0.01) [136]. 
The surprising results of the CCl4 model were verified in an independent model of TAA-
induced hepatic fibrosis. Again, Sirius red staining and measurement of hydroxyproline 
content served as markers for the extent of fibrosis and were significantly elevated in 
Mif 
–/–
 compared to wildtype control mice (Figure 1-8).  
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Figure 1-8: TAA-induced liver fibrosis in wildtype and Mif-deficient mice. Mice were challenged with TAA 
for 6 weeks (n = 12 per group). Collagen accumulation is shown by representative Sirius red stainings of 
fibrotic liver tissue (upper pictures). Sirius red-positive area of stained tissue was quantified (lower left) and 
hydroxyproline content of the livers was measured (lower right). Bars indicate mean values ± SEM 
(*p < 0.05, **p < 0.01) [136]. 
As MIF is known for its immunomodulatory action, immune cell infiltration in fibrotic 
livers was assessed for both experimental models. Accumulation of NKT cells, T cells, NK 
cell, and macrophages was analyzed via flow cytometry. Yet, there were no significant 
differences between MIF expressing and non-expressing mice in either model. 
 
Figure 1-9: Immune cell infiltration in wildtype and Mif-deficient mice in CCl4- and TAA-induced fibrosis. 
After chronic liver injury caused by treatment with CCl4 (A) or TAA (B), infiltrated NKT cells, T cells, NK 
cells, and macrophages were quantified by flow cytometry. Bars indicate mean values ± SEM from 12 ani-
mals per group [136]. 
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Both fibrosis models used in this study are well-established models for chronic hepatic 
inflammation and fibrosis. They are associated with an inflammatory response, character-
ized by infiltration of immune cells, and with the activation of HSCs, resulting in excessive 
production and remodeling of the extracellular matrix. As immune cell recruitment ap-
peared not to be the major difference between wildtype and Mif 
–/–
 mice, stellate cell 
activation was addressed next. Therefore, gene expression of several fibrosis-relevant and 
HSC activation-associated genes was analyzed via qPCR. Precisely, Col1a1, Timp1, 
Mmp2, and Tgfb1 were chosen as representative markers for HSC activity. Of note, both in 
CCl4- and in TAA-induced fibrosis, expression of those genes was enhanced in the knock-
out mice as depicted in Figure 1-10. This strongly indicates a role for MIF in the regulation 
of hepatic stellate cell activity. 
 
Figure 1-10: Gene expression analysis of genes associated with HSC activation. Relative mRNA levels were 
quantified by qPCR. Col1a1, Timp1, Mmp2, and Tgfb1 expression was analyzed in wildtype and Mif 
–/–
 mice 
treated with CCl4 (A) and TAA (B) for 6 weeks, respectively (n = 12 per group). Relative mRNA levels were 
normalized to wildtype for each transcript. Bars indicate mean values ± SEM (*p < 0.05, **p < 0.01, 
***p < 0.001) [136]. 
In summary, the previous experiments within the collaborative SFB/TRR57 project 
showed enhanced fibrosis in Mif-deficient mice in CCl4- and TAA-induced experimental 
liver injury. These in vivo studies indicate antifibrotic activities of MIF in the liver that 
involve the regulation of HSC activity rather than the recruitment of immune cells to the 
injured liver [136]. These unexpected but clear results laid the foundation for further 
mechanistic investigations that were in the center of this thesis. 
1.5 Objectives 
Liver fibrogenesis is the characteristic response to persisting liver injury and inflammation 
and the prevalent feature of all chronic liver diseases. The progressive scaring of the func-
tional liver tissue by cellular damage and replacement with connective tissue is a risk fac-
tor for the development of liver cirrhosis and hepatocellular carcinoma, including asso-
ciated clinical complications such as portal hypertension and liver failure. To date, liver 
transplantation represents the only curative treatment for end-stage cirrhosis. Therefore, a 
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fundamental understanding of the molecular processes that regulate fibrogenesis is crucial 
in order to assess risk factors and develop strategies to counter-regulate the fibrotic re-
sponse. 
In order to get a general overview about the characteristics of MIF in the context of liver 
fibrosis, hepatocytes, Kupffer cells and HSCs were characterized concerning their receptor 
expression profiles and their ability to produce and secrete MIF in response to pro- and 
anti-fibrotic and -inflammatory stimuli. These in vitro characterization studies sought to 
improve the understanding about the origin of hepatic MIF and the potential 
responsiveness of parenchymal and non-parenchymal liver cell populations to MIF 
stimulation. Sensitivity of these cells to MIF could trigger regulatory mechanisms, modi-
fying the pathological outcome of chronic liver injury. 
In the framework of project P07 of SFB/TRR57, a surprising anti-fibrotic effect of the 
pleiotropic pro-inflammatory cytokine MIF was identified in experimental hepatotoxin-
induced liver fibrosis by the observation of an exacerbated fibrotic response in Mif 
–/–
 mice 
in two independent models of fibrogenesis. This effect was related to the increased expres-
sion of genes related to myofibroblast activity. The aim of this work was therefore to 
further assess the role of hepatic stellate cells (HSCs), which are the prevalent source of 
myofibroblasts in the fibrotic liver, as mediators of the protective effect of MIF in liver 
fibrosis. An in vivo approach applying therapeutic administration of recombinant MIF to 
CCl4-treated wildtype mice sought to give further evidence for the capability of MIF to 
reduce liver fibrosis and to emphasize the importance of HSCs in this process.  
The main research objective was to identify of the underlying molecular mechanisms that 
mediate the anti-fibrotic properties of MIF. This included the analysis of relevant signal 
transduction pathways and the identification of MIF target genes within HSCs, the candi-
date cells mediating this effect. Concerning MIF signaling in HSCs, a major role was 
assumed for the AMPK pathway. This pathway is activated by MIF in the ischemic heart. 
Furthermore, it is associated with regulatory functions controlling HSC activity, such as 
PDGF-induced proliferation, migration and the expression of fibrosis-related genes. In 
vitro experiments therefore sought to establish a link between MIF stimulation and AMPK 
activity, and assess the functional relevance of this pathway for MIF-dependent anti-
fibrotic activity. Mechanistic approaches, utilizing not only HSCs but also hepatocytes, 
aimed to identify further components of the MIF/AMPK axis. Furthermore, a role for the 
JNK signaling pathway in mediating MIF’s effects in HSCs was assumed. Experiments 
therefore addressed the ability of MIF to regulate JNK activity. 
Lastly, an unbiased microarray-based approach was selected to address the question of 
whether MIF may not only regulate fibrotic activities in myofibroblastic HSCs, but also 
alter transdifferentiation by regulating gene expression. This approach sought to provide 
candidates for direct or indirect MIF target genes upon sustained or transient MIF 
stimulation, at early or late stages of HSC activation. In the future, such genomic data may 
provide a starting point for identifying other molecules required for the therapeutic effects 
of MIF in chronic liver injury. 
 2 Results 
2.1 Expression and secretion of MIF by hepatic cells 
MIF has been shown to be expressed in healthy liver tissue and upregulated upon liver 
damage in several studies focusing on different disease settings. MIF expression was 
mostly traced back to either hepatocytes and/or mononuclear cells (i.e. infiltrating cells or 
Kupffer cells) in these studies [129-131, 133, 134]. It remained unknown, however, which 
cell populations of the liver express and secrete MIF during liver fibrogenesis and what 
kind of stimuli triggers the release of MIF from those cells. Hepatocytes, Kupffer cells and 
hepatic stellate cells were therefore analyzed concerning their basal MIF expression and 
their ability to secrete MIF in response to various fibrosis- and inflammation-related 
stimuli. For this purpose, primary cells and cell lines were stimulated with the cytokines 
TGF-β, PDGF, and TNF-α, which are pro-fibrogenic mediators, IFN-γ, which has anti-
fibrotic properties, IL-6, which plays a broad role in both inflammation and fibrosis, and 
MCP-1 and IL-1β, which trigger inflammation and are involved in fibrogenesis (see 
Chapter 1.1.4). Besides cytokines, further stimuli that are implicated in liver fibrosis were 
used to analyze MIF secretion from hepatic cells. These were LPS, H2O2, Ethanol (EtOH), 
and CCl4. LPS, which reaches the liver through the portal vein, activates Kupffer cells and 
HSCs and is furthermore known to stimulate MIF secretion from macrophages [74, 137]. 
H2O2 was used representative of reactive oxygen species that mediate inflammation and 
fibrosis [138]. Ethanol is a frequent cause of liver injury and fibrosis and was thus included 
in the MIF secretion experiments. As the protective effect of MIF was shown in 
experimental liver fibrosis induced by CCl4, hepatocytes were stimulated with this hepa-
totoxin in vitro. Concentrations of all stimuli are summarized in Table 6.12. 
Cells used for secretion analysis were seeded into multiwell plates at a cell density close to 
confluency. After serum starvation, medium was replaced by fresh medium to remove 
background levels of MIF that might have been released due to starvation stress. Simulta-
neously, the different stimuli were added and cells were incubated for 20 h (long term 
release), 6 h (short term release) or 30 min (rapid release) (Chapter 6.5.3). The release of 
MIF into the cell culture medium and MIF levels in cell lysates were quantified by ELISA 
(Chapter 6.2.3). Due to experimental difficulties causing high background variation of the 
ELISA, MIF levels were normalized to untreated controls and are presented as relative 
levels.  
2.1.1 Basal MIF concentrations in hepatic cells 
Basal MIF concentrations that were measured intracellularly or in the cell culture medium 
vary considerably between the different kinds of hepatic cells. This variation was not only 
observed between the different types of hepatic cells, i.e. hepatocytes, KCs and HSCs, but 
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also between primary cells and the corresponding model cell lines. Table 2.1 shows the 
amount of MIF measured in the lysates of unstimulated cells. For better comparison, MIF 
concentrations were converted to total MIF amounts and normalized to 100,000 cells. MIF 
concentrations in primary HSC and KC lysates and supernatants under the applied condi-
tions were below the detection limit of the ELISA, and samples derived from Hepa 1-6 
cells were close to being measurable. Primary hepatocytes express considerably more MIF 
than the hepatocyte cell line. With about 7 ng MIF/100,000 cells they express almost 
30 times more MIF than Hepa 1-6 cells. In lysates of KC 13-2 cells 7 ng MIF/100,000 cells 
were measured, in GRX cell lysates about twice as much (~15 ng/100,000 cells). Yet, the 
data derived from KC 13-2 and GRX cells are not directly comparable to those derived 
from Hepa 1-6 cells and primary hepatocytes. Lysates and supernatants of these cells had 
been frozen before being measured by ELISA. The MIF standard, however, is routinely not 
frozen. It was observed that frozen samples generally give a lower signal in ELISA 
measurements than those freshly applied to the assay, although in both cases, the signal is 
linear in a suitable range of concentrations. Thus, comparing frozen samples to non-frozen 
standards underestimates the real concentrations. It is therefore assumed that intracellular 
MIF levels in the KC and HSC cell lines are higher than those in hepatocytes. 
Table 2.1: Basal quantities of MIF released from unstimulated cells over a period of 20 h. Concentrations 
were adjusted to 100,000 seeded cells. 
 Amount of MIF in cell lysates (ng MIF/100,000 cells) 
Hepa 1-6 0.25 ng 
KC 13-2 7.06 ng* 
GRX 14.70 ng* 
Primary hepatocytes 6.79 ng 
Primary KCs Below detection limit 
Primary HSCs Below detection limit 
*Differing from the others, these samples were frozen before analysis. Thus, absolute values are likely 
underestimated. 
Although MIF in primary mouse HSCs and primary rat KCs was not measureable under 
the applied conditions, Western blot analysis revealed that all three cell lines and all three 
types of primary hepatic cells express detectable basal levels of MIF (Figure 2-1). Thus, all 
of these cells may potentially secrete MIF upon appropriate stimulation. 
 
Figure 2-1: MIF expression by hepatic cell lines and primary cells. MIF in cell lysates of hepatic stellate cells 
(GRX and primary HSCs), hepatocytes (Hepa 1-6 and primary hepatocytes (HC)) and Kupffer cells (KC 13-2 
and primary KCs) and recombinant MIF (rMIF) was detected by Western blot using the anti-MIF Ka565 
antibody. 
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2.1.2 Hepatocytes 
Hepatocytes, as the metabolizing cells of the liver, are responsive to hepatotoxic agents. 
Hepatocyte damage is one of the first events in liver injury and is accompanied by the re-
lease of ROS and fibrogenic cytokines [139]. MIF expression in hepatocytes has been 
frequently shown [73, 129, 133]. Due to their high abundance, hepatocytes may be an im-
portant source of MIF in the fibrotic liver. Therefore, the mouse hepatoma cell line 
Hepa 1-6 and primary hepatocytes, isolated from C57BL/6 wildtype mice, were serum-
starved for 3 h and then stimulated with the cytokines TGF-β (5 ng/ml), TNF-α (20 ng/ml), 
IFN-γ (10 ng/ml), and IL-6 (20 ng/ml), and the hepatotoxic agents H2O2 (100 µM), ethanol 
(150 µM) and CCl4 (100 mM). Figure 2-2 shows relative MIF levels in cell culture 
supernatants (A) and cell lysates (B) of Hepa 1-6 cells that were stimulated for 20 h. On 
average, these cells had slightly increased MIF levels in the supernatants when stimulated 
with TNF-α. MIF was increased to 1.4-fold above control. This value did not reach signifi-
cance. A more obvious increase in MIF release was detected for CCl4, which caused 
2.4-fold higher levels in the supernatants. Nevertheless, this was not significant due to a 
high standard deviation. None of the tested stimuli changed intracellular MIF levels within 
20 h. Of note, both lysates and supernatants had MIF concentrations close to the lower 
detection limit of the MIF ELISA. 
 
Figure 2-2: Secretion and expression of MIF by Hepa 1-6 cells after 20 h of stimulation. Cells were stimu-
lated with TGF-β (5 ng/ml), TNF-α (20 ng/ml), IFN-γ (10 ng/ml), IL-6 (20 ng/ml), H2O2 (100 µM), EtOH 
(150 µM) or CCl4 (100 mM). MIF concentrations were measured by ELISA and normalized to the untreated 
control. MIF levels were determined in cell culture supernatants (A) and total cell lysates (B). Bars indicate 
mean values of two (IFN-γ, IL-6) or mean values ± SEM of three (TGF-β, TNF-α, H2O2, EtOH, CCl4) inde-
pendent experiments performed in duplicate each. 
Equivalent experiments were performed with primary hepatocytes. Primary hepatocytes 
generally expressed higher levels of MIF (see Chapter 2.1.1). Stimulation with the indi-
cated stimuli for 20 h at concentrations as listed above resulted in increased MIF release 
into the culture medium for all tested stimuli (Figure 2-3 A). TNF-α and IL-6 stimulation 
elevated MIF protein levels to 1.7-fold. MIF release was significantly increased by TGF-β, 
IFN-γ, H2O2, and EtOH, resulting in 1.8 – 2-fold MIF levels. As for Hepa 1-6 cells, CCl4 
potently induced MIF release from primary hepatocytes, raising the MIF concentration to 
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3.7-fold above control. Interestingly, intracellular MIF in hepatocytes was significantly 
elevated in the CCl4-treated cells as well (Figure 2-3 B). 1.5-fold more MIF was detected 
in lysates of hepatocytes treated with CCl4 than in lysates of untreated cells. None of the 
other stimuli significantly changed intracellular MIF levels, which indicates that MIF in 
the supernatants is derived from pre-formed pools. De novo synthesis obviously does not 
exceed the replacement of released MIF. 
 
Figure 2-3: Secretion and expression of MIF by primary hepatocytes after 20 h of stimulation. Hepatocytes 
were isolated from C57BL/6 wildtype mice and stimulated for 20 h with TGF-β (5 ng/ml), TNF-α 
(20 ng/ml), IFN-γ (10 ng/ml), IL-6 (20 ng/ml), H2O2 (100 µM), EtOH (150 µM) or CCl4 (100 mM). Secreted 
MIF (A) and MIF in lysates (B) were measured by ELISA and normalized to unstimulated control cells. Bars 
indicate mean values ± SEM of four independent experiments performed in duplicate each (*p < 0.05, 
**p < 0.01, ***p < 0.001). 
Release of MIF measured after a stimulation period of 20 h may include rapid release and 
accumulation over time. Similarly, MIF might be derived from pre-formed intracellular 
pools or specifically induced de novo synthesis. In order to specifically analyze rapid re-
lease of pre-stored MIF by hepatocytes, serum-starved Hepa 1-6 cells and primary 
hepatocytes were stimulated for 30 min. Figure 2-4 shows the relative levels of MIF 
released by Hepa 1-6 cells (Figure 2-4 A) and primary hepatocytes (Figure 2-4 B) that 
were exposed to the indicated stimuli. Rapid release of MIF was only observed in CCl4-
stimulated cells in both cell systems. CCl4-treatment resulted in very high MIF 
concentrations in the supernatants, particularly in the primary cells. 
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Figure 2-4: Release of MIF by hepatocytes after 30 min of stimulation. Hepa 1-6 cells (A) and primary 
hepatocytes derived from C57BL/6 wildtype mice (B) were stimulated with TGF-β (5 ng/ml), TNF-α 
(20 ng/ml), IFN-γ (10 ng/ml), IL-6 (20 ng/ml), H2O2 (100 µM), EtOH (150 µM) or CCl4 (100 mM) for 
30 min. MIF released into the cell culture medium was measured by ELISA and normalized to unstimulated 
control cells. Bars indicate mean values ± SEM of five (A) or three (B) independent experiments performed 
in duplicate each (**p < 0.01, ***p < 0.001). 
Considering that CCl4 is a hepatotoxic agent that impairs membrane integrity in hepato-
cytes [140], it was assumed that release of MIF into the supernatant was rather a result of 
hepatocyte damage than of active secretion. Therefore, Hepa 1-6 cells incubated with CCl4 
for 30 min or left untreated were stained with propidium iodide (PI) (Chapter 6.4.2). PI 
intercalates into the DNA and can be visualized by its red fluorescence. It is not able to 
cross the intact cell membrane and thus stains only cells that are damaged. Figure 2-5 
shows representative pictures of control and CCl4-stimulated Hepa 1-6 cells in phase con-
trast and fluorescence microscopy. Control cells displayed normal morphology and only 
few cells were PI-positive. After CCl4 treatment, however, morphology appeared changed 
and virtually all cells displayed PI staining indicative for a loss of membrane integrity. 
Accordingly, enhanced lactate dehydrogenase (LDH) activity was measured in superna-
tants of CCl4-treated cells (data not shown). As LDH is only released from damaged cells, 
this further supports the suggestion that CCl4-induced MIF release largely is caused by cell 
death. In addition however, more specific events may be involved as despite increased 
cellular damage elevated intracellular MIF levels suggest de novo synthesis. 
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Figure 2-5: Visualization of damaged Hepa 1-6 cells upon CCl4 treatment by PI staining. Hepa 1-6 cells were 
incubated with 100 mM CCl4 for 30 min or left untreated. Morphology was visualized by phase contrast, PI 
staining by red fluorescence. Representative pictures are shown. Droplets were observed in wells with treated 
cells due to the insolubility of CCl4 in aqueous solutions. (Magnification: 40x) 
Hepatocyte damage and cell death is one important aspect in the onset of inflammation and 
fibrogenesis. Thus, damaged hepatocytes should be considered one important source of 
MIF in liver injury. Moreover, hepatocytes seem to play an active role in the release of 
MIF, as several cytokines trigger MIF secretion from primary hepatocytes. 
2.1.3 Kupffer cells 
Kupffer cells as the resident macrophages of the liver are another possible source of MIF 
in the liver and have been shown to upregulate MIF in some hepatic disorders [131, 133]. 
Macrophages that generally respond to inflammatory cytokines are activated by IFN-γ and 
sensitive for LPS and ROS. Therefore, the murine Kupffer cell line KC 13-2 was stimu-
lated with TNF-α (20 ng/ml), IFN-γ (50 ng/ml), IL-6 (20 ng/ml), LPS (1 µg/ml), and H2O2 
(100 µM). After 6 h, cell culture supernatants and lysates were collected and analyzed by 
ELISA. Figure 2-6 shows the results of four independent experiments. TNF-α, IFN-γ, IL-6, 
and LPS stimulation did not elevate MIF secretion from KC 13-2 cells compared to un-
stimulated control cells. H2O2 caused a 1.6-fold enhanced release of MIF into the medium, 
which was statistically significant. Measurement of LDH in the supernatants did not point 
to cell death upon H2O2 stimulation (data not shown). Intracellular MIF levels did not 
change significantly in response to any of the stimuli, although slightly increased levels 
were observed in almost all treated cells. Highest intracellular MIF levels were found in 
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cells stimulated with IL-6 and LPS, which had 1.5-fold more intracellular MIF than the 
control cells. 
 
Figure 2-6: Release and expression of MIF by KC 13-2 cells after 6 h of stimulation. KC 13-2 cells were 
exposed to TNF-α (20 ng/ml), IFN-γ (50 ng/ml), IL-6 (20 ng/ml), LPS (1 µg/ml) or H2O2 (100 µM). Cell 
culture medium (A) and lysates (B) were harvested after 6 h and analyzed by ELISA. MIF levels were nor-
malized to untreated controls. Bars indicate mean values ± SEM of at least four independent experiments 
performed in duplicate each (*p < 0.05). 
To confirm and extend these findings, MIF secretion from KC 13-2 cells was determined 
after 20 h to see whether prolonged exposure to the stimuli changes the response of 
Kupffer cells. In addition to the earlier performed stimulations over period of 6 h, the 
Kupffer cell line was now treated with three different LPS concentrations (0.01 µg/ml, 
0.1 µg/ml, 1 µg/ml) to find a more suitable concentration that might induce MIF secretion. 
IFN-γ was applied at a concentration of 10 ng/ml. The stimuli were added to serum-starved 
cells for 20 h. Figure 2-7 represents the results from these experiments. Again, MIF was 
analyzed in the supernatants and in the lysates. As observed for the short term release of 
MIF, neither TNF-α, IFN-γ, IL-6 nor any of the applied concentrations of LPS changed the 
amount of MIF released into the culture medium (Figure 2-7 A). Upon H2O2 stimulation 
1.5-fold more MIF was detected in the medium. Yet, due to high variations between the 
experiments, this value did not reach significance. In the lysates, no considerable increase 
in MIF expression could be detected (Figure 2-7 B). Again, the highest concentration was 
detected in IL-6 stimulated cells, which displayed a 1.3-fold increase. The question 
whether or not this occurred in both experimental setting with short and long incubation 
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periods coincidently would require further analysis and cannot be answered at this point. 
 
Figure 2-7: Release and expression of MIF by KC 13-2 cells after 20 h of stimulation. MIF concentrations 
were measured after stimulation with TNF-α (20 ng/ml), IFN-γ (10 ng/ml), IL-6 (20 ng/ml), LPS 
(0.01-1 µg/ml) or H2O2 (100 µM) in cell culture medium (A) and lysates. (B). Bars indicate mean 
values ± SEM of at least four independent experiments performed in duplicate each. 
In summary, regarding MIF release KC 13-2 seem to be more responsive to oxidative 
stress, specifically H2O2, than to inflammatory stimuli or LPS. As enhanced oxidative 
stress is one characteristic feature of the fibrotic microenvironment, and as MIF was shown 
to be secreted upon hyperoxidative stimulation before, this is an interesting finding, indi-
cating a contribution of Kupffer cells to hepatic MIF levels. 
2.1.4 Hepatic stellate cells 
Activated HSCs not only produce large amounts of ECM protein, they also are an im-
portant source of cytokines and growth factors, which in an autocrine or paracrine manner 
regulate fibrogenic and inflammatory processes. Additionally, activation of HSCs is ac-
companied by enhanced responsiveness to various mediators [13, 139]. Whether HSCs 
secrete MIF and which stimuli trigger MIF release from HSCs has so far been unknown. 
Thus, the murine hepatic stellate cell line GRX was used for in vitro studies to investigate 
MIF secretion. GRX cells were grown under normal culture conditions (see Chapter 6.1.4) 
and therefore displayed a myofibroblastic phenotype.  
To analyze short term release of MIF, serum-starved GRX cells were stimulated with 
TGF-β (5 ng/ml), TNF-α (20 ng/ml), PDGF (20 ng/ml), IFN-γ (50 ng/ml), IL-6 (20 ng/ml), 
and MCP-1 (100 ng/ml) for 6 h. Relative MIF levels, which were measured by ELISA and 
normalized to untreated control cells, are depicted in Figure 2-8. In the GRX lysates, no 
change in MIF levels was detected in response to any of the investigated cytokines 
(Figure 2-8 B). In the supernatants, minor and non-significant changes were measured 
(Figure 2-8 A). On average, cells stimulated with TGF-β secreted only 70% of the MIF 
protein that was found in the supernatants of untreated control cells. Cell culture medium 
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from PDGF- and IFN-γ-stimulated cells contained about 80% MIF. None of the chosen 
stimuli increased MIF secretion after 6 h. 
 
Figure 2-8: MIF secretion and expression by GRX cells after 6 h of stimulation. After exposure to TGF-β 
(5 ng/ml), TNF-α (20 ng/ml), PDGF (20 ng/ml), IFN-γ (50 ng/ml), IL-6 (20 ng/ml) or MCP-1 (100 ng/ml) 
supernatants (A) and cell lysates (B) were harvested and analyzed by MIF ELISA. MIF levels were nor-
malized to untreated control cells. Bars indicate mean values ± SEM of at least four independent experiments 
performed in duplicate each. 
To see whether longer incubation periods revealed differences in MIF secretion, GRX cells 
were stimulated for 20 h with various cytokines. These were largely the same as in the pre-
viously described experiments with few differences. IFN-γ and IL-1β were used at a 
concentration of 10 ng/ml. Figure 2-9 A shows relative MIF levels measured in the cell 
culture medium after 20 h.  
 
Figure 2-9: Secretion and expression of MIF by GRX cells after 20 h of stimulation. Cell were stimulated 
with TGF-β (5 ng/ml), TNF-α (20 ng/ml), PDGF (20 ng/ml), IFN-γ (10 ng/ml), IL-6 (20 ng/ml), MCP-1 
(100 ng/ml) or IL-1β (10 ng/ml). MIF concentrations in the supernatants (A) and lysates (B) of stimulated 
and unstimulated cells were determined by ELISA and normalized to controls. Bars indicate mean 
values ± SEM of five to eleven (A) and three (B) independent experiments performed in duplicate each 
(*p < 0.05, ***p < 0.001 compared to control; #p < 0.05 compared to TNF-α stimulation). 
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Interestingly, TNF-α, which mediates some fibrotic activities, considerably increased MIF 
release up to 2.4-fold. The most potent fibrogenic mediator TGF-β and the predominant 
HSC mitogen PDGF in contrast, significantly reduced MIF release by 35% and 40%, 
respectively. TNF-α stimulation with simultaneous application of TGF-β significantly 
decreased MIF secretion compared to sole TNF-α stimulation to 1.6-fold above control. 
This indicates that TGF-β not only reduces baseline release of MIF but is furthermore able 
to inhibit specifically induced secretion of MIF from HSCs. Moreover, increased MIF 
release was detected in the supernatants of IL-6- and MCP-1- stimulated cells. MIF levels 
were elevated by 1.6- and 1.8-fold, respectively. Analysis of GRX cell lysates revealed that 
TNF-α, IFN-γ, and MCP-1 stimulation increased expression by a factor of 1.4 to 1.5. These 
changes, however, were not significant (Figure 2-9 B).In addition to using GRX cells for 
secretion analysis, pilot experiments were performed with primary HSCs isolated from 
C57BL/6 wildtype mice. However, MIF concentrations were below the detection limit of 
the MIF ELISA, possibly due to low cell numbers. Thus, further optimization of the assay 
conditions, including cell numbers and volumes, is required to compare MIF secretion 
from immortalized and primary HSCs. 
The fact that MIF concentrations in the supernatants of TGF-β- and PDGF-treated GRX 
cells were below those of control cells, raises the question whether these growth factors 
affect gene expression of Mif. Similarly, the considerably increased MIF secretion upon 
TNF-α stimulation accompanied by enhanced intracellular MIF levels is likely to result 
from enhanced gene expression. Thus, GRX cells were stimulated with TGF-β (5 ng/ml), 
TNF-α (20 ng/ml), and PDGF (20 ng/ml) for 20 h. Total RNA was extracted from cell 
lysates and Mif expression was quantified relative to the expression of the housekeeping 
gene Gapdh by qPCR (Chapter 6.3.3). Interestingly, while TGF-β and PDGF did not alter 
gene expression after 20 h of stimulation, TNF-α stimulation non-significantly increased 
Mif mRNA by 1.6-fold (Figure 2-10). Thus, TNF-α seems not only to stimulate MIF 
secretion from HSCs but also to transcriptionally control Mif expression. 
 
Figure 2-10: Mif expression by GRX cells after 20 h of stimulation. GRX cells were incubated with TGF-β 
(5 ng/ml), TNF-α (20 ng/ml) or PDGF (20 ng/ml). After 20 h, cells were harvested and RNA was extracted. 
Mif gene expression was analyzed by qPCR. Gapdh expression was used for normalization. Bars indicate 
mean values ± SEM of five independent experiments. 
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Compared to activated HSCs, quiescent HSCs are considered less responsive to fibrogenic 
stimulation and less active in the secretion of cytokines. Nevertheless, the initiation phase 
of stellate cell activation with early events that alter qHSC behavior is an important step in 
the fibrogenic response [13]. Thus, it appeared of interest whether these cells may con-
tribute to the regulation of hepatic MIF levels in response to pro- or anti-fibrotic stimuli. 
One interesting feature of the GRX cell line is its ability to transform back into a fat-stor-
ing quiescent-like phenotype upon retinol treatment [141]. Figure 2-11 schematically 
displays the different phenotypes that can be obtained by GRX cells under the appropriate 
conditions. 
 
Figure 2-11: Schematic representation of GRX phenotype modulation. Under normal culture conditions, 
GRX cells display a transitional myofibroblastic phenotype. Cytokine stimulation can induce a more acti-
vated status while retinol stimulation causes cellular reorganization, which results in a fat-storing quiescent-
like phenotype. Illustration modified according to [141]. 
Successful induction of the fat-storing phenotype in GRX (hereafter termed qGRX) proved 
very sensitive to cell density, incubation periods, and retinol concentrations. After initial 
optimization, the most reproducible results were achieved by seeding 75.000 cells in 
12-well plates and incubating them in the presence of 20 µM retinol for 96 h. Retinol was 
dissolved in ethanol. Therefore control cells were incubated with the equivalent amount of 
ethanol (i.e. 0.1%) but did not show altered behavior. Phenotypic changes were monitored 
by microscopic assessment of cell morphology, which is representatively shown in 
Figure 2-12. Retinol-treated cells were characterized by lower proliferation rates resulting 
in considerably lower cell density compared to control cells. A heterogeneous cell popula-
tion was obtained in which some cells still displayed a myofibroblast-like morphology 
whereas a high number of cells had gained a more regular shape and visibly had accumu-
lated fat vacuoles. These vacuoles are the storage sites of retinol esters. 
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Figure 2-12: Modulation of GRX phenotype by retinol. Equal numbers of GRX cells were incubated with 
20 µM retinol to obtain qGRX or 0.1% ethanol as control for 96 h. Upon retinol treatment, a slowly pro-
liferating heterogeneous population was obtained with a large portion of fat-storing cells similar to quiescent 
HSCs (black arrows) and myofibroblastic cells (white arrows). Representative pictures are shown. (Magnifi-
cation 200x) 
qGRX cells were treated as normal GRX cells and stimulated for 6 h in order to analyze 
MIF expression and secretion from these cells. As stimuli, the pro-fibrotic factors TGF-β 
and PDGF, and the anti-fibrotic IFN-γ were chosen. As depicted in Figure 2-13 A, TGF-β 
increased MIF release into the cell culture medium to 1.4-fold above control. This is in 
clear contrast to the reduced secretion by TGF-β-stimulated myofibroblastic GRX cells. 
More consistently, a moderate decrease of MIF secretion was detected in PDGF-stimulated 
qGRX cells. IFN-γ treatment slightly increased MIF levels in the cell culture medium. 
None of the changes was statistically significant and variation between individual experi-
ments was high, possibly due to the inhomogeneous differentiation state of the cells. 
Nevertheless, these data provide evidence, that also qGRX cells stimulus-dependent regu-
late MIF secretion. 
 
Figure 2-13: MIF secretion and expression by qGRX cells after 6 h of stimulation. GRX cells were 
stimulated with 20 µM retinol for 96 h to induce the fat-storing phenotype. qGRX were stimulated with 
TGF-β (5 ng/ml), PDGF (20 ng/ml), and IFN-γ (50 ng/ml) for 6 h. MIF concentrations were measured in cell 
culture supernatants (A) and cell lysates via ELISA and normalized to untreated control cells. Bars indicate 
mean values ± SEM of three independent experiments. 
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Taken together, the experiments with GRX cells, which serve as a model system for HSCs, 
suggest a contribution of HSCs to hepatic MIF levels. Of note, they show a dedicated 
regulation of both MIF expression on protein and mRNA level and MIF secretion in 
response to various stimuli. These stimuli may be of both pro- and anti-fibrogenic nature. 
2.2 Expression of MIF receptors by hepatic cells 
Hepatic cells may be both a source of hepatic MIF and MIF target cells. Therefore, it is 
reasonable to characterize those cells concerning their expression of the MIF receptors 
CXCR2, CXCR4, and CD74. 
Receptor expression by Hepa 1-6 cells was analyzed by flow cytometry and Western blot 
as described in Chapter 6.4.1 and 6.2.1. For detection of cell surface exposed receptors, a 
FITC-conjugated anti-CD74 antibody, PE-conjugated anti-CXCR4 and anti-CXCR2 anti-
bodies, and the appropriate isotype controls were applied. Figure 2-14 shows the 
histograms of this analysis. Analysis revealed surface expression of CD74, as seen by in-
creased fluorescence intensity. Surface expression of CXCR4 and CXCR2, however, was 
not detected.  
 
Figure 2-14: Cell surface expression of CD74, CXCR4, and CXCR2 by Hepa 1-6 cells. Receptor expression 
was analyzed by flow cytometry using FITC- or PE-conjugated antibodies. Histograms depict cell numbers 
over fluorescence of unstained cells (light grey), isotype control cells (dark grey), and specifically labeled 
cells (colored). 
Expression of CD74 by hepatocytes was verified by Western blot analysis of Hepa 1-6 and 
primary hepatocyte lysates, as shown in Figure 2-15 A. Weak bands representing the 
31 kDa and 41 kDa isoforms are visible on the blots. Additionally, a considerably stronger 
band between those two presumably represents a posttranslationally modified variant of 
the 31 kDa isoform. Figure 2-15 B shows a Western blot of CXCR4. Interestingly, 
although no cell surface expression of CXCR4 in Hepa 1-6 cells was measured by flow 
cytometry, CXCR4 was detected on the Western blot. The blot shows two distinct bands, 
which might present an unmodified and a posttranslationally modified variant of CXCR4. 
This indicates that CXCR4 is expressed by hepatocytes but largely retained within the cell.  
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Figure 2-15: Expression of CD74 and CXCR4 by Hepa 1-6 and primary mouse hepatocytes (HC). Cell ly-
sates were analyzed by Western blot. Primary antibodies against CD74 (A) and CXCR4 (B) were used. 
Arrows indicate different isoforms and/or posttranslationally modified variants. 
Representative of Kupffer cells, KC 13-2 cells were characterized for cell surface expres-
sion of MIF receptors. Flow cytometry revealed that of the three receptors only CD74 is 
present on the cell surface of the Kupffer cell line in detectable amounts (Figure 2-16). 
Incubation with PE-conjugated anti-CXCR4 and anti-CXCR2 antibodies did not increase 
overall fluorescence of these cells. 
 
Figure 2-16: Cell surface expression of CD74, CXCR4, and CXCR2 by KC 13-2 cells. Cells were analyzed 
by flow cytometry using a FITC-conjugated anti-CD74 antibody and PE-conjugated anti-CXCR4 and 
anti-CXCR2 antibodies. Histograms depict cell numbers over fluorescence of unstained cells (light grey), 
isotype control cells (dark grey), and specifically labeled cells (colored). 
Western blot analysis of primary rat Kupffer cells verified the expression of CD74. Both 
isoforms, p31 and p41, and a posttranslationally modified variant of p31, were detected on 
the blot. Band intensities indicate that the 31 kDa isoform is more abundant than the 
41 kDa isoform in rat KCs. Detection of CXCR4 by Western blot provided evidence, that 
this receptor is expressed in primary KCs and KC 13-2 cells as expected for macrophages. 
2.2 Expression of MIF receptors by hepatic cells 35 
 
Figure 2-17: CD74 and CXCR4 expression in primary Kupffer cells and KC 13-2. Rat Western blots 
incubated with CD74 (A) and CXCR4 (B) antibodies show the presence of both receptors in Kupffer cell 
lysates. Arrows indicate different isoforms and/or posttranslationally modified variants. 
Furthermore, GRX cells and primary HSCs were characterized for receptor expression. By 
flow cytometry, cell surface expression of CD74 and CXCR4 but not CXCR2 was de-
tected. CD74 is also expressed on the surface of activated primary HSCs. These data were 
published in the dissertation of D. Heinrichs [142] and in [136]. Beyond, no further MIF 
receptors were detected on the cell surface of activated primary HSCs as shown in 
Figure 2-18.  
 
Figure 2-18: Cell surface expression of CD74, CXCR4, and CXCR2 by primary activated Mif 
–/–
 HSCs. Pri-
mary HSCs were isolated from aged Mif 
–/–
 mice and purified by FACS sorting. 7 days after isolation, 
activated HSCs were analyzed by flow cytometry. Histograms show cell numbers over fluorescence of un-
stained cells (light grey), isotype control cells (dark grey), and specifically labeled cells (colored). CD74 
surface expression was published in the dissertation of D. Heinrichs [142] and in [136]. 
None of the MIF receptors was detected on the surface of primary HSCs immediately after 
isolation (data not shown). Accordingly, as shown in Figure 2-19, CD74 surface 
expression was detected only in a small subset of retinol-stimulated GRX cells, of which a 
majority displayed the fat-storing quiescent-like phenotype (qGRX, see Figure 2-12). 
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Figure 2-19: Cell surface expression of CD74 by qGRX cells. GRX cells were treated with 20 µM retinol for 
96 h to obtain the fat-storing phenotype and analyzed by flow cytometry. The dot plot (left) shows the two 
populations obtained after retinol stimulation. Histograms of population P1 (middle) and P2 (right) show the 
fluorescence intensities of unstained cells (grey) and cells incubated with FITC-conjugated anti-CD74 anti-
body (colored).  
By Western blot, CD74 expression in GRX cells and qGRX cells was verified, as shown in 
Figure 2-20 A. Both isoforms of 31 and 41 kDa and the posttranslationally modified vari-
ant of p31 were detected. Blots of the GRX and qGRX lysates cannot quantitatively be 
compared. Thus, a conclusion, whether qGRX generally express lower levels of CD74 or 
simply retain larger portions within the cell, cannot be drawn at this point. Similarly, while 
CXCR4 by flow cytometry was not detected on the surface of qGRX cells, lysates of GRX 
cultured under standard conditions as well as qGRX cells show distinct bands for CXCR4 
on Western blot (Figure 2-20 B). 
 
Figure 2-20: Expression of CD74 and CXCR4 in GRX cells. Lysates of GRX cells displaying the myofibro-
blastic phenotype and retinol-stimulated GRX cells displaying the fat-storing phenotype (qGRX) were 
applied for Western blot analysis. Immunodetection was performed using primary antibodies against CD74 
(A) and CXCR4 (B). Arrows indicate different isoforms and/or posttranslationally modified variants. 
Taken together, these results show that CD74 and CXCR4 are expressed by hepatocytes, 
KCs and HSCs. Yet, surface expression differs between the different cells. While surface-
exposed CD74 was evident for the hepatocyte, Kupffer cell and HSC cell lines as well as 
for primary activated HSCs, this receptor was not or less abundant on primary qHSCs and 
qGRX cells. Surface-exposed CXCR4 could only be detected on GRX cells while intra-
cellularly being present in all tested cells. 
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2.3 Beneficial effects of MIF in experimental liver fibro-
sis in mice 
Previous experiments showed an unexpected, yet clear, antifibrotic effect of MIF in ex-
perimental liver fibrosis induced by CCl4 or TAA. Interestingly, not immune cell 
infiltration, but HSC activity differed considerably between wildtype and Mif 
–/–
 mice in 
both models (Chapter 1.3.5, [136]). Western blot analysis of total liver lysates from CCl4-
treated mice provided further evidence of enhanced HSC activity in Mif 
–/–
 mice. Total 
liver lysates from those mice showed much stronger bands for α-SMA protein than lysates 
from wildtype livers. GAPDH bands proved comparable loading between the two groups 
(Figure 2-21). α-SMA is a typical marker of myofibroblasts, of which a majority originates 
from HSCs [4]. Enhanced abundance of α-SMA underlines the findings on mRNA level 
showing an upregulation of gene expression of HSC activity-associated genes (see 
Figure 1-10). 
 
Figure 2-21: Increased α-SMA expression in fibrotic livers of Mif –/– mice after CCl4 administration. Total 
liver lysates were analyzed by Western blot. GAPDH served as loading control. Each lane shows one repre-
sentative sample from a total of 12 treated animals per group [136]. Also published in the dissertation of D. 
Heinrichs [142]. 
In order to extend the findings obtained in the knockout animals, a further in vivo study 
was conducted as described in Chapter 6.6.2. The aim was to see whether exogenously 
applied MIF protein had a therapeutic effect in experimental liver fibrosis. Daily ad-
ministration of recombinant MIF in addition to CCl4 treatment decreased hepatic levels of 
α-SMA as depicted in Figure 2-22. Western blot analysis revealed decreased α-SMA pro-
tein levels in MIF-treated mice compared to vehicle-treated control mice. GAPDH bands 
proved comparable loading. Quantification of the band intensities by densitometry with 
adjustment to GAPDH levels indicated a reduction of α-SMA protein of about 40% in the 
MIF-treated group. Similarly, immunohistochemical staining of fibrotic liver tissue 
showed a lower abundance of α-SMA in the livers of MIF-treated mice. 
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Figure 2-22: Decreased protein expression of α-SMA after therapeutic application of MIF in CCl4-induced 
liver injury. Mice were daily treated with 10 µg MIF or vehicle simultaneously to CCl4 administration for 
10 days (n = 6 per group). Protein levels of α-SMA in total liver lysates were analyzed by Western blot and 
quantified by densitometry (A). Immunohistochemical staining shows α-SMA expression in fibrotic liver 
tissue (B). Bars indicate mean values ± SEM (*p < 0.05) [136]. 
Besides differences at the protein level, the α-Sma expression between MIF- and vehicle-
treated groups differed also at the mRNA level, as measured by qPCR (Figure 2-23 A). On 
average, α-Sma mRNA content was reduced by about 50% in MIF-treated animals. Fur-
thermore, therapeutic application of MIF reduced gene expression of Col1a1, Timp1, and 
Tgfb1, whereas Mmp2 expression was nearly at the same level in both groups 
(Figure 2-23 B). Increased expression of these genes generally is associated with fibrosis 
and HSC activation. Taken together, these results strengthen the findings of the previous 
experiments described in Chapter 1.4 which suggest that MIF has anti-fibrotic properties. 
They furthermore support the assumption that MIF exerts its anti-fibrotic properties by 
regulation of HSC activity. 
 
Figure 2-23: Reduced gene expression of HSC-related genes after therapeutic application of MIF in CCl4-
induced liver injury. Relative hepatic mRNA levels of α-Sma (A) and Col1a1, Timp1, Mmp2, and Tgfb1 (B) 
were analyzed by qPCR and compared between MIF-treated and vehicle-treated mice. Bars indicate mean 
values ± SEM of 6 animals per group (*p < 0.05) [136]. 
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2.4 AMPK-dependent regulation of HSC activity by MIF 
As the data presented in Chapter 2.3 suggest a correlation between MIF expression and 
HSC activity in experimental liver fibrosis, the next step was to investigate the underlying 
mechanism. Recently, a cardioprotective effect of MIF in ischemia reperfusion injury was 
discovered that, at the molecular level, has been linked to MIF-induced AMPK activation 
[104]. AMPK, a key regulator of whole body and cellular energy homeostasis, negatively 
regulates HSC activity in the context of liver fibrosis [31, 44]. Therefore, MIF-induced 
AMPK activation in HSCs was analyzed as described in Chapter 6.5.4. HSCs derived from 
Mif 
–/–
 mice were activated in vitro for 5 – 7 days with concomitant LPS stimulation. They 
were then trypsinized and seeded into 48-well plates as transdifferentiated myofibroblasts 
(MFBs). Cells were serum-starved and stimulated with increasing concentrations of MIF in 
the range of 10 - 1000 ng/ml. A stimulation period of 30 min was chosen as this appeared 
promising during pilot experiments. Metformin, a well-known AMPK activator [143], 
served as a positive control. Phosphorylation of the activity-relevant threonine residue of 
the AMPK α-subunit at position 172 [34] was analyzed by Western blot. Band intensities 
suggested that MIF dose-dependently phosphorylates AMPK at Thr172 (Figure 2-24). 
Additional quantification of band intensities with AIDA image analyzer software further 
supported this finding. Phosphorylation reached a maximum of about 1.8-fold above 
control after incubation with 500 and 1000 ng/ml MIF. Enhanced phosphorylation was 
significant at 200 and 500 ng/ml. 
 
Figure 2-24: Dose-dependent phosphorylation of AMPK in culture-activated Mif-deficient MFBs. 
Transdifferentiated MFBs were stimulated with recombinant MIF at indicated concentrations or 20 mM 
metformin for 30 min. Lysates were analyzed by Western blot for phosphorylation of AMPK at Thr172. 
Detection of total AMPK served as loading control. A representative blot is shown. Bars indicate mean 
values ± SEM of four independent experiments with cells from two independent isolations (*p < 0.05, 
**p < 0.01) [136]. 
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Equivalent experiments with primary cells derived from wildtype animals (n =3) and ex-
periments with the immortalized hepatic stellate cell line GRX (n = 8), however, were not 
in accordance with these data (Figure 2-25). AMPK phosphorylation peaked at 1.4-fold 
above control in wildtype MFBs stimulated with 50 ng/ml MIF and at 1.2-fold above con-
trol in GRX cells stimulated with 500 ng/ml MIF. These rather small variations did not 
reach significance for either concentration in either cell system. In Mif 
–/–
 MFBs, metfor-
min on average caused a 6.6-fold increase in phosphorylation of Thr172, while the increase 
was about 4.2-fold in wildtype MFBs and 1.9-fold in GRX. Reasons for the differential 
response of the different cell systems to MIF will be discussed in Chapter 3.5.2.  
 
Figure 2-25: Phosphorylation of AMPK in primary wildtype HSCs and GRX cells. Transdifferentiated 
wildtype MFBs (A) and GRX cells (B) were stimulated with recombinant MIF at indicated concentrations or 
20 mM metformin for 30 min. Lysates were analyzed by Western blot for phosphorylation of AMPK at 
Thr172. Detection of actin served as loading control. (A) and (B) show one representative blot out of three 
and eight independent experiments, respectively. Bars indicate mean values ± SEM (*p < 0.05, 
***p < 0.001). 
As recombinant MIF significantly activated AMPK in Mif 
–/–
 HSCs, the functional rele-
vance of AMPK signaling in HSCs was addressed. Activation of AMPK, e.g. by 
metformin or the AMP analog AICAR, results in decreased PDGF-induced migration and 
proliferation in HSCs [31, 44]. Therefore, the contribution of MIF-induced AMPK activa-
tion in the regulation of HSC migration and proliferation was investigated. Due to limited 
accessibility of primary HSCs, pilot experiments were performed with GRX cells and, 
despite non-significant results in the AMPK phosphorylation assay, proved suitable for the 
analysis of MIF-dependent regulation of HSC activity. Migration of GRX cells was 
measured in a modified Boyden chamber as described in Chapter 6.5.2. As shown in 
Figure 2-26 A, GRX cell migration was triggered by 100 ng/ml PDGF. Additional 
application of 500 ng/ml MIF reduced migration by about 50% compared to PDGF alone. 
Additional stimulation of the cells with 25 µM compound C 1 h prior to PDGF and MIF 
stimulation significantly blocked the inhibitory effect of MIF on PDGF-induced migration. 
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Compound C is a selective small-molecule inhibitor of AMPK [143]. This suggests that 
AMPK activity is involved in the regulation of HSC migration by MIF. 
Similarly, proliferation of GRX cells was analyzed in response to stimulation with PDGF 
and MIF in combination or alone (Figure 2-26 B). The rate of proliferation was assessed by 
measurement of bromodeoxyuridine (BrdU) incorporation 24 h after stimulation of the 
cells (see Chapter 6.5.1). Stimulation of GRX cells with PDGF alone nearly doubled the 
rate of proliferation compared to untreated controls, while MIF alone hardly showed any 
effect. Yet, upon simultaneous stimulation with PDGF and MIF, the rate of proliferation 
returned nearly back to baseline (i.e. untreated cells). As for migration, incubation of the 
cells with compound C 1 h prior to the experiment resulted in significant abrogation of the 
inhibitory effect of MIF on PDGF-induced proliferation. 
 
Figure 2-26: Inhibition of PDGF-induced proliferation and migration by MIF in HSCs. GRX cells were 
stimulated with 100 ng/ml PDGF and/or 500 ng/ml MIF. 25 µM compound C was used to block AMPK 
activity. Cells were applied to a modified Boyden chamber to analyze migration (A) or BrdU incorporation 
was measured to analyze proliferation (B). Bars indicate mean values ± SEM of at least two independent 
experiments in quadruplicate each (*p < 0.05, **p < 0.01, ***p < 0.001) [136]. 
Taken together, the above described results suggest a contribution of AMPK signaling in 
the MIF-dependent regulation of hepatic stellate cell activity. 
2.5 Modulation of JNK signaling by MIF in HSCs 
The effects of MIF on its target cells are mediated by various intracellular signaling path-
ways (see Chapter 1.3.3). Several of those pathways may be simultaneously activated in 
the same cell to control cellular behavior. Therefore, it was assumed that MIF-dependent 
regulation of HSC activity is not solely mediated by AMPK signaling but involves further 
signaling cascades. One potential candidate that may further link MIF-mediated signaling 
and the regulation of HSC behavior is the c-Jun N-terminal kinase (JNK) pathway. 
Dependent on the cellular origin and the overall context, MIF either activates or inactivates 
JNK and thus exerts distinct effects on target cells (see Chapter 1.3.3). JNK signaling is 
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involved in the regulation of fibrogenesis (see Chapter 1.2.2). Phosphorylation of the 
kinase is increased during fibrogenesis and is associated with HSC activation. While early 
HSC activation and proliferation is triggered by the activated kinase, JNK negatively 
regulates collagen expression by myofibroblasts [59]. Thus, JNK might contribute to the 
anti-fibrotic effects of MIF. Therefore, the ability of MIF to modulate JNK activity in 
HSCs of different activation states was investigated. Primary hepatic stellate cells were 
isolated from wildtype Balb/c mice and used as qHSCs at day one or as in vitro activated 
HSCs (aHSCs) at day seven after isolation (see Chapter 6.1.1). As JNK activation may 
occur rapidly while inactivation is likely to require some time, a short stimulation period of 
3 min and a longer period of 30 min were chosen. Whole cell lysates were analyzed by 
Western blot using a phospho-specific JNK antibody to detect JNK phosphorylation at 
Thr183 and Tyr185. Phosphorylation of these two residues is required for JNK activity 
[144]. Figure 2-27 shows a representative Western blot of lysates from one day old qHSCs 
that were stimulated with 100 ng/ml MIF after serum-starvation for 6-8 h. The blot shows 
increased band intensities of 54 kDa and 46 kDa JNK isoforms upon MIF stimulation. 
Interestingly, the 46 kDa protein seems generally to be stronger activated than the 56 kDa 
protein which is more obvious after 3 min than after 30 min. The bar diagram in 
Figure 2-27 summarizes the results from three independent experiments, that all showed 
the same tendencies. Band intensities were quantified by densitometry, adjusted to tubulin, 
which served as a loading control, and normalized to untreated controls (0 min). 
 
Figure 2-27: MIF-mediated JNK phosphorylation in qHSCs. Wildtype HSCs were used for the phosphoryla-
tion assay one day after isolation. Cells were stimulated with 100 ng/ml MIF for the indicated periods. Cell 
lysates were analyzed by Western blot using an anti-phospho-JNK antibody. Tubulin served as loading con-
trol. A representative blot is shown (left). Bars indicate mean values ± SEM of three independent 
experiments with cells from two independent cell isolations. 
The phosphorylation of JNK observed in qHSCs is likely to be associated with JNK ac-
tivity. In order to more directly analyze JNK activity, phosphorylation of the prototypical 
JNK substrate c-Jun was detected in the lysates of MIF-stimulated qHSCs. Active JNK 
readily phosphorylates Ser63 and Ser73 of c-Jun [144]. Phosphorylation of these residues 
was detected by using a phospho-specific antibody. As expected, c-Jun phosphorylation 
was increased by MIF stimulation. This effect was observed in lysates of cells that were 
stimulated with 100 ng/ml MIF for 30 min. Figure 2-28 shows a representative blot and 
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mean values of six independent experiments performed with HSCs derived from three 
independent cell isolations. On average, c-Jun phosphorylation was 2.5-fold higher in 
qHSCs stimulated with MIF for 30 min than in control cells. This effect was statistically 
significant.  
 
Figure 2-28: MIF-mediated c-Jun phosphorylation in qHSCs. Wildtype HSCs were stimulated with 
100 ng/ml MIF one day after isolation. Cell lysates were analyzed by Western blot using an anti-phospho-
c-Jun antibody. Tubulin served as loading control. A representative blot is shown (left). Bars indicate mean 
values ± SEM of six independent experiments with cells from three independent isolations (**p < 0.01). 
To investigate whether the observed MIF-mediated JNK activation is restricted to qHSCs, 
aHSCs were used for equivalent phosphorylation assays. The representative Western blot 
depicted in Figure 1-10 and the according bar diagram that summarizes three independent 
experiments, indicate that similarly to qHSCs, aHSCs respond to MIF stimulation by JNK 
phosphorylation. While the 46 kDa variant of JNK is rapidly phosphorylated, as observed 
in qHSCs, the phosphorylation status of the 54 kDa protein remains unchanged upon MIF 
stimulation. Possibly, this may be related to lower overall JNK activation by MIF in 
aHSCs compared to qHSCs. 
 
Figure 2-29: MIF-mediated JNK phosphorylation in aHSCs. Wildtype HSCs were used for the phosphoryla-
tion assay seven days after isolation without trypsinization. Cells were stimulated with 100 ng/ml MIF for the 
indicated time periods. Cell lysates were analyzed by Western blot using an anti-phospho-JNK antibody. 
Tubulin served as loading control. A representative blot is shown (left). Bars indicate mean values ± SEM of 
three independent experiments with cells from three independent isolations. 
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Two independent experiments showing increased c-Jun phosphorylation (Figure 2-30) sup-
port the assumption that MIF not only in qHSCs but also in aHSCs activates JNK. 
Moderately increased c-Jun phosphorylation was detected in lysates of MIF-stimulated 
cells for both stimulation periods.  
 
Figure 2-30: MIF-mediated c-Jun phosphorylation in aHSCs. Wildtype HSCs were stimulated with 100ng/ml 
MIF seven days after isolation. Cell lysates were analyzed by Western blot using an anti-phospho-c-Jun 
antibody. Tubulin served as loading control. A representative blot is shown (left). Bars indicate mean values 
of two independent experiments with cells from two independent HSC isolations. 
While the effects of MIF on JNK signaling in MFBs remain to be elucidated, the presented 
results indicate that MIF triggers activation of the JNK pathway in HSCs that display either 
the quiescent or the activated phenotype. However, the overall effect of MIF on JNK acti-
vation appears stronger in qHSCs than in aHSCs. At present, it can only be speculated 
about the functional relevance of these data as discussed in Chapter 3.3.1. 
2.6 Downstream targets of MIF in HSCs 
2.6.1 Microarray-based whole genome analysis 
Activation and transdifferentiation of HSCs is regulated by various cytokines, some of 
which trigger (e.g. TGF-β) and some of which inhibit (e.g. IFN-γ) HSC activation [4]. 
Considering its anti-fibrotic properties, MIF – besides regulating myofibroblast activity – 
could be involved in controlling the activation process of HSCs. In order to address this 
question and to identify novel MIF target genes that might help to explain the protective 
effect in liver fibrosis, microarray-based gene expression analysis was performed. For this 
purpose, three independent experiments were performed with primary Mif 
–/–
 HSCs that 
were treated according to the scheme represented in Figure 2-31 and as described in 
Chapter 6.3.4. In all three experiments, cells were left unstimulated as control (sample A) 
and stimulated daily with 200 ng/ml MIF (sample B). Transient stimulation with 200 ng/ml 
MIF for 30 min at day 1 (sample C) and day 5 (sample D) was only performed once, 
resulting in eight different samples in total. Cells were harvested at day 6 after isolation 
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and delivered to the Miltenyi Gene Expression Profiling Service for sample processing and 
microarray analysis (see Chapter 6.3.4). 
 
Figure 2-31: Schematic representation of the experimental setup to generate samples for microarray-based 
gene expression analysis. Treatments A, B, C, and D were performed in one experiment, A and B in two 
additional experiments. For each experiment, cells were pooled from three or four Mif 
–/–
 mice. 
Figure 2-32 shows a heat map that illustrates the correlation between the single samples. 
The data sets were correlated by hierarchical clustering with Euclidean distances. The 
sample tree shows higher variation between the experiments than between the different 
treatment groups, i.e. the gene data sets belonging to individual experiments, and thus 
originally derived from the same pool of cells, are more closely related than data sets of 
identically treated samples, e.g. the controls of the three experiments. 
 
Figure 2-32: Correlation between single samples. Samples of three independent experiments (II, III, IV) 
applied for four different treatments (A, B, C, D) were correlated by hierarchical clustering. The color 
scheme shows the degree of similarity with 1.0 being identical. 
In order to identify possible MIF target genes, primarily the comparison between the con-
trol group (A) and the daily stimulated group (B) was evaluated. Considering the high 
inter-experimental variation, the Miltenyi Gene Expression Profiling Service provided a 
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list of transcripts with a signal that is significant above background with p < 0.01 and 
regulated by at least 2-fold in at least two of the three experiments (two-of-three 
comparison). Table 2.2 shows this list of candidates after removal of non-coding, 
unclassifiable or hypothetical genes. Only one gene meets these conditions in all three 
experiments (highlighted in red). This gene encodes the G protein-coupled receptor 25 
(GPR25), an orphan receptor that has not further been studied. Other candidates that were 
identified by this approach and may be interesting in the context of liver fibrosis are 
Fam110c, Ahsg, and Hamp. The features of their encoding proteins in fibrosis and the 
potential relation to the protective effect of MIF will be discussed in Chapter 3.3.2. 
Table 2.2: Two-of-three comparison. The list comprises genes with a signal significant above background 
(p < 0.01) and a fold change (FC) > 2 that are similarly regulated in at least two of three experiments. Sam-
ples of MIF-stimulated (5 days, B) and control cells (A) of three independent experiments (II, III, and IV) are 
compared.  
SeqName Seqcode II FC III FC IV FC Full name 
Gpr25 A_55_P2081035 3.33 4.78 2.48 G protein-coupled receptor 25 (Gpr25) 
[NM_001101516] 
Glyctk A_55_P2096973 5.11 4.83 1.34 glycerate kinase (Glyctk), transcript 
variant 1 [NM_174846] 
Hamp A_52_P669922 -1.21 7.72 3.72 hepcidin antimicrobial peptide (Hamp) 
[NM_032541] 
Sds A_51_P249335 2.29 9.21 -5.13 serine dehydratase (Sds) [NM_145565] 
Synpo2 A_52_P223127 4.49 3.11 -1.25 synaptopodin 2 (Synpo2) [NM_080451] 
Bfsp2 A_51_P298802 3.72 5.30 -3.49 beaded filament structural protein 2, 
phakinin (Bfsp2) [NM_001002896] 
Apoc2 A_51_P334979 -2.40 -2.24 1.90 apolipoprotein C-II (Apoc2) 
[NM_009695] 
Prl7d1 A_51_P292196 -2.26 1.01 -3.48 prolactin family 7, subfamily d, member 
1 (Prl7d1) [NM_011120] 
Hoxc12 A_55_P2169099 -4.00 -4.89 3.22 homeobox C12 (Hoxc12) [NM_010463] 
Fgg A_51_P362176 -2.30 -1.44 -2.73 fibrinogen, gamma polypeptide (Fgg) 
[NM_133862] 
Ahsg A_51_P424854 -2.85 -2.29 -1.50 alpha-2-HS-glycoprotein (Ahsg) 
[NM_013465] 
Rhox2h A_55_P1984344 -1.62 -3.50 -2.08 reproductive homeobox 2H (Rhox2h) 
[NM_001100465] 
Olfr1500 A_55_P2065298 -1.40 -3.84 -2.93 olfactory receptor 1500 (Olfr1500) 
[NM_001011831] 
Fam110c A_52_P476731 -1.15 -6.23 -2.40 family with sequence similarity 110, 
member C (Fam110c) [NM_027828] 
Cyp3a11 A_55_P2121225 -8.25 3.57 -8.44 cytochrome P450, family 3, subfamily a, 
polypeptide 11 (Cyp3a11) [NM_007818] 
Syt6 A_55_P2121240 -1.50 -6.50 -6.50 synaptotagmin VI (Syt6) [NM_018800] 
Bcl11a A_55_P1958275 -3.88 -1.25 -11.42 B-cell CLL/lymphoma 11A (zinc finger 
protein) (Bcl11a), transcript variant 1 
[NM_016707] 
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Furthermore a mean value comparison of control samples (A) and daily MIF-stimulated 
samples (B) was used to identify target gene candidates. First, raw data were log2 trans-
formed, quantile normalized and median centered. The mean of the fold-change of all three 
experiments was calculated and statistically evaluated by a t-test. Filters were applied that 
select all candidates with p < 0.05 and a fold change > 1.5. Moreover, of the upregulated 
genes (B > A) only those candidates were selected that had a signal significant above 
background in the MIF-stimulated samples in at least two experiments, while in the control 
samples (A) all genes were tolerated independently on their signal intensity. This permitted 
the identification of genes that were baseline expressed in the control samples and higher 
expressed in the MIF-stimulated samples as well as genes that were induced upon MIF 
stimulation while not being significantly expressed in the control. Analyzing the down-
regulated genes (A > B), the filters were adjusted accordingly to ensure a significant signal 
in at least two control samples (A) while tolerating all signal intensities in the MIF-stimu-
lated samples (B). Figure 2-33 shows a heat map and hierarchical clustering of these 
filtered genes.  
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Figure 2-33: Hierarchical clustering and visualization of filtered data of the mean value comparison. The data 
set contains all genes whose mean values are up- or downregulated by at least 1.5-fold with p < 0.05 (t-test) 
and that are significant above background in at least two MIF-stimulated samples if upregulated and in at 
least two control samples if downregulated. Samples of daily MIF-stimulated (B, right half) and control cells 
(A, left half) of three independent experiments were compared. 
As applied for Table 2.2, non-coding, unclassifiable or hypothetical genes were removed 
from the list of filtered data. The resulting up- and downregulated candidate genes with 
their mean fold change are listed below in Table 2.3 and Table 2.4, respectively. 
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Table 2.3: Upregulated genes in the mean value comparison. The list comprises genes that are significantly 
upregulated (t-test; p < 0.05) with a mean fold change (FC) > 1.5 and a significant signal above background 
in at least two of the three MIF-stimulated samples. Samples of daily MIF-stimulated (B) and control cells 
(A) of three independent experiments are compared. 
SeqName Seqcode Full name FC 
Gpr25 A_55_P2081035 G protein-coupled receptor 25 (Gpr25) [NM_001101516] 3.52 
ENSMUST- 
00000106078 
A_55_P2063033 polyhomeotic-like 2 (Drosophila) [MGI:1860454] 
[ENSMUST00000133439] 
3.44 
Ryr1 A_52_P391110 ryanodine receptor 1, skeletal muscle (Ryr1) 
[NM_009109] 
3.09 
Ece2 A_55_P2033490 endothelin converting enzyme-2 homolog (Ece2) 
[AK031951] 
2.85 
Tmc2 A_51_P436521 transmembrane channel-like gene family 2 (Tmc2) 
[NM_138655] 
2.81 
Nepn A_51_P309530 nephrocan (Nepn) [NM_025684] 2.60 
Olfr48 A_51_P358787 olfactory receptor 48 (Olfr48) [NM_010990] 2.09 
Alms1 A_52_P240447 Alstrom syndrome 1 homolog (human) (Alms1) 
[NM_145223] 
2.06 
Snx25 A_55_P1957385 sorting nexin 25 (Snx25) [NM_207213] 2.05 
Bhmt A_55_P2103969 betaine-homocysteine methyltransferase [MGI:1339972] 
[ENSMUST00000124193] 
2.04 
Olfr417 A_55_P1952038 olfactory receptor 417 (Olfr417) [NM_207137] 2.00 
Foxo4 A_55_P2113026 forkhead box O4 (Foxo4) [NM_018789] 1.92 
Mylk3 A_55_P1990061 myosin light chain kinase 3 (Mylk3) [NM_175441] 1.89 
Zranb3 A_52_P6297 zinc finger, RAN-binding domain containing 3 (Zranb3) 
[NM_027678] 
1.83 
Paqr5 A_51_P258768 progestin and adipoQ receptor family member V (Paqr5) 
[NM_028748] 
1.83 
Snx31 A_51_P120388 sorting nexin 31 (Snx31) [NM_025712] 1.79 
ENSMUST- 
00000119760 
A_55_P2042606 plastin 1 (I-isoform) [MGI:104809] [ENSMUST- 
00000119760] 
1.78 
Il17re A_55_P2014427 interleukin 17 receptor E (Il17re), transcript variant 3 
[NM_001034031] 
1.77 
ENSMUST- 
00000112000 
A_52_P162500 DPH3 homolog (KTI11, S. cerevisiae) [MGI:1922658] 
[ENSMUST- 00000112000] 
1.74 
Zfp395 A_55_P2117590 zinc finger protein 395 (Zfp395) [NM_199029] 1.72 
Abt1 A_55_P2099860 activator of basal transcription 1 (Abt1) [NM_013924] 1.72 
Fam5b A_51_P504833 family with sequence similarity 5, member B (Fam5b) 
[NM_207583] 
1.69 
Mmp24 A_55_P2144372 matrix metallopeptidase 24 (Mmp24) [NM_010808] 1.64 
Tcrb-J A_55_P1986019 T-cell receptor beta, variable 5 [MGI:98583] 
[ENSMUST- 00000103266] 
1.62 
Zfp454 A_55_P2048775 zinc finger protein 454 (Zfp454) [NM_172794] 1.58 
Ifna7 A_55_P2030186 interferon alpha 7 (Ifna7) [NM_008334] 1.55 
Xkrx A_55_P2004746 X Kell blood group precursor related X linked (Xkrx) 
[NM_183319] 
1.55 
Fcrls A_52_P231075 Fc receptor-like S, scavenger receptor (Fcrls) 
[NM_030707] 
1.54 
Cd74 A_51_P284608 CD74 antigen (invariant polypeptide of major histo-
compatibility complex, class II antigen-associated) 
(Cd74), transcript variant 1 [NM_001042605] 
1.53 
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Gpr25 is the highest upregulated gene that meets the described selection criteria. Further 
upregulated genes that potentially mediate the protective effect of MIF in liver fibrosis are 
Nepn, Alms1, Bhmt, and the MIF receptor-encoding gene Cd74. On the other hand, there 
are genes in this list, which according to their profile or relationship to similar genes rather 
suggest pro-fibrotic activity. These are Ece2, Foxo4, Mylk3, Il17re and Mmp24. 
Table 2.4: Downregulated genes in the mean value comparison. The list comprises genes that are signifi-
cantly downregulated (t-test; p < 0.05) with a mean fold change (FC) > 1.5 and a significant signal above 
background in at least two of the three control samples. Samples of daily MIF-stimulated (B) and control 
cells (A) of three independent experiments are compared. 
SeqName Seqcode Full name FC 
Rgn A_51_P157462 regucalcin (Rgn) [NM_009060] -2.81 
Slc5a9 A_55_P2015650 solute carrier family 5 (sodium/glucose cotransporter), 
member 9 (Slc5a9) [NM_145551] 
-2.57 
Ahsg A_51_P424854 alpha-2-HS-glycoprotein (Ahsg) [NM_013465] -2.11 
Sdk2 A_51_P346565 sidekick homolog 2 (chicken) [MGI:2443847] 
[ENSMUST00000141943] 
-2.01 
Prss30 A_51_P241935 protease, serine, 30 (Prss30) [NM_013921] -1.84 
Nobox A_52_P291083 NOBOX oogenesis homeobox (Nobox) [NM_130869] -1.79 
Drd2 A_52_P529650 dopamine receptor D2 (Drd2) [NM_010077] -1.71 
Acot3 A_55_P2038347 acyl-CoA thioesterase 3 (Acot3) [NM_134246] -1.64 
Kcnrg A_55_P1980826 potassium channel regulator (Kcnrg), transcript variant 2 
[NM_206974] 
-1.62 
Spink13 A_55_P2155754 serine peptidase inhibitor, Kazal type 13 (Spink13) 
[NM_001168423] 
-1.55 
Pcdhb1 A_55_P2173288 protocadherin beta 1 (Pcdhb1) [NM_053126] -1.54 
Slc23a2 A_55_P2089025 solute carrier family 23 (nucleobase transporters), member 
2 [MGI:1859682] [ENSMUST00000127724] 
-1.53 
Among the downregulated genes especially Rgn may be an interesting candidate involved 
in the beneficial effect of MIF in liver fibrosis, while Ahsg rather is related to detrimental 
effects in liver disease. The functions or possible roles of these differentially regulated 
genes will be discussed in Chapter 3.3.2. 
Genes that typically are associated with fibrosis and HSCs activation, like Col1a1 or other 
collagens, Mmp2 and Mmp9, Timp1, and Tgf-β do not appear in any of the lists above. This 
might indicate that MIF does not considerably affect the major hallmarks of HSC activa-
tion when present during the activation process. Nevertheless, some of the other candidate 
genes may mediate a regulatory function of MIF on HSC activity. 
Candidate genes that were identified by the mean value comparison were assigned to gene 
ontology (GO) terms that describe biological processes. The numbers of differentially 
regulated genes that can be assigned to different groups of biological processes are 
represented in Figure 2-34. It is important to note that, on the one hand, not every gene is 
assigned to these GO groups and that, on the other hand, some genes may be related to 
several biological processes. While major processes to which MIF target gene candidates 
are assigned comprise cellular behavior, cellular processes, metabolism, organismal and 
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signaling processes, only some genes are related to structural processes, stress and signal-
ing mechanisms. 
 
Figure 2-34: Classification of differentially regulated genes in HSCs stimulated or not with MIF for 5 days to 
gene ontology annotations of biological processes. Any gene may be matched to no, one, or several GO 
terms. Numbers refer to the absolute numbers of genes that are assigned to each GO term. Data are derived 
from three independent experiments. 
Figure 2-35 shows the number of up- and downregulated genes (in red and green, respec-
tively) that are classified into more specific GO biological processes. 
Generally, more genes seem to be upregulated than downregulated by the presence of MIF 
during the transdifferentiation process. The classification of genes according to their func-
tion shows that these genes exert a variety of biological processes. The highest number of 
candidates is assigned to receptor signaling with further hits for G protein and 
kinase/phosphatase signaling. Also cell differentiation, cellular import/export and 
nucleotide metabolisms are affected by genes that were regulated by MIF in this experi-
ment. 
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Figure 2-35: Classification of differentially regulated genes in HSCs stimulated with or without MIF for 
5 days to more specific gene ontology annotations of biological processes. Any gene may be matched to no, 
one, or several GO terms. Numbers refer to the absolute numbers of genes that are assigned to each GO term. 
Data are derived from three independent experiments. 
Besides controlling the activation and transdifferentiation process of HSCs by permanent 
stimulation, MIF also may function as a trigger only in the early or only in the late phase of 
HSC activation. This was addressed by transient MIF stimulation of HSCs at day 1 
(sample C) or day 5 (sample D) after isolation. As only one experiment was performed that 
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included these two treatments in addition to the daily stimulation and control, it was not 
possible to apply statistics. Also the possibilities of filtering the data were restricted. 
Therefore, data from this experiment only serve to get a first impression about some poten-
tial MIF target genes. Lists of genes that were found differentially regulated upon any of 
the treatments compared to control can be found in the appendix. In these lists, non-coding, 
unclassifiable and hypothetical gene sequences were excluded as well as genes without a 
signal significant above background in the sample with higher signal intensity.  
Classification of these genes into biological processes according to GO terms is illustrated 
in Figure 2-36. The diagrams show that there are no major differences in the overall effects 
between permanent or transient stimulation of HSCs with MIF. This however, is only a 
very rough classification and further analysis will be needed to identify differential effects.  
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Figure 2-36: Classification of differentially regulated genes in primary MIF-stimulated HSCs to gene 
ontology annotations of biological processes. HSCs were stimulated daily for 5 days, transiently for 30 min 
at day 1 or transiently for 30 min at day 5 after isolation and compared to unstimulated control cells. Any 
gene may be matched to no, one, or several GO terms. Numbers refer to the absolute numbers of genes that 
are assigned to each GO term. Data are derived from one experiment that comprises the four different treat-
ments. 
2.6.2 Gpr25 expression 
One very promising candidate, which was identified by microarray analysis, is Gpr25. This 
gene was the only one identified by the two-of-three comparison that was regulated into 
the same direction with a fold change > 2 in all three experiments (Table 2.2). Further-
more, this gene was the highest regulated gene of those that met the criteria in the mean 
value comparison (Table 2.3). Expression of this gene was not identifiable by a signal 
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significant above background in the control samples whereas significant expression was 
detected in all three samples that were derived from daily MIF-stimulated HSCs and 
transiently stimulated HSCs at day 1 after isolation. Verification of the induction of Gpr25 
expression by qPCR was not possible due to the low expression levels and very limited cell 
numbers resulting in low RNA and cDNA concentrations. The expression values that were 
obtained from qPCR with the cDNA of activated HSCs were in a range that is prone to 
high variation and high noise and therefore not suitable for quantification. However, in 
RNA derived from freshly isolated quiescent HSCs, considerably higher amounts of Gpr25 
mRNA could be detected. The results of a single experiment with wildtype and Mif 
–/–
 
HSCs are depicted in Figure 2-37. Due to the extensive cellular changes HSCs undergo 
during the activation process, it is not clear whether Gapdh or any other frequently used 
housekeeping gene may serve as an appropriate reference. Therefore, relative Gpr25 
expression levels were calculated without referencing to any housekeeping gene. This 
calculation was based on the assumption that all samples had equal cDNA amounts as the 
same amounts of RNA were applied for cDNA synthesis. Both approaches led to the 
conclusion that quiescent HSCs express higher levels of Gpr25 than they do in their 
activated state. 
 
Figure 2-37: Relative gene expression of Gpr25 in quiescent and activated HSCs analyzed by qPCR. mRNA 
levels were analyzed in samples derived from wildtype and Mif 
–/–
 HSCs immediately after isolation (quies-
cent) and seven days after isolation (activated). Gapdh was used as reference (A) and relative levels were 
calculated without a reference gene assuming equal amounts of cDNA (B). For wildtype HSCs, one repre-
sentative experiment of two is shown. A single experiment was performed with Mif 
–/–
 cells. 
To extend this finding, GPR25 expression was also analyzed at the protein level. Western 
blot analysis was performed with lysates of freshly isolated and culture-activated wildtype 
and Mif 
–/–
 HSCs and is shown in Figure 2-38. The predicted size of GPR25 is about 
40 kDa. At this size, a distinct band is visible on the blot in all 4 lysates, which is likely to 
be the GPR25 band. The band intensities indicate that at the protein level, the 
downregulation during HSC activation is not apparent. 
56 2 Results 
 
Figure 2-38: Expression of GPR25 protein in quiescent and activated HSCs analyzed by Western blot. HSCs 
derived from Mif 
–/–
 or wildtype mice were either lysed immediately after isolation (quiescent) or cultured for 
7 days before lysis (activated). α-SMA proves activation of HSCs, tubulin serves as loading control. 
Taken together, Gpr25 remains an interesting candidate, which was identified by the 
microarray based approach. Further validation of MIF’s properties to induce Gpr25 
expression will need to be performed. So far, the data indicate a downregulation of Gpr25 
gene expression during HSC activation which is not reflected at the protein level in in vitro 
activated HSCs. Besides Gpr25, some of the other genes identified by microarray analysis 
will have to be analyzed concerning their possible role in mediating the anti-fibrotic 
activity of MIF. 
2.7 MIF-induced AMPK signaling in hepatocytes 
Recent data indicate that MIF, besides reducing fibrosis, has implications in hepatic me-
tabolism. In vivo studies suggest that in mouse models of fatty liver disease MIF reduces 
fatty acid accumulation [142]. As assumed for the anti-fibrotic effects of MIF, these effects 
on fatty acid metabolism may be mediated by AMPK. Furthermore, AMPK is involved in 
the regulation of priming and proliferation of hepatocytes, which contributes to resolution 
of hepatic fibrosis [25]. In view of this, it was of interest whether MIF not only in HSCs 
but also in hepatocytes activates AMPK signaling. Thus, Hepa 1-6 cells were chosen as 
model cells for hepatocytes to analyze AMPK phosphorylation in response to MIF stimu-
lation. Analysis of AMPK phosphorylation was performed by Western blot as described 
(Chapter 6.5.4 and 6.2.2). Figure 2-39 shows a representative Western blot and summa-
rizes densitometrically quantified band intensities of five independent experiments. As 
depicted, MIF dose-dependently increased phosphorylation of AMPK at Thr172 in serum-
starved Hepa 1-6 cells that were stimulated for 30 min. AMPK phosphorylation in these 
experiments was significantly increased upon stimulation with 100, 200, and 500 ng/ml 
MIF. Phosphorylation peaked at 200 ng/ml with 1.6-fold higher phosphorylation levels 
compared to unstimulated control cells. 
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Figure 2-39: Dose-dependent phosphorylation of AMPK in Hepa 1-6 cells. Hepa 1-6 cells were stimulated 
with recombinant MIF at the indicated concentrations or with 20 mM metformin for 30 min. Lysates were 
analyzed by Western blot for phosphorylation of AMPK at Thr172. Actin served as a loading control. A 
representative blot is shown. Bars indicate mean values ± SEM of five independent experiments (*p < 0.05, 
**p < 0.01). 
LKB1, CaMKK, and possibly TAK1 act as upstream kinases of AMPK [34]. To date, it is 
unknown, which of the kinases mediates MIF-induced AMPK activation. As LKB1 is the 
predominant activator of AMPK in the liver, LKB1 activation by MIF was investigated in 
Hepa 1-6 cells. Phosphorylation at Ser428 has been reported to be required for nuclear 
export and kinase activity of LKB1 [145]. For this reason, an anti-phospho-LKB1 antibody 
specific for Ser428 phosphorylation was used to analyze MIF-stimulated Hepa 1-6 cells. 
As for the detection of AMPK phosphorylation, cells were stimulated with different 
concentrations of MIF for 30 min. However, no dose-dependent LKB1 phosphorylation in 
response to MIF stimulation was detected. Metformin only moderately and non-signifi-
cantly increased Ser428 phosphorylation. Figure 2-40 shows a representative blot and a bar 
diagram summarizing relative phosphorylation levels of four independent experiments.  
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Figure 2-40: Phosphorylation of LKB1 in Hepa 1-6 cells upon stimulation with increasing MIF concentra-
tions. Hepa 1-6 cells were stimulated with MIF at the indicated concentrations or with 20 mM metformin for 
30 min. Phosphorylation of LKB1 at Ser428 was detected by Western blot. Actin served as a loading control. 
A representative blot is shown. Bars indicate mean values ± SEM of four independent experiments. 
The optimal stimulation period to obtain increased LKB1 phosphorylation may differ from 
the one for AMPK phosphorylation. Since upstream kinase activity is required prior to 
activation of AMPK itself, it was assumed that LKB1 may be activated more rapidly than 
AMPK. However, stimulation with recombinant MIF at a concentration of 100 ng/ml for 
5 – 60 min did not result in stronger phosphorylation of LKB1 for any of the tested periods 
(Figure 2-41).  
 
Figure 2-41: Phosphorylation of LKB in Hepa 1-6 cells upon MIF stimulation for various time periods. 
Hepa 1-6 cells were stimulated with 100 ng/ml MIF for the indicated periods. Cell lysates were analyzed for 
LKB1 phosphorylation at Ser428 by Western blot. Actin served as a loading control. A representative blot is 
shown. Bars indicate mean values ± SEM of four independent experiments. 
Thus, MIF dose-dependently induces AMPK phosphorylation in hepatocytes. AMPK 
activation presumably is independent on LKB1 as no phosphorylation at the Ser428 
residue was observed. Whether CaMKK, TAK1 or any other so far unknown upstream 
kinase are the missing link between MIF and AMPK remains to be investigated. 
 3 Discussion 
3.1 The origin of hepatic MIF 
Hepatic MIF expression is found in healthy tissue and is upregulated during inflammation 
and chronic liver diseases. In the healthy liver, a pericentral expression pattern of MIF has 
been reported, i.e. hepatocytes surrounding the central vein express MIF while only minor 
levels were found in hepatocytes adjacent to the portal vein [73, 129]. Hepatocytes express 
enhanced MIF levels in patients with hepatocellular carcinoma, liver cirrhosis, and alco-
holic and non-alcoholic fatty liver disease. Kupffer cells and infiltrating immune cells as 
well as endothelial cells increase MIF expression in diverse liver disorders [122, 130-132]. 
Furthermore, MIF is upregulated in fibrotic livers of thioacetamide-treated rats [134]. So 
far, no reports exist about MIF levels in CCl4-induced liver fibrosis. Considering the ele-
vated MIF levels in a wide range of inflammation-related disorders and chronic hepatic 
disorders, and the upregulation of MIF expression in in vitro activated HSCs [146], it is 
assumed that experimental liver fibrosis in mice induced by CCl4 administration will result 
in an increase in hepatic MIF as well. Experimental evidence, however, is still lacking. The 
considerably different fibrotic responses of Mif-expressing versus -deficient mice to TAA 
and CCl4 administration (Chapter 1.4) prove a functional protective role for MIF in liver 
fibrosis. As functional relevance is likely to be related to altered expression, these data 
further allow the assumption that MIF is upregulated in CCl4- and TAA-induced liver 
fibrosis in mice. 
In TAA-induced liver fibrosis, MIF expression was traced back to degenerated hepatocytes 
that were present not within but in proximity to fibrotic areas [134]. Besides this, no data 
are published to date that clarify the origin of hepatic MIF in experimental liver fibrosis. 
Thus, this project aimed to identify possible sources of MIF in the liver. Therefore, the 
three major hepatic cell populations that are implicated in fibrogenesis, i.e. hepatocytes, 
Kupffer cells and hepatic stellate cells, were characterized concerning their ability to pro-
duce and release MIF in response to a range of stimuli. For each of these cell types, the 
observed characteristics are discussed separately below. 
3.1.1 Hepatocytes release MIF upon cytokine stimulation or cell 
damage 
Hepatocytes were exposed to TGF-β, TNF-α, IFN-γ, IL-6, H2O2, ethanol or CCl4 
(Chapter 2.1.2). The most evident response of hepatocytes was observed when cells were 
treated with CCl4. Primary mouse hepatocytes released high amounts of MIF in response to 
CCl4 within 30 min. Similarly, CCl4 was the strongest inducer of MIF release after 20 h of 
stimulation. Supporting evidence arose from experiments with the hepatoma cell line 
Hepa 1-6. These cells likewise released enhanced levels of MIF into the supernatants 
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during incubation periods of 30 min and 20 h. CCl4 is a strong hepatotoxin which is 
frequently used in mouse models of chronic liver injury. CCl4 toxicity is based on the 
formation of a trichloromethyl radical, which can either directly react with lipids and 
proteins or be peroxidized. The trichloromethylperoxy radical initiates a chain reaction that 
results in lipid peroxidation. In this way, membrane integrity is disturbed [147]. In vitro, 
concentrations of 0.1-0.2 mM, achieved by allowing diffusion of CCl4 from the gas phase 
into the medium, have been described as suitable concentrations to induce cellular 
alterations that are comparable to the in vivo situation [148]. A second mechanism of CCl4 
toxicity has been identified that is directly related to the solvent properties of CCl4. Partly 
reversible solvent injury occurs more rapidly especially at higher concentrations of 10 mM 
and above and may be followed by lipid peroxidation [149]. In the described experiments, 
hepatocytes were exposed to CCl4 at a final concentration of 100 mM. Thus, increased 
MIF release in response to CCl4 stimulation is very likely related to a loss of membrane 
integrity and hepatocyte damage. This assumption was supported by positive PI staining of 
a majority of cells and increased LDH concentrations in the supernatants. Both indicate a 
loss of membrane integrity, as PI does not enter viable intact cells and LDH is retained in 
the cytoplasm of intact cells. CCl4 is poorly soluble in aqueous solutions and was insoluble 
at the applied concentration. Accordingly, CCl4 droplets were visible at the bottom of the 
multiwell dishes (see Figure 2-5). Therefore, it must be assumed that local concentrations 
of CCl4 were considerably higher or lower. After 20 h of stimulation, the lysates of CCl4-
stimulated cells contained higher MIF levels than control cells. This indicates that CCl4 did 
not entirely cause cell death, but rather reversible damage in a considerable number of 
cells. Additionally, these data suggest that de novo synthesis of MIF in CCl4-damaged 
hepatocytes is induced. Alternatively, degradation of MIF might be inhibited by CCl4 
through an unknown mechanism, which increases protein turnover and subsequent 
accumulation. To identify the origin of hepatic MIF in hepatotoxin-induced liver injury, it 
is rather negligible whether CCl4-induced MIF release is related to cell death or to 
reversible damage. The generally high numbers of hepatocytes in the liver and the high 
numbers of damaged or dying hepatocytes upon hepatotoxin treatment provide a large pool 
of MIF that subsequently may contribute to the regulation of fibrotic processes. 
Nevertheless, in order to understand the underlying mechanism, including the increase in 
intracellular MIF in CCl4-stimulated hepatocytes, it will be necessary to apply lower 
concentrations of CCl4 and in detail analyze the cellular responses of hepatocytes 
concerning MIF expression and secretion. 
Besides responding to CCl4, primary hepatocytes increased MIF release in response to all 
other tested stimuli, of which TGF-β, IFN-γ, H2O2, and ethanol caused significant eleva-
tions of MIF in the supernatants. TGF-β and IFN-γ induce apoptosis in hepatocytes [15, 
150] and ethanol and H2O2 may have toxic effects. However, no elevated LDH levels were 
measured in the supernatants of stimulated cells. Furthermore, ethanol was used at non-
toxic concentrations (150 µM ≈ 0.001%) and also H2O2 (100 µM) was applied at concen-
trations below those causing apoptotic or necrotic cell death in isolated hepatocytes [151]. 
Therefore, cell death as a cause for elevated MIF levels in the supernatants can be ruled out 
for these stimuli. Instead, the data suggest that pro-apoptotic stimuli as well as ethanol and 
oxidative stress trigger active secretion of MIF from hepatocytes. Considering the chemo-
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tactic properties of MIF this may trigger immune cell recruitment as an early event as 
discussed in Chapter 3.3. However, no changes in immune cell infiltration were detected in 
either of the hepatotoxin-induced fibrosis models after 6 weeks (Chapter 1.4). The 
responsiveness of hepatocytes to various stimuli with rather detrimental effects might 
provide a protective feedback mechanism to limit liver injury and fibrosis progression.  
When comparing the responsiveness of primary hepatocytes with the murine cell line 
Hepa 1-6, primary hepatocytes seem to be more sensitive concerning MIF release upon 
stimulation. Significantly elevated MIF levels were only found in supernatants of Hepa 1-6 
cells that were exposed to CCl4, but not to any other stimuli. As for primary hepatocytes, 
these were accompanied by elevated LDH concentrations in cell culture supernatants. 
Generally, low MIF levels were measured in cell culture supernatants and lysates of 
Hepa 1-6 cells. These were close to the detection limit of the ELISA and about 30 times 
lower than in primary hepatocytes. As Hepa 1-6 cells are mouse-derived hepatoma cells, 
this is in contrast to a study by Akbar et al. in which elevated MIF levels were found in 
hepatocytes of patients with liver cirrhosis and hepatocellular carcinoma [122].  
3.1.2 Kupffer cells release MIF in response to oxidative stress 
Macrophages are a well described source of MIF [74, 76] and Kupffer cells, as the resident 
macrophages of the liver, play an important role in the inflammatory and fibrotic processes 
upon liver injury. Therefore, it was assumed that activated Kupffer cells may contribute to 
hepatic MIF levels in hepatotoxin-induced liver injury. It is known that TNF-α and IFN-γ 
stimulate MIF secretion from murine macrophages while IL-6 does not [74]. These factors 
are released upon liver injury and exert regulatory functions in the fibrotic response. The 
potential of TNF-α, IFN-γ, and IL-6 to MIF secretion from Kupffer cells was tested using 
the Kupffer cell line KC 13-2 (see Chapter 2.1.3). Neither after 6 h nor after 20 h was in-
creased secretion of MIF measured upon stimulation with any of these cytokines. 
Unexpectedly, LPS, which is known to promote the release of MIF from macrophages [74] 
and to induce Mif gene expression in Kupffer cells in vivo [73], did not trigger MIF secre-
tion by KC 13-2 cells. Differentiated macrophages are very sensitive to low LPS concen-
trations but tend to decrease MIF secretion at higher concentrations [74, 152]. To exclude 
this effect, three different LPS concentrations, 0.01 µg/ml, 0.1 µg/ml, and 1 µg/ml, were 
applied for the stimulation period of 20 h. While these concentrations promote MIF release 
from differentiated THP-1 macrophages, from murine peritoneal macrophages, and weakly 
from RAW 264.7 cells [74, 152], none of the concentrations promoted MIF secretion in 
KC 13-2 cells. Of note, KC 13-2 cells express TLR4 and CD14. LPS binding, however, 
appears to be TLR4- and CD14-independent [153]. 
Simultaneously, the potential of H2O2 to induce MIF release was tested. Increased secre-
tion upon H2O2 stimulation was expected, because hydrogen peroxide-induced secretion 
had been shown before in macrophages and also in endothelial cells [154, 155]. Stimula-
tion of KC 13-2 cells with 100 µM H2O2 resulted in significantly increased MIF secretion 
after 6 h and increased MIF secretion after 20 h, which due to high inter-experimental 
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variation was not significant. H2O2 at a concentration of 100 µM is not toxic to 
macrophages [154] and measurement of LDH activity in the cell culture supernatants did 
not suggest cellular death as the cause for elevated MIF levels. This indicates that KC 13-2 
cells specifically release MIF under hyper-oxidative conditions. 
KC 13-2 cells have been generated and characterized as a clonal murine Kupffer cell line 
derived from transgenic mice expressing the thermolabile mutant tsA58 of the simian virus 
(SV) 40 large T antigen under the control of the H-2K
b
 promoter [153]. This cell line, in 
contrast to primary Kupffer cells, is supposed to represent a homogeneous cell population. 
During this work, however, two morphologically distinct populations were observed. How 
these two populations differ from each other remains to be analyzed. In general, KC 13-2 
cells are a helpful model to study Kupffer cell behavior. Nevertheless, the clonal nature of 
KC 13-2 cells in contrast to the heterogeneity of primary Kupffer cells concerning size and 
behavior [156, 157] makes a generalization of the obtained results difficult. The observed 
lacking response of KC 13-2 cells to LPS and IFN-γ stimulation concerning MIF secretion 
is in accordance with the inability of these cells to release TNF-α, IL-6, and IL-10 in re-
sponse to LPS and IFN-γ [153]. Thus, Kupffer cells might generally be less active in se-
creting cytokines compared to other macrophages. On the other hand, differences in cyto-
kine secretion have been found between different Kupffer cell populations [156, 157]. 
Therefore, it is not yet possible to conclude whether the observed MIF secretion profile 
with a lacking response to LPS, TNF-α, and IFN-γ and sensitivity towards oxidative stress 
is a specific characteristic of the KC 13-2 cell line or a general Kupffer cell characteristic. 
Additional experiments with primary Kupffer cells will help to address this question. So 
far, only a pilot experiment has been performed using Kupffer cells derived from a crude 
preparation from rat liver, which resulted in undetectable MIF levels, presumably due to 
low numbers of viable cells per well. Optimization of the experimental conditions is there-
fore required. 
3.1.3 Hepatic stellate cells are a differentially regulated source of 
hepatic MIF 
So far, there are no reports in the literature that identify hepatic stellate cells as MIF-
secreting cells. Skin and foreskin fibroblasts, however, secrete MIF in response to a variety 
of stimuli [158-160]. In TAA-induced liver fibrosis in rat, MIF is only detectable adjacent 
to fibrotic areas but not within these fibrotic areas, which usually harbor the highest num-
bers of activated myofibroblasts [134]. Nevertheless, MIF may have been released from 
pre-stored pools or upon de novo synthesis at earlier stages of fibrosis. The secretion 
assays with the hepatic stellate cell line GRX, presented in Chapter 2.1.4, revealed that 
there were no significant changes in MIF secretion upon application of various stimuli for 
6 h. After 20 h, significantly higher MIF levels were detected upon TNF-α stimulation and 
significantly decreased secretion upon TGF-β and PDGF stimulation. For TGF-β and 
PDGF, a non-significant tendency to downregulate MIF can already be seen after 6 h. Mif 
gene expression was not inhibited by TGF-β and PDGF after 20 h. A mere block of MIF 
release is unlikely to cause this effect as this would result in accumulation of intracellular 
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MIF. Increased intracellular levels were, however, not detected. Another possibility is the 
promotion of MIF destabilization or degradation by so far unknown TGF-β- and PDGF-
triggered pathways. The decreased induction of MIF secretion upon simultaneous applica-
tion of TGF-β and TNF-α compared to sole TNF-α stimulation would fit into this 
conception. According to this idea, TNF-α would increase MIF release while TGF-β would 
promote degradation, which in the end results in lowered extracellular MIF levels. 
What the distinct regulation of MIF secretion by TGF-β, PDGF and TNF-α means in the 
context of the highly complex fibrogenesis regulating network, is unclear. While TGF-β 
and PDGF are pro-fibrotic mediators that dominantly control HSC activation and transdif-
ferentiation, TNF-α has pro- and anti-fibrotic properties. Considering the inhibition of 
collagen production by TNF-α, TNF-α-dependent MIF release may be part of a protective 
feedback loop as MIF in turn is capable of promoting TNF-α release from macrophages 
[74]. Such a feedback loop of MIF and TNF-α has already been proposed in the context of 
their respective pro-inflammatory activities [161]. 
Interestingly, when GRX cells were treated with retinol for 96 h to induce the fat-storing 
quiescent-like phenotype, the effect of TGF-β differed from its effect on GRX cells cul-
tured under standard conditions. After 6 h, TGF-β non-significantly decreased MIF expres-
sion in GRX cells, while the level of MIF secreted from qGRX cells was non-significantly 
increased. This indicates that HSCs may alter their response to cytokine stimulation con-
cerning the release of MIF dependent on their activation status. Further experiments will be 
needed to analyze the differences in more detail. It has to be noted that it is difficult to re-
producibly retro-transdifferentiate GRX cells into qGRX cells. The system is highly 
susceptible to changes in cell numbers, medium volumes and incubation times and even 
when conditions are kept as constant as possible, including aliquoting and storage of reti-
nol under low oxygen and protected from light, the heterogeneity of the resulting popula-
tion varies considerably. Considering the limited number of primary quiescent HSCs that 
can be harvested from mice, retro-transdifferentiation of GRX cells nevertheless provides a 
helpful tool to further investigate differential MIF expression and secretion in myofibro-
blastic and fat-storing HSCs. 
Taken together, hepatocytes are triggered to release MIF by apoptotic and hepatotoxic 
stimuli in vitro. Presumably, this is of (patho-)physiological relevance as hepatocyte 
damage is one of the early events in hepatotoxin-induced liver injury. KC 13-2 cells, 
representing the resident macrophages of the liver, release MIF in response to oxidative 
stress, which is a typical hallmark of liver fibrosis and associated with CCl4- and TAA-
induced liver injury. Therefore, both cell populations may considerably contribute to he-
patic MIF levels during fibrogenesis. MIF release from HSCs is regulated in a more 
complex manner with partly opposed effects, depending on the stimulus and the 
transdifferentiation state of the cells. Possibly, this fine-tuned response is related to local 
differences in MIF concentrations, which may contribute to the differential regulation of 
cellular behavior by MIF. These findings are schematically represented in Figure 3-1. 
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Figure 3-1: Schematic summary of stimuli that trigger MIF release from hepatocytes, Kupffer cells and 
hepatic stellate cells in vitro. 
3.2 Hepatic cells display different MIF receptor profiles 
The MIF receptors CD74, CXCR4 and CXCR2 are differentially expressed by a broad 
range of cells. CD74 is mainly expressed by professional antigen presenting cells and sur-
face-exposed in combination with MHC class II proteins. However, also non-classical pro-
fessional antigen presenting cells, e.g. epithelial cells or subepithelial myofibroblasts, 
express CD74, which does not necessarily have to be related to MHC class II expression 
[84]. CXCR4 is almost ubiquitously expressed while CXCR2 expression is largely but not 
exclusively restricted to cells of the immune system, especially neutrophils and mono-
cytes/macrophages [90]. Responsiveness of different cells to MIF stimulation and the ef-
fects on cellular behavior are partly regulated by receptor expression profiles and possibly 
by homo- or heteromeric complex formation of MIF receptors. 
Almost all hepatic cells that were analyzed by flow cytometry, i.e. Hepa 1-6 cells, KC 13-2 
cells, GRX cells and primary activated HSCs, show surface exposition of CD74. This 
finding was additionally verified by Western blot analysis (Chapter 2.2). Therefore, it can 
be assumed that they all are potential MIF target cells. Only on freshly isolated quiescent 
HSCs, CD74 surface expression could not be detected, along with a negative signal for 
CXCR2 and CXCR4. Possibly, this is biased by the exposure to enzymes or by receptor 
internalization due to cellular stress during the isolation procedure. Flow cytometry analy-
sis of qGRX cells also revealed the absence of surface CD74 in most cells. Only a small 
population of about 15% displayed a positive signal. This suggests reduced or absent 
surface expressed CD74 by fat-storing HSCs. Nevertheless, intracellular CD74 is also 
present in those cells, as Western blot analysis with qGRX lysate showed distinct bands at 
the expected molecular weight. Conceivably, in quiescent HSCs further triggers are needed 
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to transfer CD74 to the cell surface. Whether this also modifies the responsiveness of 
HSCs to MIF stimulation so far is unclear. Expression of CD74 by activated HSCs is in 
accordance with previous findings. Maubach et al. showed CD74 expression in primary 
activated rat HSCs and HSC cell lines, which is further upregulated upon IFN-γ 
stimulation along with other components required for antigen presentation [162].  
CXCR4 is expressed by all tested hepatic cells. Surface expression, however, was only 
detected on GRX cells. Whether this is representative of the physiological status of HSCs 
is uncertain. Possibly, the hepatic microenvironment and heterogeneous cell-cell contact 
favors surface expression of CXCR4. On the other hand, it is possible that normal culture 
conditions using media supplemented with 10% FCS, as it was used in this work, partly 
suppress CXCR4 surface expression. It was reported that serum-starvation promotes 
CXCR4 surface expression (personal communication: J. Bernhagen et al. and [163]). As 
the exact composition of FCS is largely undefined, it is not possible to conclude whether 
serum starvation or supplementation with 10% FCS is more closely related to the normal 
microenvironmental conditions of a certain cell tested for receptor expression. Intracellular 
abundance of CXCR4 has frequently been shown. Taken together, the presence of CXCR4 
in all cell lysates indicates that all tested hepatic cells potentially may respond to MIF 
stimulation in a CXCR4-dependent manner.  
In contrast to the detection of CD74 and CXCR4, it was not possible to identify any 
CXCR2-expressing hepatic cells in this work. Surface expression of CXCR2 on any tested 
cell system was either too low to be measured (murine bone marrow derived cells showed 
a considerable shift in flow cytometry, data not shown) or not present at all. Due to a lack 
of a specific mouse CXCR2 antibody that proved suitable for Western blot application, the 
presence of CXCR2 in the lysates could not be analyzed. Flow cytometry analysis of per-
meabilized cells may provide further information about CXCR2 expression by HSCs, 
Kupffer cells and hepatocytes. In line with the literature, it is likely that GRX and Hepa 1-6 
cells express this receptor. Cxcr2 is constitutively expressed in rat HSCs during activation 
[164]. Furthermore, CXCR2 gene expression in the human HSC cell line LX-2 was re-
ported [165]. Also in hepatocytes, Cxcr2 transcription has been detected and functionally 
related to the regulation of hepatocyte proliferation and liver regeneration [166, 167]. 
3.3 HSCs mediate the protective effect of MIF in experi-
mental liver fibrosis 
Initially, it was assumed that MIF was likely to increase immune cell infiltration and 
subsequently elevate inflammation and fibrogenesis. In fact however, the in vivo 
experiments applying Mif 
–/–
 and wildtype mice in CCl4- and TAA-induced liver fibrosis 
showed that MIF had a beneficial effect in these two mouse models. Pharmacological 
application of recombinant MIF in CCl4-induced liver fibrosis, which reduced the fibrotic 
response, provided further evidence (Chapter 1.4 and 2.3). This was in clear contrast to the 
initial hypothesis. Moreover, immune cell infiltration was comparable between Mif 
–/–
 and 
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wildtype mice in both experimental models. This does not exclude altered immune cell 
recruitment as a very early event, as immune cell infiltration was not analyzed at early time 
points. Altered immune cell infiltration might be measurable druing the first days or weeks 
of hepatotoxin administration. If indeed MIF promotes early immune cell recruitment, this 
either does not play a major role in fibrosis development or may be counter-balanced by 
the protective effect of MIF as the outcome of fibrosis is clearly worsened instead of 
ameliorated in Mif-deficient mice. Similarly, in α-naphthylisothiocyanate (ANIT)-induced 
liver injury the rate of neutrophil infiltration, which is reduced in Cxcr2-deficient mice, 
does not affect the degree of injury and fibrosis [168]. 
The elevated expression of the fibrosis- and myofibroblast activity-associated genes 
Col1a1, Mmp2, Timp1, and Tgf-β in Mif –/– mice in both models of hepatotoxin-induced 
liver fibrosis indicates a role for HSCs mediating the beneficial effect of MIF rather than 
immune cells (Chapter 2.3). Higher levels of α-SMA in CCl4-treated Mif 
–/–
 mice and lower 
levels in CCl4- and MIF-treated wildtype mice further support this assumption. The regu-
lation of myofibroblast activity by MIF may include indirect effects that generally reduce 
HSC-activating microenvironmental factors, such as discussed in Chapter 3.4, but also 
comprise the direct regulation of HSC behavior by modulating signaling events as dis-
cussed below. 
3.3.1 Signaling pathways regulating fibrotic activity 
The protective effect of MIF in experimental liver fibrosis, which was associated with re-
duced markers of myofibroblast activity, was surprising considering the detrimental effects 
of MIF in many acute and inflammatory diseases. Yet, MIF had been shown to exert bene-
ficial effects in different contexts as well. As such, MIF protects the heart during 
ischemia/reperfusion injury by increasing glucose uptake through activation of the AMPK 
pathway [104]. The protective effect of MIF in liver fibrosis is, at least partly, mediated by 
AMPK as well. MIF stimulation dose-dependently increased AMPK phosphorylation in in 
vitro transdifferentiated Mif 
–/–
 myofibroblasts. Functionally, MIF-dependent AMPK activ-
ity was linked to the inhibition of PDGF-induced proliferation and migration of GRX cells, 
as the inhibitory effect of MIF was blocked upon usage of the AMPK inhibitor com-
pound C (Chapter 2.4). The role for AMPK as a protective regulator of fibrogenesis is 
widely known and has been linked to its inhibitory function on PDGF-induced HSC activ-
ity when activated, e.g. by adiponectin, AICAR or metformin [31, 44]. Activated AMPK 
furthermore inhibits TGF-β-induced Col1a1 and α-Sma expression and IL-1-dependent 
release of MCP-1 [31, 45]. Pilot experiments with GRX cells and primary HSCs did not 
show convincing changes in gene expression of the fibrosis markers Col1a1 and α-Sma 
after MIF stimulation for 6 h and 24 h (data not shown). These experiments, however, will 
have to be repeated. Beyond this, further analysis with co-stimulated GRX cells applying 
PDGF, TGF-β, or IL-1 together with MIF will be helpful to further characterize the effects 
of the MIF/AMPK pathway in HSCs. 
Another signaling pathway possibly linking the regulation of fibrogenesis and MIF activity 
is the JNK pathway. JNK signaling promotes liver fibrogenesis in vivo and triggers early 
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HSC activation in vitro by inducing α-SMA expression and HSC proliferation. At the same 
time, JNK mediates suppression of collagen expression, especially at early stages of HSC 
activation [58, 59]. The effect of MIF on JNK activity varies contextually. Both activation 
and inhibition of JNK phosphorylation by MIF have been reported and it has been assumed 
that pre-stimulated or stressed cells rather tend to downregulate JNK activity in response to 
MIF while activation occurs in resting cells [101, 102]. In this work, a rapid induction of 
JNK phosphorylation in primary qHSCs, resulting also in phosphorylation of the JNK 
substrate c-Jun, was shown. Similarly, but less pronounced, MIF rapidly induced JNK 
phosphorylation in 7 days old aHSCs. In both qHSCs and aHSCs the phosphorylation of 
the 46 kDa protein was considerably stronger than that of the 54 kDa JNK isoform. 
Whether or not differential phosphorylation of the JNK isoforms in HSCs affects different 
downstream signaling events is unknown so far. Moreover, the functional relevance of 
MIF-dependent activation of JNK in HSCs remains uncertain. Inhibition of JNK activity in 
quiescent HSCs was reported to decrease expression of α-Sma and to increase expression 
of Col1a1 while the effect was less profound in activated HSCs [59]. This suggests that 
JNK activation in quiescent HSCs results in activation but also diminishes the extent to 
which HSCs contribute to scar formation. Although this effect in itself is ambiguous 
concerning its role in fibrosis regulation, it may represent a further mechanism that 
contributes to the protective effect of MIF by reducing the release of collagen from HSCs. 
So far, the effect of MIF on JNK signaling in myofibroblastic HSCs has not been 
elucidated. According to the model that MIF exerts opposite effects on stimulated and 
resting cells, MIF may inhibit JNK signaling in MFBs instead of activating the pathway. 
Inhibition of JNK signaling results in reduced HSC/MFB proliferation at all stages of 
activation [59]. Thus, MIF might reduce the overall number of MFBs in the fibrotic liver 
not only through AMPK but additionally through JNK signaling. However, in order to get 
a more detailed insight into the role of the MIF/JNK axis and to find out whether this 
pathway at all is linked to the beneficial activity of MIF liver fibrosis further experiments 
will have to be performed. 
3.3.2 MIF target genes as potential mediators 
The microarray-based gene expression analysis comparing in vitro-activated MIF-stimu-
lated and unstimulated HSCs sought to identify, by an unbiased approach, novel MIF 
target genes and potential mediators of the protective effect of MIF in liver fibrosis. 
Expecting increased responsiveness to exogenous MIF and therefore more pronounced 
effects, Mif 
–/–
 cells were chosen for this approach instead of wildtype cells. Wildtype cells 
might be less sensitive to MIF stimulation due to endogenous MIF. Daily stimulation of 
HSCs with or without MIF during their activation in cell culture was supposed to simulate 
the presence or absence of MIF during the progression of liver fibrosis, e.g. in Mif 
–/–
 or 
wildtype livers. The chosen in vitro approach provides a simplified model to analyze MIF-
dependent gene expression during the activation process of HSCs. Considering the long 
incubation period the observed effects may include the regulation of primary and 
secondary target genes as well as subsequently affected genes. In addition to the daily 
stimulations, transient stimulations for 30 min at day 1 and day 5 after HSC isolation were 
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performed with the aim to get a first idea whether there are more pronounced effects of 
MIF at early or later stages of HSC activation. As can be seen from the correlation analysis 
in Chapter 2.6.1, samples of the same experiment derived from HSCs upon daily 
stimulation and transient stimulation at day 1 show highest similarity. Thus, translated to 
the in vivo situation, the behavior of HSCs appears to be the same in the case of an early 
peak of MIF release from other hepatic or infiltrated cells or in the case of constantly high 
MIF levels during fibrogenesis. According to the sample tree, HSCs transiently stimulated 
at day 5 mostly differ from all other samples. This could mean that the effect of MIF is 
highest in already activated cells. However, the handling of this sample reflects a drawback 
of the chosen experimental conditions. While in all samples half of the cell culture 
supernatant was replaced by fresh medium every day, the transient stimulation at day 5 
made it necessary to remove the medium completely after 30 min in order to remove all 
residual MIF that might stimulate the cells beyond this period. Inevitably, in this case also 
autocrine factors were removed at the last day before harvest, while in all other samples, 
including the control sample, some autocrine factors remained in the cell culture 
supernatants. This may have influenced the gene expression profile of these cells in 
addition to the specific MIF effects. This experimental drawback did not apply to the day 1 
stimulated sample as medium of all cells was completely renewed at day 1. Furthermore, 
cells stimulated at day 5 were analyzed for gene expression only 24 h after stimulation, 
while in all other treatments the period between either transient stimulation or initial 
stimulation and cell harvest was much longer. Effects that are observed in the cells 
stimulated at day 5 may thus have been present also in all other MIF-stimulated cells but 
disappeared over time.  
The Euclidean distances between the A and B samples, i.e. control and daily stimulated 
cells, are comparable in two of the three experiments, while being smaller in the third 
experiment. This means that the overall effect of MIF was lower in this experiment. 
Whether this was caused by lower bioactivity of the applied MIF or by lower 
responsiveness of the cells for unknown reasons is impossible to conclude. The closer re-
lationship of samples within a single experiment, i.e. within the same pool of cells, than of 
the replicates makes it difficult to draw unambiguous conclusions. Nevertheless, the lists of 
candidate genes, which will have to be verified by qPCR, may be helpful as a first insight 
into the regulatory functions of MIF in HSCs. Moreover, the given circumstances may 
even increase the probability that selected candidates, being similarly regulated despite the 
high experimental variations, will prove true MIF target genes with physiological 
relevance. 
The most interesting gene being identified by the gene expression analysis is Gpr25. It is 
not only the highest regulated gene in the mean value comparison with a mean fold change 
of 3.5, but also the only gene meeting the requirements of the two-of-three comparison, i.e. 
being significantly expressed and regulated by at least 2-fold into the same direction, in all 
three experiments. Furthermore, Gpr25 is not significantly expressed in any of the control 
samples while being significantly expressed in all daily MIF-stimulated samples. Also the 
cells stimulated transiently at day 1 upregulated Gpr25 by 2-fold. The overall level of 
Grp25 mRNA in the MIF-stimulated samples was relatively low. For this reason, the 
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verification of the microarray-derived result by qPCR was not possible. In qPCR, the 
fluorescence signal did not increase before cycle 30 of the PCR reaction, which is not 
suitable for relative quantification due to inaccuracy. Possibly, greater cell numbers would 
deliver RNA amounts that will be suitable for relative quantification of Gpr25 mRNA. 
These, however, are difficult to reach due to limitations of the HSC isolation and 
purification procedure. Pilot experiments with GRX cells stimulated with MIF for 6 h and 
24 h did not show a convincing upregulation of Gpr25 expression (data not shown). How-
ever, quiescent HSCs show considerably higher levels of Gpr25 mRNA when adjusted to 
total RNA and Gapdh expression, respectively (Chapter 2.6.2). Therefore, Gpr25 expres-
sion might be seen as a characteristic of quiescent HSCs, which is downregulated upon 
activation. Higher expression in MIF-stimulated compared to unstimulated HSCs might 
then indicate a reduction of HSC activation or at least of some properties being related to 
Gpr25. Physiologically relevant properties related to Gpr25 expression are completely 
unknown to date. Gpr25 was identified by Jung et al. in 1997 as an intronless gene local-
ized to chromosome 1q32.1 of the human genome [169]. The low expression levels 
identified by microarray analysis and qPCR may explain why Jung et al. did not identify 
the transcript in liver tissue using Northern blot analysis. Gpr25 encodes the G protein-
coupled orphan receptor GPR25, which consists of about 300 amino acids. This receptor 
shares highest sequence homology with the receptor being encoded by Gpr15, angioten-
sin II type 1 receptor (AGTR1), and somastasin receptor 5, but has not further been 
characterized [169]. The homology of GPR25 and AGTR1 is very interesting considering 
the fibrosis-promoting role of the angiotensin-renin system and its capability to promote 
HSC activation [170]. Conceivably, GPR25 may compete with AGTR1 for angiotensin II 
binding and thereby antagonize angiotensin signaling. An upregulation of GPR25 by MIF 
would then be in accordance with the protective effect of MIF in liver fibrosis. Moreover, 
the homology of GPR25 and AGTR1 provides a potential link to MIF signaling as an in-
teraction of AGTR1 with the MIF receptor CD74 has been identified [171]. If the CD74 
interaction site of AGTR1 is also present in GPR25, this receptor may be a novel interac-
tion partner of CD74 that possibly is involved in the modulation of CD74-dependent MIF 
signaling. In line with these considerations, GPR25 remains an interesting candidate that 
should be further investigated in the context of MIF signaling and the regulation of liver 
fibrosis. 
Further candidate genes were identified by the two-of-three comparison or the mean value 
comparison that, due to their known characteristics, are related to the regulation of liver 
fibrosis. The properties of some of the encoded proteins are in accordance with the anti-
fibrotic effect of MIF. These are listed below:  
Hamp was identified as one of the upregulated genes by the two-of-three comparison (fold 
change = -1.21 / 7.72 / 3.72). Hamp encodes the hepcidin antimicrobial peptide, which 
regulates iron homeostasis. Hepcidin is present at reduced levels in serum and livers in 
diverse chronic liver diseases [172-174]. Reduced hepcidin levels have been functionally 
linked to hepatic iron overload, which is associated with fibrogenesis and HSC activation 
[175, 176]. While iron metabolism has mainly been ascribed to hepatocytes and macro-
phages, expression of hepcidin and other factors involved in iron metabolism in HSCs 
indicates a role for these cells as well [177]. Thus, by upregulating hepcidin expression or 
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antagonizing its downregulation, MIF might reduce hepatotoxin-associated iron overload 
and therefore reduce fibrogenesis.  
Fam110c, which encodes the protein family with sequence similarity 110 member C, is 
one of the downregulated candidates of the two-of-three comparison (fold 
change = -1.15 / -6.23 / -2.40). Fam110c is involved in the regulation of cell spreading, 
migration and induction of filopodia [178]. Although experimental evidence exists only for 
some cell lines, it is possible that these effects also apply for HSCs. If so, a downregulation 
of Fam110c expression by MIF will go along with reduced HSC migration.  
Nepn expression was upregulated by daily MIF stimulation, resulting in a mean fold 
change of 2.60. The homolog of Nepn in human and other primates is a pseudogene [179]. 
In mice, the encoded protein is nephrocan, an inhibitor of TGF-β signaling [180]. Due to 
the key role for TGF-β in HSC activation and fibrogenesis, MIF-dependent upregulation of 
nephrocan might account for a decreased fibrotic response.  
Alms1 is the homolog to the human Alström syndrome 1 gene. This gene is mutated in a 
rare genetic disorder called Alström syndrome, which is associated with high levels of fi-
brosis in virtually all organs. The symptoms are caused by excessive deposition of ECM 
proteins and impaired apoptosis of myofibroblasts [181]. Increased expression of this gene 
upon MIF stimulation (mean fold change = 2.06) might therefore have an inhibitory effect 
on fibrogenesis.  
Bhmt displayed a 2.04-fold upregulation in the mean value comparison. The product, be-
taine-homocysteine methyltransferase (BHMT), is involved in the methylation and 
subsequent removal of homocysteine, a mediator of oxidative stress. BHMT was reported 
to have a protective function when being upregulated in ethanol-induced liver injury in rat 
[182]. Upon HSC activation expression of this gene is downregulated [146], which seems 
to be antagonized by MIF. This may result in reduced oxidative stress upon liver injury.  
Cd74, encoding the MHC class II-associated invariant chain and one of the MIF receptors, 
was upregulated with a mean fold change of 1.53 in the daily MIF-stimulated HSCs. Up-
regulation of its own receptor may increase the responsiveness of HSCs to MIF 
stimulation, which possibly amplifies the beneficial activities of MIF.  
Rgn expression was decreased upon MIF stimulation by a mean fold change of -2.81. Rgn 
encodes the calcium-binding protein regucalcin, which is also known as senescence marker 
protein 30 (SMP30). It has been identified as a serum marker of chronic liver injury in pa-
tients suffering from chronic liver disease and in CCl4-treated rats [183-185]. While 
overexpression of regucalcin suppresses α-Sma expression in kidney myofibroblasts, the 
genetic deletion of Rgn in the liver counter-regulates HSC activation and fibrogenesis upon 
CCl4-induced liver injury [186, 187]. Therefore, the reduced expression of regucalcin in 
response to MIF stimulation may contribute to an attenuated fibrotic response. 
Mmp24, was found to be upregulated by 1.64 fold in the mean value comparison. How-
ever, this cannot clearly be linked to pro- or antifibrotic activities. A role for the 
membrane-bound matrix metallopeptidase MMP24 in liver fibrosis has not been reported, 
but its ability to activate MMP2 possibly provides a link to fibrogenesis. MMP2 is up-
regulated in hepatotoxin-induced fibrosis and promotes HSC migration and proliferation. 
Its enzymatic activity is important in early degradation of the existing ECM, but largely 
inhibited during fibrogenesis by Timp-2, which abolishes the degradation of the fibrotic 
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ECM [188]. Thus, further activation of MMP2 by MIF-mediated upregulation of Mmp24 
expression might trigger HSC activation on the one hand and shift the MMP/Timp equilib-
rium towards higher ECM degrading activity on the other hand. 
In contrast to the above listed genes, the regulation of other genes by MIF stimulation is 
apparently contradictory to MIF’s beneficial effect. These are the following:  
Ece2 encodes the endothelin-converting enzyme-2 homolog. ECE-2 is a membrane-bound 
metalloprotease that activates the vasoactive endothelin-1 (ET-1) by cleaving its inactive 
precursor [189]. Increased expression of Ece2, as seen in the MIF-stimulated HSCs (mean 
fold change = 2.85), therefore increases the amount of ET-1, a cytokine with pro-fibrotic 
properties [6].  
Foxo4, the gene encoding the transcription factor forkhead box O4 (FoxO4), was upregu-
lated by 1.92-fold in MIF-stimulated cells. FoxO4, activated by the NADPH oxidase 1 
(NOX1)/Akt pathway, promotes HSC proliferation [190]. Therefore, FoxO4 can be con-
sidered pro-fibrotic and its upregulation likely does not support the protective effect of 
MIF.  
Il17re, which was upregulated by MIF stimulation by 1.77-fold, encodes the IL-17 recep-
tor. IL-17 promotes fibrogenesis and induces collagen expression in HSCs by activating 
STAT3 signaling [191]. Increased expression of its receptor likely sensitizes HSCs to 
IL-17 stimulation and might therefore increase the fibrotic response.  
Mylk3, encodes the myosin light chain kinase 3. Myosin light chain kinase was shown to 
be upregulated upon HSC activation and suggested to be involved in Ca
2+
-dependent con-
striction of hepatic sinusoids in experimental rat liver cirrhosis [192]. In MIF-stimulated 
HSCs Mylk3 was upregulated by 1.89-fold and is therefore unlikely to mediate protection 
in liver fibrosis.  
Ahsg displayed a downregulation by a mean fold change of -2.11. Moreover, the gene is 
one of the downregulated candidates of the two-of-three comparison (fold 
change = -2.85 / -2.29 / -1.50). Ahsg encodes α-2-HS-glycoprotein, also known as fetuin A, 
a TGF-β antagonist that inhibits collagen synthesis in HSCs [193]. The decreased expres-
sion of this anti-fibrotic factor upon MIF stimulation is not in accordance with the anti-
fibrotic properties of MIF. 
Expression of Col1a1, Timp-1, the myofibroblast marker α-Sma, and Tgf-β was not shown 
to be differentially regulated upon stimulation with exogenous MIF by this microarray-
based approach. However, previous experiments with cultured rat HSCs identified a link 
between expression levels of Mif and α-Sma. While overexpression of Mif did not affect 
α-Sma expression during in vitro transdifferentiation, a knockdown of Mif abolished 
α-Sma expression (personal communication: S. Zierow and J. Bernhagen). The effect of 
MIF on HSCs may involve the regulation of further key fibrotic genes that have not been 
identified by microarray analysis. These effects may be concentration-dependent and only 
be apparent at very low or very high local MIF concentrations in the liver. Transferred to 
the in vivo situation in patients, this possibly links Mif gene promoter polymorphisms and a 
predisposition to fibrosis development. 
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Considering the variety of MIF target gene candidates including pro- and anti-fibrotic me-
diators, it is possible that, depending on disease context, MIF exerts both pro- and anti-
fibrotic functions. The equilibrium and additional regulating factors will then define the 
pathologic outcome. Such an ambiguous effect of cytokines on HSC activation and myofi-
broblast activity would not be unique to MIF. TNF-α, for instance, triggers HSC activation, 
i.e. loss of retinyl esters, expression of α-SMA and fibronectin, but inhibits collagen type I 
and III expression [20]. For MIF, the microarray-based whole genome analysis provided 
more candidates that support than those that oppose the protective role of MIF in liver fi-
brosis. This is in line with the observed effect in CCl4- and TAA-induced liver fibrosis in 
mice. 
3.4 Further proposed mechanisms of MIF’s protective 
effect 
Besides regulating HSC activity, and thus their fibrogenic potential, MIF might addition-
ally act on other resident hepatic cells to exert its protective effect in CCl4- and TAA-
induced liver injury and possibly in other chronic liver diseases. Animal models that apply 
CCl4 and TAA to induce liver damage and subsequent fibrogenesis share the occurrence of 
high oxidative stress levels, which results in hepatocyte damage and necrosis. Bioactiva-
tion of both hepatotoxins involve cytochrome P450 activity. Degradation of CCl4 yields 
trichloromethyl radicals that initiate a chain reaction, which forms organic free radicals and 
increases oxidative stress. These radicals interact with cellular proteins or induce lipid per-
oxidation, which results in the loss of membrane integrity and is a major cause of damage 
and cellular death in hepatocytes [147]. Biotransformation of TAA involves the conversion 
to its S-oxide and the formation of H2O2. TAA-induced liver fibrosis is associated with 
iron overload, impaired fatty acid β-oxidation and lipid peroxidation [194]. In this context, 
it is interesting to note that MIF comprises a oxidoreductase activity and participates in 
cellular redox homeostasis by increasing cellular glutathione concentrations [155]. Thus, 
by reducing oxidative stress and possibly by mediating pro-survival signals (Chap-
ter 1.3.3), MIF might exert hepatoprotective effects and lower the number of necrotic 
hepatocytes, which represent a major trigger for inflammation and HSC activation. More-
over, MIF promotes proliferation and AMPK, which was shown to be activated by 
exogenous MIF in Hepa 1-6 cells (Chapter 2.7), mediates priming and proliferation of 
hepatocytes in liver regeneration [25]. By activating the AMPK pathway or other survival 
pathways, MIF could promote the replacement of necrotic hepatocytes and facilitate liver 
regeneration. So far, no mechanistic data have been published about MIF and hepatocytes 
in liver fibrosis, but in the context of liver fibrosis, mechanistic investigation of this axis 
will certainly be important for the understanding of the increased fibrotic response in 
Mif 
–/–
 cells. 
In addition to HSCs and hepatocytes, Kupffer cells might also perform MIF-mediated 
protective activities. It has been reported that AMPK activation drives alternative activa-
tion of Kupffer cells, resulting in the anti-inflammatory M2 phenotype [195]. Whether MIF 
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regulates Kupffer cell polarization and whether this is mediated by AMPK or other sig-
naling pathways has yet to be investigated. 
3.5 Mechanistic considerations about the MIF/AMPK 
pathway 
The AMPK pathway was identified as a mediator of the anti-fibrotic properties of MIF in 
experimental liver fibrosis in this work. MIF was shown to induce AMPK phosphorylation 
in HSCs and to inhibit PDGF-induced proliferation and migration of GRX cells in an 
AMPK-dependent manner (Chapter 2.4). Furthermore, AMPK phosphorylation was in-
creased in MIF-stimulated Hepa 1-6 cells (Chapter 2.7). So far, only little is known about 
the mechanisms and components involved in the MIF/AMPK axis. 
3.5.1 Pathway components 
The inhibitory effect of MIF on PDGF-induced proliferation and migration of HSCs, 
which is mediated by AMPK, was linked to the MIF receptor CD74 by D. Heinrichs in the 
framework of the collaborative project P07 of SFB/TRR57. Applying a neutralizing CD74 
antibody in the in vitro assays reversed the MIF-dependent reduction on HSC activity, as 
seen for the AMPK inhibitor compound C. A role for CD74 in the regulation of liver fibro-
sis was furthermore demonstrated in in vivo experiments with Cd74 
–/–
 mice that were 
injected with CCl4 and displayed an increased fibrotic phenotype comparable to the Mif 
–/–
 
phenotype [136, 142]. Whether CXCR4 or CXCR2, which are involved in several MIF-
mediated signaling pathways, are components of the CD74/MIF/AMPK pathway has not 
been elucidated. So far, also the upstream kinase responsible for AMPK activation upon 
MIF stimulation is unknown. Three AMPK kinases are discussed in the literature. In some 
contexts, LKB1 is responsible, mainly in conjunction with increased AMP:ATP ratios. 
Other effects are linked to CaMKK activity. These usually involve Ca
2+
 signaling. There is 
also some evidence for TAK1 as a third AMPK kinase [34-37]. As in liver LKB1 is the 
predominant kinase, first experiments aimed at investigating its role in MIF-stimulated 
AMPK activation in Hepa 1-6 cells. Some reports suggest a requirement of 
phosphorylation at Ser428 (equal to Ser431 in mouse, but termed Ser428 hereafter) for 
translocation of LKB1 into the cytoplasm and its ability to phosphorylate AMPK [145, 
196]. Therefore, LKB1 phosphorylation at Ser428 was analyzed in MIF-stimulated 
Hepa 1-6 cells. However, neither dose- nor time-dependent phosphorylation was observed 
(Chapter 2.7). This might indicate that LKB1 is not involved in the MIF/AMPK pathway 
and would be in accordance with recently published data that exclude a role for LKB1 in 
MIF-dependent AMPK inactivation in non-small cell lung carcinoma [107]. However, 
since activation and inactivation of AMPK in different cell systems are controversial, as 
discussed in Chapter 3.5.2, these effects might involve different cellular components. 
Furthermore, the role of LKB1 Ser428 phosphorylation is not unambiguously resolved. 
Besides those studies linking Ser428 phosphorylation to AMPK activation, further reports 
claim the opposite [197]. The inability of MIF to induce LKB1 phosphorylation in 
74 3 Discussion 
Hepa 1-6 cells therefore does not explicitly exclude the possibility that LKB1 is involved 
in this pathway. Knockdown experiments with LKB1 siRNA may help to further clarify 
the requirement of LKB1 for MIF-mediated AMPK. Beyond that, it will be necessary to 
consider CaMKK and TAK1 as possible links between MIF and AMPK. Specific 
inhibitors for both kinases are available, and knockdown experiments may help to analyze 
their role in MIF-dependent AMPK phosphorylation.  
3.5.2 Differential effects depending on the cellular context 
MIF dose-dependently induced the phosphorylation of AMPK at Thr172 in in vitro trans-
differentiated Mif 
–/–
 MFBs. Wildtype MFBs and the immortalized HSC cell line GRX did 
not show significantly increased phosphorylation of AMPK in response to exogenously 
applied MIF. The positive control metformin, however, proved functionality of the assay 
(Chapter 2.4). The fact that these cells constitutively express MIF suggests an autocrine 
desensitization effect. Desensitization of G protein-coupled receptors upon ligand binding 
is a well described phenomenon and is associated with posttranslational modifications, 
such as phosphorylation and ubiquitination, binding of β-arrestin, and receptor internaliza-
tion [198, 199]. Whether the G protein-coupled MIF receptors CXCR2 or CXCR4 are in-
volved in MIF-mediated AMPK activation is unknown so far. If, in addition to CD74, one 
of the CXC receptors is required for the activation of the AMPK signaling pathway, GPCR 
desensitization may be one reason for the reduced sensitivity of the MIF-expressing HSCs 
that were utilized in this work. Moreover, desensitization may occur at any other stage of 
the signaling cascade. However, if desensitization was the reason for a detectable phos-
phorylation response in Mif-deficient but not in Mif-expressing cells, it does not seem to 
entirely abolish the activation of the AMPK pathway. While detecting AMPK activation 
by trapping the transient phosphorylation signal proved difficult in GRX cells, AMPK-
mediated inhibition of PDGF-induced proliferation and migration could be analyzed using 
GRX cells. Thus, the read-out of downstream effects appears to provide a more robust 
system than the phosphorylation assay, which is less prone to minimal disturbing influ-
ences and probably includes several stages of amplification. 
Consistent with the MIF-mediated AMPK activation in HSCs, MIF activates AMPK in the 
ischemic heart and in hypoxia-exposed fibroblasts by autocrine stimulation [104]. In con-
trast, in non-small cell lung carcinoma (NSCLC) cells, an inhibitory effect of MIF on 
AMPK was reported. The authors of this publication argue that the different effect of MIF 
on AMPK activity may be the result of a different receptor expression profile and possibly 
of different upstream events, including the regulation of glucose uptake and ATP 
generation and the activity of CaMKK [107]. Furthermore, MIF receptor complex 
formation may differentially regulate MIF signaling and the availability of receptors on the 
cell surface might also determine the intensity of activation or inactivation of other MIF 
signaling pathways. Cross-talk of these pathways, which may either potentiate each other 
or interfere with each other, will then define the cellular outcome of MIF stimulation. 
 
 4 Conclusion 
The cytokine MIF is a pro-inflammatory protein with chemotactic properties and is cru-
cially involved in the regulation and development of various acute and chronic inflamma-
tory diseases. Despite these often detrimental properties, MIF displays an anti-fibrogenic 
effect in experimental hepatotoxin-induced liver fibrosis that is related to decreased 
myofibroblast activity but not to altered immune cell infiltration. Beyond these findings, 
little is known about the role of MIF in liver fibrosis. This work therefore investigated the 
underlying molecular mechanisms of this recently identified beneficial effect of MIF. 
In order to characterize hepatic cells as potential sources and/or targets of MIF in the liver, 
hepatocytes, Kupffer cells, and hepatic stellate cells were analyzed for their capability to 
produce and secrete MIF and to express MIF receptors. All of these cell populations, in-
cluding primary cells and cell lines, constitutively express MIF. Hepatocytes, i.e. primary 
hepatocytes and Hepa 1-6 hepatoma cells, specifically released MIF in response to apop-
totic stimuli, ethanol and oxidative stress. They furthermore released considerable amounts 
of MIF upon cell damage, which is a frequent phenomenon in hepatotoxin-induced liver 
injury. The Kupffer cell line KC 13-2 secreted MIF in response to oxidative stress, which 
usually is increased during hepatic inflammation and fibrogenesis. So far, HSCs had not 
been related to hepatic MIF expression. Yet, the immortalized cell line GRX, being repre-
sentative for HSCs, displayed a differential response to fibrosis-regulating cytokines by up- 
or downregulating MIF secretion, which is apparently dependent on the activation status of 
these cells. Thus, all three hepatic cell types are potential sources of MIF in the fibrotic 
liver. Their differential regulation concerning MIF release may account for local 
differences in hepatic MIF abundance. Further in vitro studies will show whether the 
observed effects account for both cell lines and primary cells. Immunohistochemical 
detection of MIF protein in fibrotic livers at different stages during hepatotoxin 
administration may further help to localize MIF expression and activity. Receptor 
expression analysis identified hepatocytes, Kupffer cells, and HSCs as potential MIF target 
cells. CD74 and CXCR4 expression were detected in all of these cells. Detection of 
CXCR2 was not possible but ought to be further analyzed. Moreover, differences in the 
receptor expression profile of quiescent and activated HSCs require further analysis in 
order to allow conclusions about their responsiveness to MIF at different stages of liver 
injury and fibrosis. 
The anti-fibrotic properties of MIF, which were recently identified by a comparison of Mif-
deficient and Mif-expressing mice in experimental liver fibrosis, were supported in this 
work by showing that recombinant MIF attenuated hepatic fibrosis when being injected 
into wildtype mice together with CCl4. This in vivo experiment also strengthened the 
conception of HSC activity as an important parameter in the MIF-dependent regulation of 
liver fibrosis, as expression of α-Sma and further HSC-related genes were downregulated 
in MIF-treated mice. Accordingly, a regulatory effect of MIF on HSC activity was 
identified in vitro that was linked to signaling through the AMPK pathway. AMPK was 
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phosphorylated in primary myofibroblastic HSCs upon MIF stimulation in a dose-
dependent manner, and AMPK activity was required for MIF-mediated inhibition of 
PDGF-induced proliferation and migration. The MIF/AMPK axis includes the MIF recep-
tor CD74, as has recently been shown. First experiments were performed in this work to 
identify further components of this pathway. The prototypical AMPK kinase LKB1 does 
not seem to be involved. In Hepa 1-6 cells, MIF was not able to induce LKB1 phosphory-
lation, which has been stated to be required for AMPK kinase activity by some research 
groups. Knockdown experiments may help to conclude whether LKB1, CaMKK, TAK1, 
or any other kinase mediate the activation of AMPK induced by MIF. In addition to the 
AMPK pathway, this work identified the c-Jun N-terminal kinase pathway as a MIF-regu-
lated signaling cascade. MIF rapidly induced JNK phosphorylation and subsequent c-Jun 
phosphorylation in quiescent and in vitro activated HSCs. JNK signaling has been related 
to several pro-fibrotic but also to some anti-fibrotic processes. Investigating the effect of 
MIF on myofibroblasts and the functional relevance of the MIF/JNK axis for the regulation 
of HSC activity will be of great interest in order to extend the knowledge about MIF-medi-
ated signaling in HSCs. 
Microarray-based whole genome expression analysis provided a number of candidate 
genes that potentially are involved in the regulation of HSC transdifferentiation and activi-
ty by MIF. Gene expression of in vitro activated Mif 
–/–
 cells being permanently or transi-
ently stimulated with MIF was compared to gene expression of unstimulated cells. Among 
those genes that were identified as possible MIF target genes by statistical evaluation and 
filtering of the data, some genes may be involved in mediating the protective effect on 
HSCs. The regulation of some others, however, may rather drive pro-fibrotic processes. 
Due to most consistent regulation in three independent experiments, Gpr25, encoding an 
uncharacterized orphan G protein-coupled receptor, appeared most interesting and prom-
ising. This gene was found to be higher expressed in quiescent than in activated HSCs and 
upregulated upon MIF stimulation. Further validation of the microarray data by qPCR and 
verification at the protein level and the subsequent analysis of the functional relevance will 
be helpful to identify novel mechanisms by which MIF regulates cellular behavior. 
Taken together, this work linked the beneficial effect of MIF in experimental liver fibrosis 
to the MIF-dependent regulation of HSC activity. The MIF/AMPK axis seems to play a 
pivotal role in this context, with the activation of JNK signaling and the regulation of gene 
expression possibly contributing to reduced fibrotic activity in HSCs in the presence of 
MIF. The protective effect of MIF in the mouse models was unexpected but unambiguous. 
The successful reduction of fibrosis by MIF administration strongly suggests a possible 
clinical approach. Thus, delineation of the molecular process underlying the protective 
effect of MIF will prove invaluable. This work has provided first insight into these 
processes and may be the starting point for further detailed investigations. 
 5 Materials 
5.1 Chemicals and reagents 
Chemicals and reagents Manufacturer 
Accutase PAA Laboratories GmbH, Österreich 
Acrylamide/Bis solution 30% BioRad, München 
Agarose, electrophoresis grade Invitrogen, Karlsruhe 
Albumin fraction V (BSA) Carl Roth, Karlsruhe 
Albumine, bovine serum, minimum 98% (BSA) Sigma-Aldrich, München 
Ammonium persulfate (APS) Sigma-Aldrich, München 
Carbon tetrachloride (CCl4) Merck, Darmstadt 
Cell culture media Gibco, Karlsruhe 
Cell culture supplements Gibco, Karlsruhe 
Collagen G Biochrom AG, Berlin 
Collagenase 2 Worthington Biochemical Company, USA 
Collagenase CLS Biochrom AG, Berlin 
Collagenase P Roche, Mannheim 
Complete protease inhibitor cocktail set I Calbiochem, USA 
Compound C Sigma-Aldrich, München 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich, München 
Disodium hydrogen phosphate (Na2HPO4) Merck, Darmstadt 
Dithiothreitol (DTT) Sigma-Aldrich, München 
Ethanol (70% or 98%) Carl Roth, Karlsruhe 
Ethidium bromide Sigma-Aldrich, München 
Fetal calf serum (FCS) Gibco, Karlsruhe 
GeneRuler™ 50bp DNA Ladder Fermentas, Thermo Fisher Scientific, USA 
Gentamycine Gibco, Karlsruhe 
Glucose Sigma-Aldrich, München 
Glycine Fluka Chemie AG, Switzerland 
GoTaq
®
 Green Master Mix Promega, USA 
HT Supplement (hypoxanthine, thymidine) Gibco, Karlsruhe 
Hydrochloric acid (HCl) Fluka Chemie AG, Schweiz 
Hydrogen peroxide (H2O2) 30% (w/v) Sigma-Aldrich, München 
Isopropanol Carl Roth, Karlsruhe 
L-Glutamine Gibco, Karlsruhe 
Lipopolysaccharide (LPS) Sigma-Aldrich, München 
Magnesium chloride (MgCl2) Sigma-Aldrich, München 
Metformin Sigma-Aldrich, München 
Methanol Carl Roth, Karlsruhe 
Mycokill AB PAA Laboratories GmbH, Österreich 
Non-essential amino acids Gibco, Karlsruhe 
Nonfat dried milk powder Applied Chemical Laboratories, USA 
Novex Sharp Pre-stained Protein Standard Invitrogen, Karlsruhe 
NuPAGE
® 
LDS sample buffer Invitrogen, Karlsruhe 
NuPAGE
® 
transfer buffer Invitrogen, Karlsruhe 
Penicilline/ Streptomycine solution (100x) Gibco, Karlsruhe 
PhosSTOP phosphatase inhibitor cocktail Roche, Mannheim 
Poly-L-lysine solution Sigma-Aldrich, München 
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Chemicals and reagents Manufacturer 
Ponceau S solution Sigma-Aldrich, München 
Potassium chloride (KCl) Merck, Darmstadt 
Potassium dihydrogen phosphate (KH2PO4) Merck, Darmstadt 
Pronase E Merck, Darmstadt 
Propidium iodide Sigma-Aldrich, München 
Retinol BioXtra, ≥ 99,0% Sigma-Aldrich, München 
Sodium azide (NaN3) Serva, Heidelberg 
Sodium chloride (NaCl) Merck, Darmstadt 
Sodium dodecyl sulfate (SDS) Merck, Darmstadt 
Sodium hydroxide (NaOH) Fluka Chemie AG, Schweiz 
Sodium pyruvate Gibco, Karlsruhe 
Streptavidin-peroxidase Roche, Mannheim 
Sucrose Sigma-Aldrich, München 
Sulfuric acid (H2SO4) Merck, Darmstadt 
SuperSignal
®
 West Dura Extended Duration Signal Pierce, Thermo Fisher Scientific, USA 
SuperSignal
®
 West Femto Substrate Pierce, Thermo Fisher Scientific, USA 
Tetramethylethylenediamine (TEMED) BioRad, München 
TMB ELISA substrate (H2O2 + Tetramethyl-
benzidine) 
Pierce, Thermo Fisher Scientific, USA 
Tris Carl Roth, Karlsruhe 
Triton X-100 Fluka Chemie AG, Schweiz 
Trypan blue stain 0.4% Gibco, Karlsruhe 
Trypsin/EDTA Invitrogen, Karlsruhe 
Tween 20 Sigma-Aldrich, München 
β-Mercaptoethanol Sigma-Aldrich, München 
5.2 Basic buffers 
Buffer Components 
PBS pH 7.2 137 mM NaCl 
2.7 mM KCl 
1.5 mM KH2PO4 
8.1 mM Na2HPO4 
  
TBE pH 7.3 89 mM Tris base 
90 mM Boric acid 
2 mM EDTA 
  
TBS pH 7.2 20 mM Tris-HCl 
150 mM NaCl 
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5.3 Kits 
Kit Manufacturer 
Cell Proliferation ELISA Kit, colorimetric Roche, Mannheim 
CytoTox-ONE™ Homogeneous Membrane 
Integrity Assay-Kit 
Promega, USA 
First Strand cDNA Synthesis Kit Fermentas, Thermo Fisher Scientific, USA 
Hemacolor
®
 staining kit Merck, Darmstadt 
Micro BCA™ Protein Assay Reagent-Kit Pierce, Thermo Fisher Scientific, USA 
NucleoSpin
®
 Tissue DNA Extraction Kit Macherey-Nagel, Düren 
RNeasy Mini Kit Qiagen, Hilden 
SensiMix™ SYBR No-ROX Kit, 2x Peqlab, Erlangen 
5.4 Cytokines 
Cytokine Manufacturer 
IFN-γ (murine, recombinant) PeproTech, USA 
IL-1β (human, recombinant) PeproTech, USA 
IL-6 (human, recombinant) AG Müller-Newen, RWTH Aachen 
MCP-1 (human/murine, recombinant) PeproTech, USA 
MIF (murine, recombinant) AG Bernhagen, RWTH Aachen 
PDGF-B (human, recombinant) R&D Systems, USA 
TGF-β1 (human, recombinant) PeproTech, USA 
TNF-α (murine, recombinant) PeproTech, USA 
5.5 Antibodies 
Primary Western blot antibodies 
Antibody Description Dilution Manufacturer 
Anti-Aktin Mouse, monoclonal 1: 1,000,000 MP Biomedicals, USA 
Anti-AMPK Rabbit, monoclonal 1: 1,000 Cell Signaling Technologies, USA 
Anti-CXCR4 Rabbit, polyclonal 1: 1,000 Abcam, UK 
Anti-MIF Ka565 Rabbit, polyclonal 1: 1,000 AG Bernhagen, RWTH Aachen 
Anti-mouse CD74 (In-1) Mouse, monoclonal 1: 1,000 BD Bioscience, Heidelberg 
Anti-Phospho-AMPK 
(Thr172) 
Rabbit, monoclonal 1: 1,000 Cell Signaling Technologies, USA 
Anti-Phospho-c-Jun 
(Ser63) 
Rabbit, monoclonal 1: 1,000 Cell Signaling Technologies, USA 
Anti-Phospho-JNK 
(Tyr185/Thr183) 
Rabbit, monoclonal 1: 1,000 Cell Signaling Technologies, USA 
Anti-Phospho-LKB1 
(Ser428) 
Rabbit, monoclonal 1: 1,000 Cell Signaling Technologies, USA 
Anti-Tubulin Mouse, monoclonal 1:10,000 Sigma-Aldrich, München 
Anti-α-SMA  Mouse, monoclonal 1: 1,000 Sigma-Aldrich, München 
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ELISA antibodies 
Antibody Description Conc. Manufacturer 
Anti-MIF BAF289 Goat, polyclonal, 
biotinylated 
0.2 µg/ml R&D Systems, USA 
Anti-MIF XIV.14.3 Rabbit, monoclonal 1.5 µg/ml AG Bernhagen, RWTH Aachen / 
AG Bucala, Yale University 
Secondary antibodies 
Antibody Description Dilution Manufacturer 
Anti-mouse-HRP Rat, monoclonal 1: 5,000 Abcam, UK 
Anti-rabbit-HRP Donkey, F(ab')₂ 1:10,000 GE Healthcare, München 
Anti-rat-HRP Mouse, monoclonal 1: 5,000 Abcam, UK 
Labeled Antibodies for flow cytometry 
Antibody Description Volume / 
200,000 cells 
Manufacturer 
Anti-mouse CD74-FITC Rat IgG2b 2 µl BD Bioscience, Heidelberg 
Anti-mouse CXCR2-PE Rat IgG2a 2 µl BD Bioscience, Heidelberg 
Anti-mouse CXCR4-PE Rat IgG2b 10 µl R&D Systems, USA 
Rat IgG2a-FITC Isotype control 10 µl R&D Systems, USA 
Rat IgG2a-PE Isotype control 10 µl R&D Systems, USA 
Rat IgG2b-PE Isotype control 10 µl R&D Systems, USA 
5.6 Primer sequences 
Primer for mycoplasma detection 
Primer Sequence 5’ → 3’ 
GPO-1 ACT CCT ACG GGA GGC AGC AGT A 
MGSO TGC ACC ATC TGT CAC TCT GTT AAC CTC 
MGH I TTC CCG CCA TGC CCT TGT CCA GTC 
MGH II CAA GGC CTG GGA CTA CTC ACG GTT C 
Primer for qPCR 
Primer Sequence 5’ → 3’ 
α-Sma for TAT GTG TGA AGA GGA AGA CAG CA 
α-Sma rev ACA GCC TGA ATA GCC ACA TAC AT 
Gapdh for GCC TCA AGA TCA TCA GC 
Gapdh rev ACC ACT GAC ACG TTG GC 
Mmp2 for GCA AGT TTC CGT TCC GCT TCC 
Mmp2 rev CAG TAC CAG TGT CAG TAT CAG C 
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Primer assays for qPCR 
Primer assay Manufacturer 
Col1a1, Assay on Demand Applied Biosystems, Darmstadt 
Gpr25, Quantitect Primer Assay Qiagen, Hilden 
Tgf-β1, Assay on Demand Applied Biosystems, Darmstadt 
Timp1, Assay on Demand Applied Biosystems, Darmstadt 
5.7 Cells and cell culture media 
EA.hy926  
Origin and description Human endothelial cell line 
Derived from fusion of human umbilical vein endothelial cells 
(HUVEC) with the permanent human cell line A549 [200] 
  
Culture medium RPMI 1640 
+ 10% FCS 
+ 2 mM L-Glutamine 
+ 1 mM Sodium pyruvate 
+ 1.5 mM HEPES 
+ 2% HT Supplement 
+ 1% Non-essential amino acids 
+ 0.25% Glucose 
+ 15 µg/ml Gentamycine 
 
GRX  
Origin and description Mouse hepatic stellate cells 
Derived from fibrotic schistosomal granulomas [201] 
  
Culture medium DMEM 
+ 10% FCS 
+ 2 mM L-Glutamine 
+ 1 mM Sodium pyruvate 
+ 100 U/ml Penicilline 
+ 100 µg/ml Streptomycine 
 
Hepa 1-6   
Origin and description Mouse hepatoma cell line [202] 
  
Culture medium DMEM 
+ 10% FCS 
+ 2 mM L-Glutamine 
+ 1 mM Sodium pyruvate 
+ 100 U/ml Penicilline 
+ 100 µg/ml Streptomycine 
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Hepatocytes, primary  
Origin and description See Chapter 6.1.2 
  
Culture medium Williams’ Medium E 
+ 10% FCS 
+ 100 U/ml Penicilline 
+ 100 µg/ml Streptomycine 
 
Hep G2  
Origin and description Human hepatoma cell line [203] 
  
Culture medium RPMI 1640 
+ 10% FCS 
+ 2 mM L-Glutamine 
+ 1 mM Sodium pyruvate 
+ 1.5 mM HEPES 
+ 2% HT Supplement 
+ 1% Non-essential amino acids 
+ 0.25% Glucose 
+ 15 µg/ml Gentamycine 
 
HSC, primary  
Origin and description See Chapter 6.1.1 
  
Culture medium DMEM 
+ 10% FCS 
+ 25 mM HEPES 
+ 4 mM L-Glutamine 
+ 1 mM Sodium pyruvate 
+ 100 U/ml Penicilline 
+ 100 µg/ml Streptomycine 
 
KC 13-2  
Origin and description Mouse Kupffer cell line 
Clonal cell line derived from H-2K
b
 –tsA58 mice [153] 
  
Culture medium RPMI 1640 
+ 10% Hep G2 supernatants 
+ 10% EA.hy926 supernatants 
+ 5% FCS 
+ 2 mM L-Glutamine 
+ 1 mM Sodium pyruvate 
+ 1.5 mM HEPES 
+ 1% Non-essential amino acids 
+ 15 µg/ml Gentamycine 
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Kupffer cells, primary  
Origin and description See Chapter 6.1.3 
  
Culture medium RPMI 1640 
+ 1% FCS 
+ 2 mM L-Glutamine  
+ 100 U/ml Penicilline 
+ 100 µg/ml Streptomycine  
+ 2 mM L-Glutamine 
5.8 Animals 
All animal procedures were approved by the animal welfare committee of the 
Bezirksregierung Cologne, Germany.  
Species, Strain Genotype Application 
Mouse, C57BL/6J Mif 
–/–
 HSC isolation 
Mouse, derived from a Cxcr2
+/-
 
strain on a Balb/c background 
Wildtype HSC isolation 
Mouse, C57BL/6J Wildtype Fibrosis model / hepatocyte isolation 
Rat, Sprague-Dawley  Wildtype Kupffer cell isolation 
5.9 Devices 
Device Manufacturer 
-152°C Freezer Ultra Low MDF-1155 Sanyo Electric Biomedical Co., Japan 
-20°C Freezer Economic-super Bosch, Stuttgart 
-20°C Freezer Premium Liebherr, Ochsenhausen 
4°C Fridge Premium frost-free Liebherr, Ochsenhausen 
-80°C Freezer Ultra Low Sanyo Electric Biomedical Co., Japan 
Analytical balance Adventurer Ohaus, Gießen 
Analytical balance Analytical plus Ohaus, Gießen 
BD Aria SORP instrument BD Bioscience, Heidelberg 
Centrifuge 5417 R/5403 Eppendorf, Wesseling-Berzdorf 
Centrifuge Z 383 K/Z 400 K Hermle, Wehingen 
Clean bench Biowizard Kojair Tech Oy, Finland 
Clean bench HERAsafe  Heraeus Instruments, Hanau 
CO2 Incubator MCO-17AIC SANYO Electric Biomedical Co., Japan 
Electrophoresis power supply EPS 601 Amersham, München 
Evos
® 
fl microscope Advanced Microscopy Group, USA 
FACS Canto II™ Flow Cytometer BD Bioscience, Heidelberg 
Glas beakers and bottles Schott-Duran, Mainz 
Heater UBD Grant Instruments, UK 
Hemocytometer, Neubauer improved Marienfeld, Lauda-Königshofen 
Horizon
®
 58 Horizontal Gel Electrophoresis 
Apparatus 
Biometra, Göttingen 
Ice Flaker AF100 Scotsman, Italy 
LAS-3000 Image Reader Fujifilm, Düsseldorf 
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Device Manufacturer 
Microscope Olympus CK40 Olympus, Hamburg 
PHM82 standard pH meter Radiometer, Denmark 
Pipettes Pipetman Gilson, USA 
Pipettor Pipetboy IBS Integra Biosciences, Fernwald 
Rotilabo
®
-mini-centrifuge Carl Roth, Karlsruhe 
Rotor-Gene 6000 Corbett Life Science/Qiagen 
SDS-PAGE NuPAGE
® 
XCell SureLock Mini Cell Invitrogen, Karlsruhe 
Shaker MM1 Desaga, SARSTEDT-Group, Nümbrecht 
Shaker Rocky Fröbel Labortechnik, Lindau 
Shaker Vibrax VXR electronic IKA, Staufen 
Sonifier Cell Disruptor B15 Branson USA 
Spektrophotometer Nanodrop ND-1000 NanoDrop Technologies 
Thermocycler T3000 Biometra, Göttingen 
Thermomixer Comfort + Compact Eppendorf, Wesseling-Berzdorf 
VICTOR
2
 1420 Multilabel Counter PerkinElmer, USA 
Vortex MS2 Minishaker IKA, Staufen 
Water bath type 1004 GFL, Burgwedel 
Western Blot NuPAGE
® 
/ X Cell II Blot Module Invitrogen, Karlsruhe 
5.10 Software 
Software Manufacturer 
AIDA image analyzer Raytest Isotopen GmbH, Berlin 
FlowJo 8.8.6 Celeza, USA 
GraphPad Prism 5 GraphPad Software Inc., USA 
MeV 4.8.1, TM4 Microarray Software Suite Open Source software [204] 
Rotor-Gene 6000 Series Software 1.7 Corbett Life Science/Qiagen 
5.11 Consumables 
Consumables Manufacturer 
Blotting paper Schleicher & Schuell Bioscience, Dassel 
Cell culture dishes Cellstar Greiner Labortechnik, Frickenhausen 
Cell culture T-flasks (25 cm
2
, 75 cm
2
) Greiner Labortechnik, Frickenhausen 
Cell culture T-flasks Cell
+
 (75 cm
2
) Sarstedt, Nümbrecht 
Cell scraper Nalgene, USA  
Cryo tubes Nalgene, USA 
Nunc-Immuno™ Plate F96 Maxisorp™ Nunc, Thermo Fisher Scientific, USA 
Polystyrene tubes, 5 ml Falcon, Heidelberg 
Fluoresbrite
®
 YG Microspheres 1.0 µm  Polysciences, USA 
Greiner tubes (15 ml, 50 ml) Greiner Labortechnik, Frickenhausen 
Micro tubes 1.5 ml, 2 ml Sarstedt, Nümbrecht / Eppendorf, Wesseling-
Berzdorf 
Multiwell-plates Cellstar  
(6‐well, 12‐well, 24‐well, 96‐well) 
Greiner Labortechnik, Frickenhausen 
Nitrocellulose transfer membrane Schleicher & Schuell Bioscience, Dassel 
NuPAGE
®
 cassettes Invitrogen, Karlsruhe 
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Consumables Manufacturer 
NuPAGE
® 
combs Invitrogen, Karlsruhe 
Parafilm “M” American National Can, USA 
Pipette tips 1000 µl Brand, Wertheim 
Pipette tips 20 µl Brand, Wertheim 
Pipette tips 200 µl Brand, Wertheim / Sarstedt, Nümbrecht 
Reagent reservoir Sigma-Aldrich, München 
Strip tubes and caps 0.1 ml  Corbett Life Science/Qiagen 
Transwell inserts, 5 µm pore size Corning, USA 
Whatman filter paper Greiner Labortechnik, Frickenhausen 
Whatma Puradisc FP30 syringe filters, 0.2 µm Whatman/GE Healthcare, München 
 6 Methods 
6.1 Cell culture techniques 
All cell culture techniques were performed under sterile conditions, using laminar air flow 
and sterile media, working solutions and equipment. Unless otherwise stated, all primary 
cells and cell lines were cultivated at 37°C and 5% CO2 in a humidified incubator. Cell 
culture media that were used for primary cells and cell lines are listed in Chapter 5.7. 
6.1.1 Isolation and cultivation of primary mouse hepatic stellate 
cells 
Primary hepatic stellate cells (HSCs) were isolated from mice at the age of 40-50 weeks. 
Mice were Mif 
–/–
 mice on a C57BL/6J background or wildtype mice on a Balb/c 
background. The isolation procedure was based on collagenase/pronase digestion of the 
liver and subsequent density centrifugation on a Nycodenz gradient. HSC isolation was 
routinely performed by members of the core facility Q3 of SFB/TRR57 according to a 
protocol by Maschmeyer et al. [205]. Briefly, mice received 7 mg/kg i.p. xylazine and 
100 mg/kg i.p. ketamine for anesthesia. After laparotomy, the inferior vena cava and the 
vena porta were dissected and a cannula was inserted into the vena porta for perfusion. For 
this purpose, the flow of the perfusion solution was started and the vena porta was cut to 
decrease the pressure. The liver was perfused with 50 mg/100 ml pronase E (Merck) and 
42.5 mg/100 ml collagenase P (Roche) at a flow rate of 6.5 ml/min for 4.5 min each. The 
liver was isolated and further digested with 25 mg pronase E, 50 mg collagenase P, and 
1 mg DNase I in a total volume of 60 ml for 20 min. To obtain a homogenous cell suspen-
sion, the tissue was dissected and filtered through a nylon mesh. HSCs were purified from 
the resulting cell suspension by density gradient centrifugation with 8% Nycodenz. Cell 
purity, viability and cell numbers were assessed by microscopy using a hemocytometer and 
trypan blue staining. 
For RNA isolation, HSCs were further purified by FACS sorting. Sorting was performed 
with a BD Aria SORP instrument (BD Biosciences) that was equipped with a 355 nm UV 
laser. FACS sorting helped to exclude most contaminating cells as well as cell doublets, 
which mostly consist of Kupffer cells attached to HSCs. 
Primary hepatic stellate cells were cultivated in cell culture medium with additives as listed 
in Chapter 5.7. Medium was changed 24 h after isolation and then every 2-3 days. Cells 
were either used at day 1 after isolation as quiescent hepatic stellate cells (qHSC) or 
allowed to get activated and transdifferentiate for 5-7 days. Cells were then directly used as 
activated hepatic stellate cells (aHSC) or trypsinized and seeded for the use as myofibro-
blastic HSCs (MFB). For some experiments, HSCs were additionally exposed to daily 
stimulation with 100 ng/ml LPS during their activation process for 5 days to partly com-
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pensate for the observed differences in gene expression patterns between in vivo and in 
vitro activated HSCs as described by De Minicis et al. [206]. Nevertheless, LPS treatment 
was not performed for all experiments. LPS treatment in combination with JNK signaling, 
for example, might interfere with the signaling events that were to be analyzed. LPS 
treatment, if applied in the experiment, is denoted in the text. 
6.1.2 Isolation and cultivation of primary mouse hepatocytes 
Hepatocyte isolation was routinely performed by members of the core facility Q3 of 
SFB/TRR57 from wildtype C57BL/6J mice at the age of 8-12 weeks. Briefly, mice were 
anesthetized by 7 mg/kg i.p. xylazine and 100 mg/kg i.p. ketamine. After laparotomy, a 
cannula was inserted into the inferior vena cava. The liver was perfused with 20 ml of an 
EDTA-containing buffer solution and with 30-50 ml collagenase 2 (35 mg/50 ml, 
Worthington Biochemical Company) for enzymatic digestion. Flow rates were about 
7.5 ml/min at a temperature of 37°C. Before usage, all solutions were sparged with 
carbogen and entering of air into the perfusion system was avoided. Upon perfusion, the 
liver was dissected and the cell suspension filtered through a 100 µm nylon mesh. 
Hepatocytes were washed by several centrifugation steps (4 min, 4°C, 16 g) and counted 
using a hemocytometer. Viability was assessed by trypan blue staining. 
After isolation, hepatocytes were directly seeded for experiments without further cultiva-
tion. For collagen coating, collagen G (~ 4 mg/ml; Biochrom AG) was diluted 1:50 in PBS. 
12-well plates were incubated with 0.5 ml diluted collagen per well at 4°C. Residual colla-
gen was removed by washing with PBS. About 1 h after seeding, medium was replaced by 
fresh medium to remove unbound cells and to avoid agglomeration of hepatocytes. 
6.1.3 Isolation and cultivation of primary rat Kupffer cells 
Primary Kupffer cells were isolated by members of the core facility Q3 of SFB/TRR57 
from a Sprague-Dawley rat by a crude enzymatic preparation method. The liver was per-
fused through the vena porta with pronase E (35 mg/70 ml Merck) at a flow rate of 
12 ml/min and recirculating pronase E and collagenase CLS (6 mg/60 ml + 14 mg/60 ml) 
for 30 min with 32 ml/min. After liver dissection, the tissue was further digested by pro-
nase E and collagenas CLS (5 mg/90 ml + 22 mg/90 ml) and DNase I (1 mg/90 ml) for 
30 min. From the obtained cell suspension Kupffer cells and endothelial cells were en-
riched by density gradient centrifugation with 16.7% Nycodenz. Kupffer cells were further 
enriched by selective adhesion, based on the fact that Kupffer cells adhere more rapidly 
than endothelial cells. 10-15 min after seeding in RPMI supplemented with 1% FCS, non-
adherent cells were removed by extensive washing and the remaining cells were cultivated 
for 24 h before being applied for secretion experiments or lysed for Western blot analysis. 
In addition, the purity of the resulting cell population was estimated 24 h after isolation by 
the portion of cells capable of microbead (Fluoresbrite® YG Microspheres 1.0 µm, Poly-
sciences) phagocytosis. For this purpose, Kupffer cells were incubated with beads for 
30-40 min at 37°C. After extensive washing, ingestion was analyzed by visualization of the 
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green fluorescence of the beads under the microscope. According to this, the cell popu-
lation was 80-90% pure. 
6.1.4 Cultivation of mammalian cell lines 
Mammalian cell lines were cultivated for up to 20-30 passages. All utilized cell lines were 
adherent cells. They were grown to 80-90% confluency and then subcultivated by washing 
with PBS, detaching with trypsin and then transferring portions of the cell suspension to a 
new cell culture flask containing fresh medium (for medium composition see Chapter 5.7). 
Subcultivation dilutions varied between 1:5 and 1:20, depending on the cell line, cell den-
sity and the desired cultivation duration. 
Hep G2 and Ea.hy926 cells were used for collecting the supernatants for KC 13-2 cultiva-
tion. These cells were grown to 100% confluency, then medium was exchanged and the 
cells were left for several days (7 days Hep G2, 3 days Ea.hy926) to release a cocktail of 
growth factors and other mediators into the supernatant. Supernatants were collected, 
sterile filtered and stored at -20°C until they were added to KC 13-2 culture medium 
immediatedly before usage (see Chapter 5.7). 
KC 13-2 cells were cultivated in special cell culture flasks (Cell
+
, Sarstedt) as they poorly 
adhere in normal cell culture flasks. Furthermore, these cells require a temperature of 33°C 
for proliferation. For stimulation, KC 13-2 cells were seeded into poly-L-lysine-coated cell 
culture plates. Coated plates were prepared by diluting a poly-L-lysine solution (Sigma-
Aldrich) to 15 µg/ml in ddH2O and incubating the plates for 1 h at 37°C. After seeding, 
cells were transferred to a 37°C incubator until the end of the experiment. 
6.1.5 Cryopreservation of cell lines 
For long-term storage of cell lines, cells were cryopreservated at -152°C. To prepare cells 
for cryopreservation, cells were detached as described above (Chapter 6.1.4), pelleted by 
centrifugation and resuspended in their adequate growth medium containing 20% FCS and 
10% DMSO. About 2 x 10
6
 cells were transferred to each 1 ml cryotube and then frozen 
down to -80°C in an isopropanol containing freezing container, which yields an 
approximate cooling rate of about 1°C/min. After 24 h, the cells were transferred to a 
freezer at -152°C. 
6.1.6 Detection of mycoplasma contamination 
Mycoplasma species are the smallest free-lining microbes with a size of 0.3-0.8 µm. They 
readily infect cell cultures as this provides optimal growth conditions. Mycoplasma 
infections may alter a range of the host’s cellular properties such as growth, metabolism, 
cytokine secretion, membrane composition and others [207]. Therefore, the cell lines used 
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for this work were tested for mycoplasma contamination by a PCR-based method.
2
 DNA 
was extracted from 1 – 5 x 106 cells using the NucleoSpin® Tissue-Kit (Macherey-Nagel) 
according to the manufacturer’s instructions. PCR was performed using a mycoplasma 
genus-specific primer (MGSO) together with a primer that specifically binds prokaryotic 
DNA (GPO-1). Simultaneous amplification of mouse growth hormone (MGH) served as 
internal control. Primer sequences are listed in Chapter 5.6. Table 6.1 shows the composi-
tion of the PCR reaction mix for one sample using GoTaq
®
 Green Master Mix (Promega). 
The temperature program used for DNA amplification is listed in Table 6.1.  
Table 6.1: Composition of the PCR reaction mix for mycoplasma detection. Volumes are sufficient for one 
reaction. 
Component Volume Final concentration 
2x GoTaq
®
 Green Master Mix 12.5 µl 1x 
100 µM MGSO 0.25 µl 1 µM 
100 µM GPO-1 0.25 µl 1 µM 
100 µM MGH I 0.25 µl 1 µM 
100 µM MGH II 0.25 µl 1 µM 
DNA template 2 µl  
ddH2O ad 25 µl  
 
Table 6.2: PCR program for mycoplasma detection 
 Temperature Time 
Denaturation 95°C 2 min 
   
Denaturation 95°C 30 sec 
Annealing 60°C          39x 50 sec 
Elongation 72°C 30 sec 
   
Elongation 72°C 5 min 
Amplification products of the PCR reaction were separated by agarose gel electrophoresis. 
For this purpose, a 1% agarose gel was run at 120 V for 30 min. To visualize the DNA, the 
gel was incubated in 0.5 µg/ml ethidium bromide for 10 min and illuminated with UV 
light. The expected band sizes were 715 bp for mycoplasma and 400 bp for MGH. The 
GeneRuler™ 50bp DNA Ladder (Fermentas) was used to estimate the size of the DNA 
fragments. 
Table 6.3: Composition of agarose gel 
Gel Composition 
1 % Agarose gel 1 % (w/v) Agarose 
 TBE-Buffer, pH 7.3 
                                                 
2
 Mycoplasma testing was not routinely performed throughout the whole period of the present work. Thus, it 
cannot fully be ruled out that some experiments were performed with contaminated cells. 
90 6 Methods 
6.1.7 Preparation of cell lysates 
Whole cell lysates were used for several applications and prepared with the different 
buffers listed in Table 6.4, depending on the following method of analysis. 
For Western blotting, cells were directly lysed in electrophoresis sample buffer. If the aim 
was to detect phosphorylation, PhosSTOP phosphatase inhibitor cocktail (Roche) was 
added freshly. Lysates were further treated as described in Chapter 6.2.2. 
Cells that were lysed in Triton lysis buffer were used for ELISA (Chapter 6.2.3) and 
quantification of total protein via BCA assay (Chapter 6.2.4). In this case, cells were first 
washed with PBS and then incubated with lysis buffer for 45 min at 4°C. In order to re-
move cell debris, the lysates were centrifuged at 14,000 g and 4°C for 10 min. Triton lysis 
buffer was supplemented with Protease Inhibitor Cocktail Set I (Calbiochem) at the day of 
the experiment. 
If lysates were to be used for RNA isolation (Chapter 6.3.1), RLT lysis buffer, a compo-
nent of the RNeasy Mini Kit (Qiagen), was used for lysis of the cells. β-Mercaptoethanol 
was added to inhibit RNase activity. 
Table 6.4: Lysis buffers used for preparation of whole cell lysates for different applications 
Buffer Components 
Sample buffer (PAGE) NuPAGE
® 
LDS sample buffer (4x) 
 100 mM DTT 
 1x PhosSTOP (freshly added if required) 
  
Triton lysis buffer PBS 
 1% Triton-X 100 
 1x Protease Inhibitor Cocktail Set I (freshly added) 
  
RLT lysis buffer RLT lysis buffer 
 1% β-Mercaptoethanol 
6.2 Biochemical methods 
6.2.1 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
Discontinuous SDS-PAGE was used to separate proteins from whole cell lysates according 
to their molecular weight. During SDS-PAGE, proteins are denatured by the reducing rea-
gent dithiothreitol (DTT) and by sodium dodecyl sulfate (SDS), which additionally masks 
the intrinsic charge of the protein. This results in a negative charge proportional to the 
molecular weight of the protein. Discontinuous PAGE, using the tris-glycine buffer system 
developed by Lämmli [208], is characterized by a stacking gel with large pore size at 
pH 6.8, in which the proteins are focused due to an ion gradient between glycine and 
chloride ions, and a resolving gel at pH 8.8, in which the proteins are separated according 
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to their molecular weight. Separation is achieved by applying an electrical field across the 
gel which causes migration of the negatively charged proteins to move towards the anode. 
The small pore size of the resolving gel leads to a sieving effect, which allows higher mo-
tility for small protein while large proteins move slower. 
Depending on the size of the protein of interest, 7.5%, 10% or 15% polyacrylamide gels 
were used. The composition of the gels was as listed in Table 6.5. 
Table 6.5: Composition of stacking and resolving gel for SDS-PAGE 
Gel Composition 
Stacking gel 4% Acrylamide/Bis solution (30%) 
 125 mM Tris pH 6.8 
 0.1% SDS 
 0.1% APS 
 0.1% TEMED 
  
Resolving gel 7.5% / 10% / 15% Acrylamide/Bis solution (30%) 
 600 mM Tris pH 8.8 
 0.1% SDS 
 0.1% APS 
 0.1% TEMED 
Samples were mixed with 4x sample buffer which in most cases was also used for cell ly-
sate preparation as described in Chapter 6.1.6. Samples were heated to 70°C for 10 min 
and sonicated before being applied to the gel. Gels were run at 150 V for 60-90 min in 
SDS running buffer. 
Table 6.6: Composition of buffers used for SDS-PAGE 
Buffer Composition 
Sample buffer NuPAGE
® 
LDS sample buffer (4x) 
 100 mM DTT 
  
SDS running buffer 25 mM Tris 
 192 mM Glycine 
 2% SDS 
After separation of the proteins, the gels were used for Western blotting (Chapter 6.2.2). 
6.2.2 Western blotting and immunodetection 
Transfer of proteins from SDS polyacrylamide gels to membranes allows for detection of 
the protein of interest by applying specific antibodies. This was used to detect site-specific 
phosphorylation of kinases to draw conclusions about the activation status of these kinases. 
The separated proteins were blotted onto nitrocellulose using a tank blot system. For this 
purpose, a sandwich of sponges, filter paper, nitrocellulose membrane and the gel was pre-
pared. Before assembly, all components were soaked in transfer buffer. After removing all 
air bubbles, the sandwich was then transferred to a Western Blot NuPAGE
® 
/ X Cell II Blot 
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module (Invitrogen) and filled up with transfer buffer. A voltage of 35 V was applied for 
90 min while the blotting module was cooled with ice water from the outside. 
Successful transfer of the proteins was verified by Ponceau S staining for some minutes, 
which also simplified correct cutting of the membrane when several proteins of different 
size were supposed to be detected at the same time. In order to saturate unspecific binding 
sites the membrane was incubated in TBS-T containing 5% BSA or 5% non-fat milk for 
1 h at room temperature. Residual milk was removed by washing in TBS-T. The mem-
brane was incubated with primary antibodies in an appropriate dilution in TBS-T 
containing 1% or 5% BSA overnight at 4°C. To remove unbound antibody, the membrane 
was washed three times for about 5 min each, followed by incubation with a horseradish 
peroxidase (HRP)-linked secondary antibody at room temperature for at least 1 h or at 4°C 
overnight. Application of SuperSignal West Dura Substrate or, in case of very low signal, 
SuperSignal West Femto Substrate (both Pierce) allowed for detection of a chemilumines-
cent signal via the CCD camera of the Luminescent Image Analyzer LAS-3000 (Fujifilm). 
Semi-quantitative analysis of the detected bands was done by densitometry using AIDA 
image analyzer software (Raytest). 
In order to reprobe the membrane with a different antibody, the membrane was incubated 
with stripping buffer for 15 min at 55°C. After washing thoroughly, the membrane was 
blocked and incubated with antibodies again. 
Table 6.7: Composition of buffers used for Western blotting 
Buffer Composition 
Transfer buffer 1x NuPAGE
® 
Transfer buffer (20x, Invitrogen) 
 10-20% Methanol 
  
TBS-T TBS 
 0.05% Tween 20 
  
Blocking buffer TBS-T 
 5% BSA or non-fat milk 
  
Stripping buffer 62.5 mM Tris-Cl pH 6.8 
 2% SDS 
 100 mM β-mercaptoethanol 
6.2.3 Enzyme-linked immunosorbent assay (ELISA) 
The concentration of MIF in cell culture supernatants or cell lysates was determined by 
ELISA. This method allows the quantitative measurement of a certain protein in solution 
via an antibody-based approach. The typical setup of a sandwich ELISA includes a capture 
antibody, which is immobilized on the plastic surface of a 96-well plate, and a detection 
antibody. The capture antibody binds the protein of interest in the sample while all other 
proteins can be removed by washing. The detection antibody, which is biotin-labeled, 
binds any other epitope of the antigen. Incubation with a streptavidin-peroxidase (POD) 
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conjugate links the enzymatic activity to the bound antibodies which can be used for the 
conversion of a chromogenic substrate. 
To quantify MIF in samples derived from murine primary cells or cell lines, the mouse 
monoclonal anti-MIF antibody XIV.14.3 was used as capture antibody. 1.5 µg/ml were 
immobilized on the plastic surface of 96-well plates (Nunc-Immuno™ Plate F96 
Maxisorp™, Nunc Thermo Fisher Scientific) by incubation overnight at room temperature. 
Unbound antibody was removed by washing and unspecific binding sites were blocked by 
incubation with a blocking solution for 2 h. 
Table 6.8: Composition of buffers used for ELISA 
Buffer Composition 
Washing buffer PBS 
 0.05% Tween 20 
  
Blocking solution PBS 
 1 % BSA 
 5 % Sucrose 
The plate was incubated with cell lysates or supernatants and an appropriate standard over-
night at 4°C. The standard was made of different concentrations of recombinant mouse 
MIF in cell lysis buffer or cell culture medium, depending on the samples that were ana-
lyzed. After incubation, unbound protein was removed by washing. The plate was then 
incubated with the biotinylated capture antibody BAF289 (0.2 µg/ml) for 2 h and strep-
tavidin-POD (1:1000 in TBS) for 20 min, both at room temperature. Subsequently, the 
substrate solution, containing H2O2 and tetramethylbenzidine (TMB) (Pierce), was applied 
to the wells and incubated in the dark until a change in color was visible. To stop the reac-
tion 0.5 M H2SO4 was added. Color intensity could then be measured by VICTOR
2™ 1420 
Multilabel Counter (PerkinElmer) at 450 nm. 
6.2.4 Bicinchoninic acid (BCA) assay 
The BCA assay was used for quantification of total protein in cell lysates. It is a colori-
metric assay based on the reduction of Cu
2+
 to Cu
1+
 and the selective detection of Cu
1+
 by 
bicinchoninic acid, resulting in a purple-colored water soluble complex that strongly ab-
sorbs light at 562 nm. The assay was performed in 96-well plates using the Micro BCA 
Protein Assay Reagent Kit (Pierce) according to the manufacturer’s instructions. 
6.3 Molecular biology methods 
6.3.1 RNA isolation 
Total RNA was isolated from cultured hepatic cells in order to analyze changes in gene 
expression via qPCR or whole genome microarray analysis. RNA was isolated with the 
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RNeasy Mini Kit (Qiagen) according to the manufacturer’s instructions. Concentrations of 
the extracted RNA samples were analyzed via photometric measurement with the 
ND-1000 spectrophotometer (NanoDrop Technologies). The ND-1000 measures the ab-
sorption of a 1-2 µl sample over a path of 0.2 mm at a wavelength of 260 nm.  
The RNA concentration c is calculated applying the absorption A260nm, which the instru-
ment normalizes to a 10 mm path, to the following equation: 
c [ng/ml] = 40 x A260nm 
6.3.2 First-strand cDNA synthesis 
First-strand cDNA synthesis was performed using the First Strand cDNA Synthesis Kit 
(Fermentas) according to the manufacturer’s instructions. The amount of RNA for each 
reaction was the same for all samples of one experiment and was geared to the lowest con-
centrated sample with a maximum amount of 1 µg per reaction. Random hexamer primers 
were used as starting point for the recombinant M-MuLV Reverse Transcriptase. cDNA 
was diluted 1:2 or 1:5 in ddH2O. 
6.3.3 Quantitative real-time PCR (qPCR) 
Quantitative real-time PCR (qPCR) was performed to analyze gene expression in hepatic 
stellate cells. Quantification of the DNA product was achieved by utilization of the inter-
calating dye SYBR Green I, which was included in the 2x SensiMix™ SYBR No-ROX Kit 
(Peqlab). The PCR reaction mix was as listed in Table 6.9. Each sample was analyzed in 
duplicate and a non-template control was included for each master mix, containing the 
complete mixture without cDNA. 
Table 6.9: Components of the qPCR mix. Volumes are sufficient for one reaction. 
Component Volume Final concentration 
2x SensiMix™ SYBR & No-ROX 5 µl 1x 
2 µM Forward primer 1 µl 200 nM 
2 µM Reverse Primer 1 µl 200 nM 
   or 10x Quantitect Primer Assay 1 µl 1x 
Template cDNA 2 µl  
ddH2O, RNase free ad 10 µl  
The polymerase chain reaction was performed using Rotor-Gene 6000 (Corbett Life 
Science/Qiagen) by starting with a heating step to 95°C for 10 min to activate the hot-start 
DNA polymerase and finishing with a melting curve analysis to exclude formation of un-
specific side-products. The complete temperature program is listed in Table 6.10. 
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Table 6.10: Temperature program for qPCR using Rotor-Gene 6000 
Note Temperature Time 
Activation of DNA polymerase 95°C 10 min 
   
Denaturation 95°C 15 sec 
Annealing 60°C          40x 15 sec 
Elongation, Acquiring 72°C 15 sec 
   
Melt analysis 60°C-95°C 5 sec/1°C 
qPCR data were analyzed via Rotor-Gene 6000 Series Software 1.7 (Corbett Life 
Science/Qiagen). Relative mRNA levels were calculated utilizing Gapdh as a 
housekeeping gene and were normalized to an untreated control sample. 
6.3.4 Whole genome microarray analysis 
Whole genome microarray analysis was performed to identify MIF target genes that are 
differentially expressed in hepatic stellate cells that, during their transdifferentiation, were 
treated with or without recombinant MIF. For this purpose, HSCs were isolated from about 
50 weeks old male Mif 
–/–
 mice, which had grown up under identical conditions, and were 
purified by FACS sorting (see Chapter 6.1.1). Three independent experiments were per-
formed with cells that were pooled from three or four animals each. 400.000 cells were 
seeded into 6-well plates and allowed to adhere for 24 h. Medium was renewed at day 1 
after isolation and cells were cultured for another 5 days to allow in vitro activation of 
HSCs. Cells were either left unstimulated as control, daily stimulated with 200 ng/ml MIF 
or transiently stimulated with 200 ng/ml MIF for 30 min at day 1 or day 5. In order to pre-
vent excessive accumulation of MIF in the daily treated group on the one hand but on the 
other hand allow autocrine signaling of HSCs, which promotes the activation process, half 
of the medium was replaced by fresh medium every day. To keep the influence of auto-
crine stimulation comparable, this was done in all samples. Upon transient stimulation for 
30 min, the complete MIF-containing medium was removed and cells were washed with 
PBS to remove residual MIF. At day 6 after isolation, HSCs were lysed with RLT buffer 
(Chapter 6.1.6) and samples were delivered to the Miltenyi Gene Expression Profiling Ser-
vice for sample processing and microarray analysis. There, RNA was isolated with the 
RNeasy Mini Kit (Qiagen) and quality-checked via the Agilent 2100 Bioanalyzer Platform 
(Agilent Technologies). The software generates an RNA integrity number (RIN) in the 
range from 1 (low RNA quality) to 10 (high RNA quality). A RIN number of >6 is suffi-
cient for gene expression profiling experiments [209]. All RNA samples had RIN values 
between 9.4 and 10 and were accepted for analysis. 100 ng of each RNA sample was used 
to produce Cy3-labeled cRNA by a linear T7-based amplification step using the Agilent 
Low Input Quick Amp Labeling Kit (Agilent Technologies). Dye-incorporation rates and 
yields were checked with the ND-1000 Spectrophotometer (NanoDrop Technologies). 
Hybridization of Agilent Whole Mouse Genome Oligo Microarrays 8x60K (one-color) was 
performed with the Agilent Gene Expression Hybridization Kit (Agilent Technologies) 
according to the Agilent 60-mer oligo microarray processing protocol. 600 ng Cy3-labeled 
fragmented cRNA was used for each array. Fluorescence of the hybridized arrays was de-
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tected using Agilent’s Microarray Scanner System (Agilent Technologies). Image and data 
analysis was performed using the Agilent Feature Extraction Software (FES) and the 
Rosetta Resolver
®
 gene expression data analysis system (Rosetta Biosoftware). Further 
data analysis and illustration of the results was performed using Excel and MeV 4.8.1, an 
open-source software that is part of the TM4 Microarray Software Suite [204]. 
6.4 Fluorescence-based methods 
6.4.1 Flow cytometry 
Flow cytometry is based on the emission of optical signals by cells while they pass a laser 
beam. A single cell suspension is forced into a focused liquid stream in which the cells 
pass the laser beam in a single file. Forward scatter (FSC), side scatter (SSC) and 
fluorescence are measured by various detectors. Measurement of FSC gives information 
about size distribution and SSC represents granularity and structural complexity inside the 
cell. Measurement of fluorescence enables to draw conclusions about cell surface expres-
sion of antigens that were specifically labeled by fluorophore-conjugated antibodies. 
Analysis of intracellular fluorescence signals are possible as well, when the dye is able to 
cross the cell membrane or when cells were permeabilized prior to incubation with the dye 
or labeled antibody. 
In this work, flow cytometry was used to analyze cell surface expression of the MIF re-
ceptors CD74, CXCR2 and CXCR4. To prepare cells for flow cytometry, cells were 
detached from cell culture dishes by accutase treatment. In contrast to trypsinization, this 
allows for analysis of cell surface markers. 200.000 cells per sample were incubated with 
FITC- or PE-conjugated antibodies or their appropriate isotype controls for 30-40 min on 
ice in the dark. Washing with flow cytometry buffer (Table 6.11) was performed before 
and after antibody incubation by centrifugation (350 g, 5 min, 4°C) to remove residual 
accutase and unbound antibody, respectively. After the last washing step, the pellet was 
resuspended in 400 µl flow cytometry buffer and transferred into FACS tubes for analysis 
with a FACS Canto II™ flow cytometer (BD Biosciences). The software FlowJo 8.8.6 was 
used for data analysis. 
Table 6.11: Composition of the buffer used for flow cytometry 
Buffer Components 
Flow cytometry buffer PBS 
 0.5% BSA 
 0.1% NaN3 
6.4.2 Propidium iodide staining 
To assess membrane integrity of CCl4-treated cells, propidium iodide (PI) staining was 
performed. PI intercalates into the DNA and can be measured by its red fluorescence. As 
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PI is unable to pass through the intact cell membrane, it only stains damaged cells. It can 
therefore be used to visualize cellular damage and distinguish viable from dead cells. For 
PI staining, cells were washed with PBS to remove residual culture medium and incubated 
with PI diluted 1:20 in PBS for 30 min at room temperature. PI-positive cells were visual-
ized by fluorescence microscopy. 
6.4.3 Lactate dehydrogenase assay 
Determination of MIF secretion may be biased by enhanced cell death in response to some 
stimuli. Therefore, some samples were tested with the CytoTox-ONE™ Homogeneous 
Membrane Integrity Assay (Promega). This assay is based on the assumption that lactate 
dehydrogenase (LDH) is only released from cells with a damaged membrane. LDH activity 
in the cell culture supernatants is measured by a coupled enzymatic reaction in which 
resazurin is converted into a fluorescent product. The assay was performed according to 
the manufacturer’s instructions using cell culture supernatants from the secretion assays 
(Chapter 6.5.3). Medium was used to determine background fluorescence, whole cell ly-
sates served as 100% reference. Fluorescence was measured with the VICTOR
2™ 1420 
Multilabel Counter (PerkinElmer) at 590 nm. 
6.5 Functional assays 
6.5.1 Cell proliferation assay 
Proliferation of GRX cells was assessed by measurement of the bromodeoxyuridine 
(BrdU) incorporation rate. This method is based on the incorporation of the thymidine 
analog BrdU into the genomic DNA of proliferating cells during the S phase of the cell 
cycle instead of thymidine. Specific anti-BrdU antibodies can be used to detect and 
quantify the incorporated BrdU which enables to draw conclusions about the proliferative 
activity of the cells.  
The assay was performed with the colorimetric Cell Proliferation ELISA Kit (Roche) ac-
cording to the manufacturer’s instructions. Cells were seeded into 96-well plates. After 
adhesion, they were serum-starved overnight in serum-free DMEM and then stimulated 
with 100 ng/ml PDGF-B and/or 500 ng/ml recombinant MIF for 24 h. After pre-incuba-
tion, BrdU was added for 2 h to label newly synthesized DNA. Finally, cells were fixed 
and DNA was denatured with a ready-to-use solution provided in the kit, and incorporated 
BrdU was quantified via an ELISA-like procedure. 
In order to inhibit AMPK activity, cells were pre-incubated with 25 µM compound C for 
1 h prior to stimulation with PDGF-B and MIF. 
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6.5.2 Cell migration assay 
Cell migration of GRX cells in the context of MIF stimulation was analyzed with a modi-
fied Boyden chamber. The modified Boyden chamber consists of a lower chamber with 
medium and the substance of interest and an upper chamber, which at the beginning of the 
experiments contains the cells. The cells migrate through a gelatin-coated filter towards the 
stimulus in the lower chamber. 2 x 10
5
 cells in 800 µl serum-free DMEM were added to 
the upper chamber at the beginning of the experiment, while the lower chamber was filled 
with 250 µl serum-free DMEM and 100 ng/ml PDGF-B and/or 500 ng/ml MIF. Cells were 
allowed to migrate through the filter for 4 h at 37°C and 5% CO2. Next, the filter was re-
moved, cells at the upper side were wiped away and the filter was stained using the 
Hemacolor
®
 staining kit (Merck). Staining was performed by sequentially incubating the 
filter in fixation solution (methanol), red color reagent (eosin), blue color reagent 
(hemalum) and tap water for 1 min each. Quantification of the migrated cells was done 
microscopically by counting three randomly chosen fields. For blocking of AMPK activity, 
the cells were pre-incubated with 25 µM compound C 1 h prior to the experiment. 
6.5.3 Secretion assay 
MIF secretion from various hepatic cells upon stimulation was measured via ELISA 
(Chapter 6.2.3). As stimuli, chemokines, growth factors, other mediators and chemicals 
were chosen that were known to regulate cell behavior in the context of fibrosis or 
inflammation and/or induce MIF secretion in other cell systems. A complete list of the 
stimuli and their final concentration can be found in Table 6.12. 
Table 6.12: Stimuli used for secretion assays with different hepatic cells 
Stimulus Concentration 
CCl4 100 mM  
Ethanol  150 μM  
H2O2 100 μM  
IFN-γ (murine)   10 ng/ml,  50 ng/ml 
IL-1β (human)   10 ng/ml  
IL-6 (human)   20 ng/ml  
LPS (E. coli)     1 µg/ml, 0.1 µg/ml, 0.01 µg/ml  
MCP-1 (human/murine) 100 ng/ml  
TGF-β1 (human)     5 ng/ml  
TNF-α (murine)   20 ng/ml  
PDGF-B (human)   20 ng/ml  
Of note, not all stimuli were used for every cell type. The chosen concentrations were 
based on literature data. Only for CCl4, which is routinely used for in vivo models, the con-
centration was roughly estimated in accordance to scale-down factors of other compounds 
used in vivo and in vitro. When recombinant proteins were used in their human variant, 
literature and datasheets were checked for cross-reactivity with mouse cells. 
To perform the secretion assay, cell numbers, FCS concentrations and the duration of se-
rum starvation prior to stimulation had to be adjusted for every cell type and stimulation 
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period to assure nearly confluent cultures with a minimum of dead cells at the time of har-
vest. For 6 h stimulation, 1.5 x 10
5
 (GRX) or 2.5 x 10
5
 (KC 13-2) cells were seeded in 12-
well plates, allowed to adhere for several hours and serum-starved overnight in DMEM 
containing 0.5% FCS. Medium was replaced by serum-free DMEM, stimuli were added 
and the cells were incubated for 6 h at 37°C and 5% CO2. For longer stimulation (20 h), 
1 x 10
5
 (GRX, Hepa 1-6) or 2.5 x 10
5
 (KC 13-2, primary hepatocytes) cells were seeded in 
12-well plates and allowed to adhere overnight. Cells were serum-starved in DMEM 
containing 1% FCS for 3 h, medium was replaced by fresh serum-reduced DMEM (1% 
FCS) and stimuli were added. Supernatants and cell lysates were collected after incubation 
at 37°C and 5% CO2 for 20 h. For 30 min stimulation, the conditions were as for 20 h. 
At the end of the assay, supernatants were collected and centrifuged for 5 min at 350 g and 
4°C. Supernatants were transferred to a fresh tube to remove detached cells and cell debris. 
Simultaneously, cells were lysed in Triton lysis buffer as described in Chapter 6.1.6. 
Samples were either directly used or stored at –20°C for later application in ELISA 
(Chapter 6.2.3), BCA assay (Chapter 6.2.4) or LDH assay (Chapter 6.4.3). 
6.5.4 Phosphorylation assay 
In order to analyze signaling pathways that were activated upon MIF stimulation, the 
phosphorylation status of the kinases AMPK, LKB1, and JNK and of the JNK substrate 
c-Jun was detected by Western blotting (Chapter 6.2.2). Hepatic stellate cells (GRX or 
primary cells) or Hepa 1-6 cells were seeded into 6-, 12-, or 24-well plates at a density that 
resulted in near-confluency after some hours of incubation. Cells were allowed to adhere 
for several hours and serum-starved overnight in their adequate cell culture medium 
containing 0.5% FCS. Cells of one plate were either simultaneously stimulated with MIF 
in different concentrations or sequentially for different time periods using the same 
concentration of MIF for all wells. Dilutions were prepared in a way that allowed addition 
of the same volume to each well. After incubation at 37°C for the desired period of time, 
the plate was removed from the incubator and immediately placed on a cool pack. To avoid 
stress-related variances in phosphorylation levels due to slide differences in handling 
between the wells, medium was removed from all wells at the same time by tipping and 
lysis buffer (electrophoresis sample buffer with phosphatase inhibitors, see Chapter 6.1.6) 
was simultaneously added using a multichannel pipette. Lysates were transferred to 1.5 ml 
reaction tubes and further treated as described in Chapter 6.2.1. 
6.6 Experimental liver fibrosis in mice 
6.6.1 Induction of liver fibrosis by CCl4 
Induction of hepatic injury by CCl4 administration is a commonly used in vivo mouse 
model to investigate molecular and cellular processes during chronic liver injury and fibro-
sis [140]. To induce fibrosis, wildtype and Mif 
–/–
 mice (n = 12 per group) were 
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intraperitoneally injected with CCl4 at a concentration of 0.6 mg/kg body weight. Injec-
tions were repeated twice a week for 6 weeks. Mice were sacrificed by cervical dislocation 
3 days after the last injection. After laparotomy, the liver was perfused with 10 ml PBS. 
Fibrosis of the dissected livers was histologically and biochemically assessed by Sirius red 
staining and measurement of hydroxyproline content, as published elsewhere [136, 142]. 
Total liver lysates were analyzed for α-SMA expression (see Chapter 2.3). 
6.6.2 Therapeutic application of MIF 
To assess the therapeutic potential of MIF in hepatotoxin-induced liver fibrosis, wildtype 
C57BL/6 mice (n = 6 per group) received daily intraperitoneal injections of 10 µg recom-
binant MIF or equivalent amounts of 20 mM sodium phosphate buffer as vehicle control. 
Concomitantly, mice were injected with CCl4 as described above for 10 days. Dissected 
livers were analyzed for α-SMA expression by immunohistochemistry of formalin-fixed 
paraffin embedded tissue (staining was performed by members of the core facility Q1 of 
SFB/TRR57) and by Western blot of total liver lysates. RNA was isolated from liver tissue 
to analyze gene expression of α-Sma and other fibrosis-relevant genes by qPCR. 
6.7 Statistical Analysis 
Data are given as mean values ± SEM. Experimental groups were compared by one-way 
ANOVA of logarithmic transformed data with Dunnett’s post test or as described in 
Heinrichs, Knauel et al. [74, 136]. P values lower than 0.05 were considered significant. 
Statistical tests were performed by GraphPad Prism 5.  
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 A Appendix 
A.1 Upregulated genes in HSCs upon daily MIF 
stimulation 
Listed are upregulated genes in daily MIF-stimulated cells (sample IIB) compared to 
control (sample IIA). The list comprises genes that are upregulated with a mean fold 
change (FC) > 3 and a significant signal above background in the sample of daily 
stimulated cells. 
SeqName Seqcode Full name FC 
Cacna1f A_55_P2043718 calcium channel, voltage-dependent, alpha 1F subunit 
(Cacna1f) [NM_019582] 
117.60 
Trim61 A_55_P1962329 tripartite motif-containing 61 (Trim61), transcript 
variant 1 [NM_153110] 
11.99 
Nhedc1 A_51_P187679 Na+/H+ exchanger domain containing 1 (Nhedc1) 
[NM_028946] 
11.43 
Olfr1137 A_55_P2011635 olfactory receptor 1137 (Olfr1137) [NM_001011833] 11.40 
Eapa2 A_55_P1959041 family with sequence similarity 115, member E 
(Fam115e) [NM_203396] 
8.95 
Mybpc1 A_55_P2008443 myosin binding protein C, slow-type (Mybpc1) 
[NM_175418] 
8.95 
Tff1 A_55_P2021585 trefoil factor 1 (Tff1) [NM_009362] 8.75 
ENSMUST-
00000076452 
A_66_P133872 PDZ domain containing 7 (Pdzd7) [NM_001195265] 7.81 
Tff1 A_55_P2112005 trefoil factor 1 (Tff1) [NM_009362] 7.55 
Rgs8 A_55_P2004861 regulator of G-protein signaling 8 (Rgs8) 
[NM_026380] 
7.46 
Tmem9b A_55_P1982767 TMEM9 domain family, member B (Tmem9b) 
[NM_020050] 
7.46 
Tpsb2 A_55_P2089143 tryptase beta 2 (Tpsb2) [NM_010781] 6.62 
Uts2 A_51_P334689 urotensin 2 (Uts2) [NM_011910] 6.38 
Gcnt2 A_55_P2025595 glucosaminyl (N-acetyl) transferase 2, I-branching 
enzyme (Gcnt2), transcript variant 1 [NM_008105] 
5.40 
Tbx19 A_52_P95930 T-box 19 (Tbx19) [NM_032005] 5.22 
Tmem132b A_55_P2035792 transmembrane protein 132B (Tmem132b) 
[NM_001190352] 
5.10 
Elovl2 A_55_P2062737 elongation of very long chain fatty acids (FEN1/Elo2, 
SUR4/Elo3, yeast)-like 2 (Elovl2) [NM_019423] 
5.09 
Glyctk A_55_P2096973 glycerate kinase (Glyctk), transcript variant 1 
[NM_174846] 
5.02 
Hyal6 A_55_P2052325 hyaluronoglucosaminidase 6 (Hyal6) [NM_028920] 4.76 
Klra22 A_55_P2170350 killer cell lectin-like receptor subfamily A, member 22 
(Klra22) [NM_053152] 
4.75 
Plcd4 A_52_P327588 phospholipase C, delta 4 (Plcd4), transcript variant 2 
[NM_148937] 
4.66 
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SeqName Seqcode Full name FC 
Slpi A_52_P472324 secretory leukocyte peptidase inhibitor (Slpi) 
[NM_011414] 
4.51 
Abpe A_55_P2061432 androgen binding protein epsilon (Abpe) 
[NM_207262] 
4.49 
Synpo2 A_52_P223127 synaptopodin 2 (Synpo2) [NM_080451] 4.42 
Ntng1 A_55_P1989341 netrin G1 (Ntng1), transcript variant a [NM_030699] 4.34 
ENSMUST-
00000118194 
A_55_P2029116 Mperoxisomal biogenesis factor 11c [AK165461] 4.32 
ENSMUST-
00000106078 
A_55_P2063033 polyhomeotic-like 2 (Drosophila) [MGI:1860454] 
[ENSMUST-00000133439] 
4.31 
Dbx1 A_51_P156144 developing brain homeobox 1 (Dbx1) 
[NM_001005232] 
4.28 
Nfasc A_55_P2173011 neurofascin (Nfasc), transcript variant 1 [NM_182716] 4.15 
DXBay18 A_55_P2177278 DNA segment, Chr X, Baylor 18 (DXBay18) 
[NM_001025384] 
4.13 
Tjp3 A_55_P1960291 tight junction protein 3 (Tjp3) [NM_013769] 4.10 
H2-M9 A_55_P2166148 histocompatibility 2, M region locus 9 (H2-M9) 
[NM_008205] 
4.09 
Ccdc105 A_55_P2111108 coiled-coil domain containing 105 (Ccdc105) 
[NM_027630] 
4.05 
Olfr975 A_66_P116028 olfactory receptor 975 (Olfr975) [NM_146828] 4.03 
Tmem200c A_55_P2089402 transmembrane protein 200C (Tmem200c) 
[NM_001206661] 
3.97 
Nkx2-5 A_51_P173285 NK2 transcription factor related, locus 5 (Drosophila) 
(Nkx2-5) [NM_008700] 
3.96 
Ankrd56 A_51_P464146 ankyrin repeat domain 56 (Ankrd56) [NM_175270] 3.91 
Itk A_55_P1953788 IL2-inducible T-cell kinase (Itk) [NM_010583] 3.84 
Kif23 A_51_P153734 kinesin family member 23 [MGI:1919069] 
[ENSMUST-00000055275] 
3.79 
Zscan10 A_55_P1970274 zinc finger and SCAN domain containing 10 (Zscan10) 
[NM_001033425] 
3.79 
Kcnj14 A_51_P250559 potassium inwardly-rectifying channel, subfamily J, 
member 14 (Kcnj14) [NM_145963] 
3.79 
Dcpp2 A_55_P2158510 demilune cell and parotid protein 2 (Dcpp2) 
[NM_001039238] 
3.76 
Sis A_51_P328631 sucrase isomaltase (alpha-glucosidase) (Sis) 
[NM_001081137] 
3.76 
Lrrc6 A_51_P249559 leucine rich repeat containing 6 (testis) (Lrrc6) 
[NM_019457] 
3.74 
Ttbk1 A_55_P2124070 tau tubulin kinase 1 (Ttbk1) [NM_001162864] 3.69 
Usp43 A_55_P2219243 ubiquitin specific peptidase 43 (Usp43) [NM_173754] 3.69 
C1ql4 A_55_P2069602 complement component 1, q subcomponent-like 4 
(C1ql4) [NM_001024702] 
3.66 
Olfr124 A_55_P1980661 olfactory receptor 124 (Olfr124) [NM_147062] 3.65 
Sult5a1 A_51_P471458 sulfotransferase family 5A, member 1 (Sult5a1) 
[NM_020564] 
3.61 
Gabbr2 A_52_P612928 gamma-aminobutyric acid (GABA) B receptor, 2 
(Gabbr2) [NM_001081141] 
3.60 
Lamc3 A_55_P2017939 laminin gamma 3 (Lamc3) [NM_011836] 3.60 
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Bfsp2 A_51_P298802 beaded filament structural protein 2, phakinin (Bfsp2) 
[NM_001002896] 
3.60 
Olfr372 A_55_P2151284 olfactory receptor 372 (Olfr372) [NM_207555] 3.59 
Defb45 A_55_P2090840 defensin beta 45 (Defb45) [NM_001037752] 3.59 
Chst5 A_55_P2054027 carbohydrate (N-acetylglucosamine 6-O) 
sulfotransferase 5 (Chst5) [NM_019950] 
3.58 
Rims4 A_55_P2025883 regulating synaptic membrane exocytosis 4 (Rims4) 
[NM_183023] 
3.57 
Olfr607 A_66_P119550 olfactory receptor 607 [MGI:3030441] [ENSMUST-
00000045546] 
3.57 
Pilrb2 A_55_P1970763 paired immunoglobin-like type 2 receptor beta 2 
(Pilrb2) [NM_001024932] 
3.54 
Flrt2 A_65_P05152 fibronectin leucine rich transmembrane protein 2 
(Flrt2) [NM_201518] 
3.52 
Pgk2 A_55_P2051444 phosphoglycerate kinase 2 (Pgk2) [NM_031190] 3.51 
Kirrel3 A_51_P384693 kin of IRRE like 3 (Drosophila) (Kirrel3), transcript 
variant B [NM_026324] 
3.51 
Gabrb3 A_52_P344138 gamma-aminobutyric acid (GABA) A receptor, subunit 
beta 3 (Gabrb3), transcript variant 1 [NM_008071] 
3.50 
ENSMUST-
00000097955 
A_51_P207801 cache domain containing 1 [MGI:2444177] 
[ENSMUST-00000097955] 
3.48 
Fam131c A_55_P1962766 family with sequence similarity 131, member C 
(Fam131c) [NM_001085513] 
3.42 
Atp12a A_52_P329398 ATPase, H+/K+ transporting, nongastric, alpha 
polypeptide (Atp12a) [NM_138652] 
3.42 
Dppa4 A_55_P2065549 developmental pluripotency associated 4 (Dppa4), 
transcript variant 1 [NM_028610] 
3.39 
Cyp2c66 A_51_P471126 cytochrome P450, family 2, subfamily c, polypeptide 
66 (Cyp2c66) [NM_001011707] 
3.39 
Vwa5a A_66_P131754 von Willebrand factor A domain containing 5A 
(Vwa5a) [NM_172767] 
3.38 
Cxxc4 A_55_P2070603 CXXC finger 4 [MGI:2442112] [ENSMUST-
00000166288] 
3.36 
Gpr25 A_55_P2081035 G protein-coupled receptor 25 (Gpr25) 
[NM_001101516] 
3.34 
Cyp2b10 A_55_P2044653 cytochrome P450, family 2, subfamily b, polypeptide 
10 (Cyp2b10), transcript variant 2 [NM_009999] 
3.31 
Cyp27b1 A_55_P2088237 cytochrome P450, family 27, subfamily b, polypeptide 
1 (Cyp27b1) [NM_010009] 
3.30 
Gal3st4 A_52_P1174 galactose-3-O-sulfotransferase 4 (Gal3st4) 
[NM_001033416] 
3.29 
Lhfpl3 A_66_P106774 lipoma HMGIC fusion partner-like 3 (Lhfpl3), 
transcript variant 1 [NM_029990] 
3.28 
Rhox2c A_55_P2111756 reproductive homeobox 2C (Rhox2c) 
[NM_001099318] 
3.21 
Nkx3-2 A_55_P2177113 NK3 homeobox 2 (Nkx3-2) [NM_007524] 3.18 
ENSMUST-
00000091674 
A_55_P1988918 CDK5 regulatory subunit associated protein 1-like 1 
[MGI:1921765] [ENSMUST-00000091674] 
3.18 
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A.2 Downregulated genes in HSCs upon daily MIF 
stimulation 
Listed are downregulated genes in daily MIF-stimulated cells (sample IIB) compared to 
control (sample IIA). The list comprises genes that are downregulated with a mean fold 
change (FC) > 3 and a significant signal above background in the sample of daily 
stimulated cells. 
SeqName Seqcode Full name FC 
Zmat4 A_51_P422685 zinc finger, matrin type 4 (Zmat4) [NM_177086] -106.24 
Slc17a1 A_55_P1969506 solute carrier family 17 (sodium phosphate), member 1 
(Slc17a1), transcript variant 1 [NM_009198] 
-79.07 
Vmn2r75 A_55_P1966634 vomeronasal 2, receptor 75 (Vmn2r75) 
[NM_001102578] 
-50.23 
Pira6 A_52_P18236 paired-Ig-like receptor A6 (Pira6), transcript variant 2 
[NM_011093] 
-28.80 
Nlrc4 A_52_P655136 NLR family, CARD domain containing 4 (Nlrc4) 
[NM_001033367] 
-24.55 
Orm1 A_51_P336325 orosomucoid 1 (Orm1) [NM_008768] -21.26 
Myt1l A_55_P2001793 myelin transcription factor 1-like (Myt1l), transcript 
variant 1 [NM_001093775] 
-18.97 
Ppp1r1a A_52_P144818 protein phosphatase 1, regulatory (inhibitor) subunit 
1A (Ppp1r1a) [NM_021391] 
-17.73 
Il12rb2 A_55_P1978416 interleukin 12 receptor, beta 2 (Il12rb2) [NM_008354] -16.31 
Col19a1 A_55_P2019631 procollagen, type XIX, alpha 1 [AK149136] -15.32 
Adamts3 A_55_P2163541 a disintegrin-like and metallopeptidase (reprolysin 
type) with thrombospondin type 1 motif, 3 (Adamts3), 
transcript variant 1 [NM_177872] 
-14.33 
Neurod1 A_55_P2004972 neurogenic differentiation 1 (Neurod1) [NM_010894] -13.53 
Gh A_51_P104687 growth hormone (Gh) [NM_008117] -13.49 
Gli1 A_55_P2080658 GLI-Kruppel family member GLI1 [MGI:95727] 
[ENSMUST-00000105252] 
-13.16 
Olfr1387 A_55_P2162718 olfactory receptor 1387 (Olfr1387) [NM_146473] -13.11 
Slitrk3 A_52_P47781 SLIT and NTRK-like family, member 3 (Slitrk3) 
[NM_198864] 
-12.49 
Vmn2r27 A_55_P2159969 vomeronasal 2, receptor27 (Vmn2r27) 
[NM_001104642] 
-11.99 
Caps2 A_55_P2089091 calcyphosphine 2 (Caps2) [NM_178278] -11.67 
Yipf7 A_52_P313102 Yip1 domain family, member 7 (Yipf7) [NM_023784] -11.03 
Olfr1132 A_55_P2072671 olfactory receptor 1132 (Olfr1132) [NM_146836] -10.91 
ENSMUST-
00000118205 
A_66_P120309 TRANSMEMBRANE PROTEIN VEZATIN homolog 
[Homo sapiens] [AK042540] 
-10.73 
Cdh29 A_52_P120122 cadherin-like 29 (Cdh29) [NM_177090] -10.32 
ENSMUST-
00000112310 
A_51_P186487 phosphoinositide-3-kinase, class 2, beta polypeptide 
[MGI:2685045] [ENSMUST-00000124934] 
-9.87 
Olfr716 A_51_P211978 olfactory receptor 716 (Olfr716) [NM_146604] -9.23 
Vmn1r61 A_55_P1972169 vomeronasal 1 receptor 61 (Vmn1r61) 
[NM_001166733] 
-8.36 
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Cyp3a11 A_55_P2121225 cytochrome P450, family 3, subfamily a, polypeptide 
11 (Cyp3a11) [NM_007818] 
-8.07 
Nlrp1b A_66_P106290 NLR family, pyrin domain containing 1B (Nlrp1b), 
transcript variant 1 [NM_001040696] 
-7.80 
Il5 A_55_P2138386 interleukin 5 (Il5) [NM_010558] -7.40 
Mybpc2 A_55_P2013665 myosin binding protein C, fast-type (Mybpc2), 
transcript variant 2 [NM_146189] 
-7.15 
Olfr1342 A_55_P2100000 olfactory receptor 1342 (Olfr1342) [NM_146713] -6.87 
Vwa5b1 A_55_P2081990 von Willebrand factor A domain containing 5B1 
(Vwa5b1) [NM_029401] 
-6.74 
Eda A_55_P2030667 ectodysplasin-A (Eda), transcript variant 7 
[NM_001177942] 
-6.57 
Adad2 A_51_P140042 adenosine deaminase domain containing 2 (Adad2) 
[NM_029428] 
-6.39 
Tmem190 A_51_P490337 transmembrane protein 190 (Tmem190) [NM_030028] -6.14 
Slc25a21 A_55_P2033393 solute carrier family 25 (mitochondrial 
oxodicarboxylate carrier), member 21 (Slc25a21), 
transcript variant 1 [NM_172577] 
-6.07 
Etv1 A_55_P1986321 ets variant gene 1 (Etv1), transcript variant 1 
[NM_007960] 
-6.07 
Gzme A_55_P1971010 granzyme E (Gzme) [NM_010373] -5.94 
Efcab5 A_55_P2138217 EF-hand calcium binding domain 5 (Efcab5) 
[NM_176965] 
-5.77 
Ifltd1 A_55_P1954960 intermediate filament tail domain containing 1 (Ifltd1) 
[NM_028742] 
-5.51 
Vmn2r88 A_55_P2017140 vomeronasal 2, receptor 88 (Vmn2r88) [NM_011686] -5.41 
Krt71 A_51_P364639 keratin 71 (Krt71) [NM_019956] -5.40 
Trex2 A_55_P2073094 three prime repair exonuclease 2 (Trex2) 
[NM_011907] 
-5.38 
Stx8 A_55_P2176989 syntaxin 8 (Stx8) [NM_018768] -5.35 
Plxna4 A_52_P650037 plexin A4 (Plxna4) [NM_175750] -5.16 
Chchd2 A_55_P2170589 coiled-coil-helix-coiled-coil-helix domain containing 2 
(Chchd2) [NM_024166] 
-5.14 
Agxt2 A_55_P2186282 alanine-glyoxylate aminotransferase 2 (Agxt2) 
[NM_001031851] 
-5.10 
Oxct2b A_55_P2022629 3-oxoacid CoA transferase 2B (Oxct2b) [NM_181859] -5.08 
Ugt2b37 A_51_P302856 UDP glucuronosyltransferase 2 family, polypeptide 
B37 (Ugt2b37) [NM_053215] 
-4.94 
Tdrd9 A_55_P1989369 tudor domain containing 9 (Tdrd9) [NM_029056] -4.94 
Olfr462 A_55_P2086797 olfactory receptor 462 (Olfr462) [NM_146411] -4.94 
Ugt2b5 A_55_P1975080 UDP glucuronosyltransferase 2 family, polypeptide B5 
(Ugt2b5) [NM_009467] 
-4.91 
Scgb1c1 A_52_P156775 secretoglobin, family 1C, member 1 (Scgb1c1) 
[NM_001099742] 
-4.88 
Olfr432 A_55_P2127100 olfactory receptor 432 (Olfr432) [NM_146716] -4.82 
Mmel1 A_55_P2001078 membrane metallo-endopeptidase-like 1 (Mmel1) 
[NM_013783] 
-4.80 
Mmp28 A_55_P2150612 matrix metallopeptidase 28 (epilysin) (Mmp28), 
transcript variant 1 [NM_080453] 
-4.80 
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Vmn1r183 A_55_P1978847 vomeronasal 1 receptor 183 (Vmn1r183) 
[NM_203489] 
-4.72 
Zfp57 A_55_P2172201 zinc finger protein 57 (Zfp57), transcript variant 3 
[NM_001168502] 
-4.64 
Sprr2e A_55_P2109569 small proline-rich protein 2E (Sprr2e) [NM_011471] -4.62 
Loxhd1 A_51_P238009 lipoxygenase homology domains 1 [MGI:1914609] 
[ENSMUST-00000035501] 
-4.59 
Crmp1 A_55_P2017600 collapsin response mediator protein 1 (Crmp1), 
transcript variant 2 [NM_007765] 
-4.56 
Olfr901 A_55_P2045581 olfactory receptor 901 (Olfr901) [NM_001011806] -4.56 
Mtmr7 A_66_P117578 myotubularin related protein 7 (Mtmr7) 
[NM_001040699] 
-4.50 
Fbp1 A_51_P474701 fructose bisphosphatase 1 (Fbp1) [NM_019395] -4.49 
Akr1c20 A_51_P382764 aldo-keto reductase family 1, member C20 
[BC021607] 
-4.40 
Unc13a A_55_P2017964 unc-13 homolog A (C. elegans) (Unc13a) 
[NM_001029873] 
-4.37 
Ints10 A_65_P13545 integrator complex subunit 10 [MGI:1918135] 
[ENSMUST-00000034328] 
-4.31 
Cpamd8 A_55_P2074766 murinoglobulin 2 (Mug2) [NM_008646] -4.21 
Car1 A_55_P2099952 carbonic anhydrase 1 (Car1), transcript variant 1 
[NM_009799] 
-4.20 
Duox2 A_55_P1974760 dual oxidase 2 (Duox2) [NM_177610] -4.19 
Prb1 A_52_P71756 proline-rich protein BstNI subfamily 1 (Prb1) 
[NM_198669] 
-4.19 
Rgn A_51_P157462 regucalcin (Rgn) [NM_009060] -4.13 
Rabgap1l A_55_P2002815 RAB GTPase activating protein 1-like [MGI:1352507] 
[ENSMUST-00000028048] 
-4.12 
Kcnip4 A_52_P319774 Kv channel interacting protein 4 (Kcnip4), transcript 
variant 4 [NM_030265] 
-4.10 
Ms4a5 A_55_P1958171 membrane-spanning 4-domains, subfamily A, member 
5 (Ms4a5) [NM_183190] 
-4.08 
Aim2 A_55_P2080130 absent in melanoma 2 (Aim2) [NM_001013779] -4.06 
Tpbpb A_51_P130808 trophoblast specific protein beta (Tpbpb) 
[NM_026429] 
-4.04 
Lrriq3 A_52_P173580 leucine-rich repeats and IQ motif containing 3 (Lrriq3) 
[NM_028938] 
-3.99 
Hoxc12 A_55_P2169099 homeobox C12 (Hoxc12) [NM_010463] -3.99 
Utp6 A_52_P33927 UTP6, small subunit (SSU) processome component, 
homolog (yeast) [MGI:2445193] [ENSMUST-
00000108241] 
-3.98 
Afm A_52_P425734 afamin (Afm) [NM_145146] -3.98 
Crtam A_51_P150302 cytotoxic and regulatory T cell molecule (Crtam) 
[NM_019465] 
-3.95 
Six3 A_55_P2082408 sine oculis-related homeobox 3 homolog (Drosophila) 
[MGI:102764] [ENSMUST-00000043819] 
-3.92 
Rbm20 A_55_P2102444 RNA binding motif protein 20 (Rbm20) 
[NM_001170847] 
-3.89 
LOC435333 A_55_P2011950 immunoglobulin heavy variable 1-85 [MGI:3645723] 
[ENSMUST-00000103552] 
-3.85 
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Slc17a2 A_66_P118430 solute carrier family 17 (sodium phosphate), member 2 
[MGI:2443098] [ENSMUST-00000006786] 
-3.84 
Col2a1 A_55_P2004179 collagen, type II, alpha 1 (Col2a1), transcript variant 2 
[NM_001113515] 
-3.83 
Mug1 A_55_P2105413 murinoglobulin 1 (Mug1) [NM_008645] -3.82 
Cer1 A_55_P1970100 cerberus 1 homolog (Xenopus laevis) (Cer1) 
[NM_009887] 
-3.81 
C4bp A_52_P60194 complement component 4 binding protein (C4bp) 
[NM_007576] 
-3.80 
Sox11 A_55_P2094721 SRY-box containing gene 11 (Sox11) [NM_009234] -3.80 
Pla2g4d A_55_P1987775 phospholipase A2, group IVD (Pla2g4d) 
[NM_001024137] 
-3.80 
Hoxa1 A_55_P2066123 homeobox A1 (Hoxa1) [NM_010449] -3.79 
Btn1a1 A_52_P196097 butyrophilin, subfamily 1, member A1 [AK021333] -3.79 
Bcl2l11 A_52_P348214 BCL2-like 11 (apoptosis facilitator) [MGI:1197519] 
[ENSMUST-00000129206] 
-3.78 
Nhlrc4 A_66_P139052 NHL repeat containing 4 (Nhlrc4) [NM_001039038] -3.77 
Bend5 A_51_P158018 BEN domain containing 5 (Bend5), transcript variant 1 
[NM_026279] 
-3.76 
Wnt8b A_55_P2140913 wingless related MMTV integration site 8b (Wnt8b) 
[NM_011720] 
-3.75 
Il19 A_55_P2128144 interleukin 19 (Il19) [NM_001009940] -3.74 
Bcl11a A_55_P1958275 B-cell CLL/lymphoma 11A (zinc finger protein) 
(Bcl11a), transcript variant 1 [NM_016707] 
-3.73 
Olfr1314 A_52_P629709 olfactory receptor 1314 (Olfr1314) [NM_146450] -3.72 
Cdh16 A_51_P287100 cadherin 16 (Cdh16) [NM_007663] -3.70 
Ly86 A_51_P465350 lymphocyte antigen 86 (Ly86) [NM_010745] -3.67 
Mrgprb3 A_52_P320394 MAS-related GPR, member B3 (Mrgprb3) 
[NM_207537] 
-3.61 
Olfr1052 A_55_P1982643 olfactory receptor 1052 (Olfr1052) [NM_147010] -3.59 
Defa-rs2 A_55_P2018869 defensin, alpha, related sequence 2 (Defa-rs2) 
[NM_007847] 
-3.57 
ENSMUST-
00000044022 
A_55_P2108790 erythrocyte protein band 4.1-like 4b [MGI:1859149] 
[ENSMUST-00000044022] 
-3.57 
Nmur2 A_55_P2179582 neuromedin U receptor 2 (Nmur2) [NM_153079] -3.57 
Meox1 A_55_P2034245 mesenchyme homeobox 1 (Meox1) [NM_010791] -3.55 
Pde6c A_66_P134394 phosphodiesterase 6C, cGMP specific, cone, alpha 
prime (Pde6c), transcript variant 1 [NM_033614] 
-3.54 
Slc16a5 A_55_P2024046 solute carrier family 16 (monocarboxylic acid 
transporters), member 5 (Slc16a5) [NM_001080934] 
-3.52 
Slc38a4 A_52_P48569 solute carrier family 38, member 4 (Slc38a4) 
[NM_027052] 
-3.52 
Kif17 A_51_P442023 kinesin family member 17 (Kif17), transcript variant 1 
[NM_010623] 
-3.49 
Saa3 A_55_P1953169 serum amyloid A 3 (Saa3) [NM_011315] -3.49 
Mrgpra2b A_55_P2019557 MAS-related GPR, member A2B (Mrgpra2b) 
[NM_153101] 
-3.46 
Hist1h1d A_55_P2183508 histone cluster 1, H1d (Hist1h1d) [NM_145713] -3.44 
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Elavl4 A_55_P1990309 ELAV (embryonic lethal, abnormal vision, 
Drosophila)-like 4 (Hu antigen D) (Elavl4), transcript 
variant 1 [NM_010488] 
-3.41 
Wdfy3 A_55_P2161530 WD repeat and FYVE domain containing 3 (Wdfy3) 
[NM_172882] 
-3.39 
Lcn5 A_55_P1963727 lipocalin 5 (Lcn5), transcript variant 1 [NM_007947] -3.38 
Ptpro A_55_P2227355 protein tyrosine phosphatase, receptor type, O (Ptpro), 
transcript variant 1 [NM_011216] 
-3.38 
Ms4a3 A_51_P364210 membrane-spanning 4-domains, subfamily A, member 
3 (Ms4a3) [NM_133246] 
-3.37 
Ctsg A_51_P416546 cathepsin G (Ctsg) [NM_007800] -3.37 
Avp A_51_P136508 arginine vasopressin (Avp) [NM_009732] -3.34 
Ror1 A_52_P212025 receptor tyrosine kinase-like orphan receptor 1 
[MGI:1347520] [ENSMUST-00000039630] 
-3.32 
Steap2 A_51_P438584 six transmembrane epithelial antigen of prostate 2 
(Steap2), transcript variant 1 [NM_001103157] 
-3.28 
Cela1 A_52_P578634 chymotrypsin-like elastase family, member 1 (Cela1) 
[NM_033612] 
-3.26 
Neurl1B A_55_P2011722 neuralized homolog 1b (Drosophila) (Neurl1b) 
[NM_001081656] 
-3.26 
M35492 A_55_P1976297 T cell receptor alpha variable 6D-5 [MGI:3649416] 
[ENSMUST-00000103582] 
-3.25 
Cacna1g A_51_P466910 calcium channel, voltage-dependent, T type, alpha 1G 
subunit (Cacna1g), transcript variant 1 [NM_009783] 
-3.25 
Olfr441 A_52_P506250 olfactory receptor 441 (Olfr441) [NM_146655] -3.22 
Pnmal1 A_51_P222993 PNMA-like 1 (Pnmal1) [NM_001007569] -3.21 
Srgap1 A_55_P2042510 SLIT-ROBO Rho GTPase activating protein 1 
(Srgap1), transcript variant 1 [NM_001081037] 
-3.17 
Efcab1 A_55_P2143995 EF hand calcium binding domain 1 (Efcab1) 
[NM_025769] 
-3.16 
S100b A_51_P468260 S100 protein, beta polypeptide, neural (S100b) 
[NM_009115] 
-3.14 
Adamts17 A_66_P124114 a disintegrin-like and metallopeptidase (reprolysin 
type) with thrombospondin type 1 motif, 17 
(Adamts17) [NM_001033877] 
-3.14 
Ttr A_65_P19832 transthyretin (Ttr) [NM_013697] -3.10 
Col9a3 A_66_P101732 collagen, type IX, alpha 3 (Col9a3) [NM_009936] -3.10 
Trim61 A_65_P10737 tripartite motif-containing 61 (Trim61), transcript 
variant 1 [NM_153110] 
-3.08 
Gstt4 A_51_P432229 glutathione S-transferase, theta 4 (Gstt4) 
[NM_029472] 
-3.01 
Stfa2 A_66_P139618 stefin A2 (Stfa2) [NM_001082545] -3.01 
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A.3 Upregulated genes in HSCs upon transient MIF 
stimulation at day 1 
Listed are upregulated genes in transiently MIF-stimulated cells at day 1 (sample IIC) 
compared to control (sample IIA). The list comprises genes that are upregulated with a 
mean fold change (FC) > 3 and a significant signal above background in the sample of 
transiently stimulated cells. 
SeqName Seqcode Full name FC 
Ptgfr A_52_P153019 prostaglandin F receptor (Ptgfr) [NM_008966] 44.04 
Olfr714 A_55_P2278850 olfactory receptor 714 (Olfr714) [NM_147033] 38.79 
Rragb A_52_P599549 Ras-related GTP binding B (Rragb) [NM_001004154] 16.81 
Tsga10ip A_55_P2096224 testis specific 10 interacting protein [MGI:1925556] 
[ENSMUST-00000044527] 
14.27 
Spag11b A_55_P2171764 sperm associated antigen 11B (Spag11b), transcript 
variant c [NM_001039563] 
12.10 
Olfr1016 A_51_P413216 olfactory receptor 1016 (Olfr1016) [NM_001011758] 11.94 
Muc1 A_51_P467346 mucin 1, transmembrane (Muc1) [NM_013605] 11.40 
Sectm1b A_51_P317882 secreted and transmembrane 1B (Sectm1b) 
[NM_026907] 
10.22 
ENSMUST-
00000103324 
A_55_P2132533 immunoglobulin kappa chain variable 15-103 
[MGI:96513] [ENSMUST-00000103324] 
10.09 
Plek2 A_52_P488437 pleckstrin 2 (Plek2) [NM_013738] 8.93 
ENSMUST-
00000107184 
A_55_P2130238 SH3-domain GRB2-like 2 [MGI:700009] 
[ENSMUST-00000107184] 
8.49 
Tmem9b A_55_P1982767 TMEM9 domain family, member B (Tmem9b) 
[NM_020050] 
8.07 
Lca5 A_66_P113818 Leber congenital amaurosis 5 (human) (Lca5), 
transcript variant 1 [NM_029434] 
7.61 
Olfr1126 A_51_P143040 olfactory receptor 1126 (Olfr1126) [NM_146837] 7.15 
Tmprss12 A_55_P1987321 transmembrane (C-terminal) protease, serine 12 
(Tmprss12) [NM_183109] 
6.95 
Gramd2 A_55_P1970900 GRAM domain containing 2 (Gramd2) 
[NM_001033498] 
6.56 
Kcnj14 A_51_P250559 potassium inwardly-rectifying channel, subfamily J, 
member 14 (Kcnj14) [NM_145963] 
6.13 
Anxa10 A_51_P216679 annexin A10 (Anxa10), transcript variant 2 
[NM_011922] 
5.74 
Abo A_55_P2037977 ABO blood group (transferase A, alpha 1-3-N-
acetylgalactosaminyltransferase, transferase B, alpha 
1-3-galactosyltransferase) (Abo) [NM_030718] 
5.66 
Ahsp A_52_P534583 alpha hemoglobin stabilizing protein (Ahsp) 
[NM_133245] 
5.33 
Slc17a4 A_55_P2094019 solute carrier family 17 (sodium phosphate), member 4 
(Slc17a4) [NM_177016] 
5.26 
Masp2 A_55_P2185504 mannan-binding lectin serine peptidase 2 (Masp2), 
transcript variant 2 [NM_010767] 
5.22 
Pdcd1lg2 A_55_P2122075 butyrophilin-like protein (Btdc) mRNA, complete cds. 
[AF142780] 
4.94 
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Prm3 A_55_P2115435 protamine 3 (Prm3) [NM_013638] 4.77 
Fndc1 A_55_P1989519 fibronectin type III domain containing 1 (Fndc1) 
[NM_001081416] 
4.76 
Ccdc105 A_55_P2111108 coiled-coil domain containing 105 (Ccdc105) 
[NM_027630] 
4.61 
Atcay A_52_P262201 ataxia, cerebellar, Cayman type homolog (human) 
(Atcay) [NM_178662] 
4.61 
ENSMUST-
00000118194 
A_55_P2029116 peroxisomal biogenesis factor 11c [AK165461] 4.52 
Tjp3 A_55_P1960291 tight junction protein 3 (Tjp3) [NM_013769] 4.32 
Syn3 A_52_P352299 synapsin III (Syn3), transcript variant 2 
[NM_001164495] 
4.14 
Accn2 A_55_P2104988 amiloride-sensitive cation channel 2, neuronal (Accn2) 
[NM_009597] 
4.13 
Ssxb8 A_55_P2009812 synovial sarcoma, X member B, breakpoint 8 (Ssxb8) 
[NM_001081565] 
4.11 
Tmem213 A_51_P401501 transmembrane protein 213 (Tmem213) [NM_029921] 4.10 
Srcin1 A_55_P2081123 SRC kinase signaling inhibitor 1 (Srcin1) 
[NM_018873] 
4.05 
Amy2a4 A_55_P2318090 amylase 2a4 (Amy2a4) [NM_001160150] 4.01 
Cyp2b10 A_55_P2044653 cytochrome P450, family 2, subfamily b, polypeptide 
10 (Cyp2b10), transcript variant 2 [NM_009999] 
4.01 
Slc24a4 A_55_P1974804 solute carrier family 24 (sodium/potassium/calcium 
exchanger), member 4 (Slc24a4) [NM_172152] 
3.99 
Zfp207 A_52_P486234 zinc finger protein 207 [MGI:1340045] [ENSMUST-
00000108216] 
3.96 
Mif A_55_P2068265 macrophage migration inhibitory factor (Mif) 
[NM_010798] 
3.91 
Popdc3 A_52_P486279 popeye domain containing 3 (Popdc3) [NM_024286] 3.90 
Iqsec1 A_55_P2052416 IQ motif and Sec7 domain 1 (Iqsec1), transcript 
variant 1 [NM_001134383] 
3.88 
Dclk2 A_55_P1991019 doublecortin-like kinase 2 [MGI:1918012] 
[ENSMUST-00000094144] 
3.88 
ENSMUST-
00000091674 
A_55_P1988918 CDK5 regulatory subunit associated protein 1-like 1 
[MGI:1921765] [ENSMUST-00000091674] 
3.87 
Odz1 A_55_P1999833 odd Oz/ten-m homolog 1 (Drosophila) (Odz1) 
[NM_011855] 
3.82 
Ppef1 A_52_P567200 protein phosphatase with EF hand calcium-binding 
domain 1 (Ppef1) [NM_011147] 
3.82 
ENSMUST-
00000070075 
A_55_P1993775 vesicle transport through interaction with t-SNAREs 
homolog 1A (yeast) [BC019386] 
3.81 
Il18 A_66_P105046 interleukin 18 (Il18) [NM_008360] 3.77 
Nkx2-5 A_51_P173285 NK2 transcription factor related, locus 5 (Drosophila) 
(Nkx2-5) [NM_008700] 
3.75 
Gcnt2 A_55_P2025595 glucosaminyl (N-acetyl) transferase 2, I-branching 
enzyme (Gcnt2), transcript variant 1 [NM_008105] 
3.73 
ENSMUST-
00000109107 
A_55_P2015887 WW domain-containing oxidoreductase 
[MGI:1931237] [ENSMUST-00000109107] 
3.68 
Klhl31 A_52_P90684 kelch-like 31 (Drosophila) (Klhl31) [NM_172925] 3.68 
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Pkd1l1 A_55_P1966024 polycystic kidney disease 1 like 1 [MGI:2156538] 
[ENSMUST-00000154153] 
3.67 
Tff3 A_51_P456208 trefoil factor 3, intestinal (Tff3) [NM_011575] 3.65 
Pdia2 A_55_P2131964 protein disulfide isomerase associated 2 (Pdia2) 
[NM_001081070] 
3.57 
LOC100045853 A_55_P1985400 potassium channel, subfamily K, member 15 
[MGI:2675209] [ENSMUST-00000109396] 
3.55 
Gnrh1 A_55_P2110860 gonadotropin releasing hormone 1 (Gnrh1) 
[NM_008145] 
3.52 
Asb12 A_55_P2100360 ankyrin repeat and SOCS box-containing 12 (Asb12) 
[NM_080858] 
3.52 
Clec12b A_51_P192964 C-type lectin domain family 12, member B (Clec12b) 
[NM_027709] 
3.52 
Itgb1bp3 A_51_P369762 integrin beta 1 binding protein 3 (Itgb1bp3) 
[NM_027120] 
3.51 
Insm2 A_55_P2058335 insulinoma-associated 2 (Insm2) [NM_020287] 3.48 
Crhbp A_52_P460734 corticotropin releasing hormone binding protein 
(Crhbp) [NM_198408] 
3.46 
Vwa5a A_66_P131754 von Willebrand factor A domain containing 5A 
(Vwa5a) [NM_172767] 
3.41 
Ikzf4 A_55_P1979682 IKAROS family zinc finger 4 (Ikzf4) [NM_011772] 3.40 
Synpo2 A_52_P223127 synaptopodin 2 (Synpo2) [NM_080451] 3.39 
Olfr1426 A_55_P2087547 olfactory receptor 1426 (Olfr1426) [NM_146809] 3.38 
Elovl2 A_55_P2062737 elongation of very long chain fatty acids (FEN1/Elo2, 
SUR4/Elo3, yeast)-like 2 (Elovl2) [NM_019423] 
3.37 
Itgb1bp2 A_52_P298088 integrin beta 1 binding protein 2 (Itgb1bp2) 
[NM_013712] 
3.36 
Gal3st4 A_52_P1174 galactose-3-O-sulfotransferase 4 (Gal3st4) 
[NM_001033416] 
3.34 
Dbx1 A_51_P156144 developing brain homeobox 1 (Dbx1) 
[NM_001005232] 
3.30 
Orm2 A_51_P141546 orosomucoid 2 (Orm2) [NM_011016] 3.28 
ENSMUST-
00000103383 
A_52_P186262 immunoglobulin kappa chain variable 6-25 
[MGI:4439867] [ENSMUST-00000103383] 
3.28 
ENSMUST-
00000106799 
A_55_P2112564 endoplasmic reticulum (ER) to nucleus signalling 1 
[MGI:1930134] [ENSMUST-00000106799] 
3.26 
ENSMUST-
00000097955 
A_51_P207801 cache domain containing 1 [MGI:2444177] 
[ENSMUST-00000097955] 
3.26 
Chit1 A_55_P2129945 chitinase 1 (chitotriosidase) (Chit1) [NM_027979] 3.25 
F7 A_51_P484054 coagulation factor VII (F7) [NM_010172] 3.24 
Caskin1 A_55_P2057469 CASK interacting protein 1 (Caskin1) [NM_027937] 3.23 
Zfyve28 A_55_P2058671 zinc finger, FYVE domain containing 28 (Zfyve28) 
[NM_001015039] 
3.23 
H60c A_55_P2118525 histocompatibility 60c (H60c) [NM_001204916] 3.22 
Fer1l4 A_55_P2071064 fer-1-like 4 (C. elegans) (Fer1l4) [NM_001136556] 3.21 
Usp24 A_51_P480320 ubiquitin specific peptidase 24 [MGI:1919936] 
[ENSMUST-00000106798] 
3.20 
Tmem154 A_52_P523503 transmembrane protein 154 (Tmem154) [NM_177260] 3.19 
Wbscr17 A_51_P202920 Williams-Beuren syndrome chromosome region 17 
homolog (human) (Wbscr17) [NM_145218] 
3.17 
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Nat8l A_55_P1997821 N-acetyltransferase 8-like (Nat8l) [NM_001001985] 3.16 
Kbtbd12 A_55_P2091116 kelch repeat and BTB (POZ) domain containing 12 
(Kbtbd12), transcript variant 1 [NM_001142724] 
3.14 
Kndc1 A_52_P312189 kinase non-catalytic C-lobe domain (KIND) containing 
1 (Kndc1) [NM_177261] 
3.14 
Zfp287 A_51_P489702 zinc finger protein 287 (Zfp287) [NM_133208] 3.13 
Sez6 A_55_P1978028 seizure related gene 6 (Sez6) [NM_021286] 3.12 
Fastkd2 A_51_P226134 FAST kinase domains 2 (Fastkd2) [NM_172422] 3.11 
ENSMUST-
00000103743 
A_51_P483576 immunoglobulin lambda constant 3 [MGI:99886] 
[ENSMUST-00000103743] 
3.11 
ENSMUST-
00000111183 
A_55_P2115181 pyruvate dehydrogenase complex, component X 
[MGI:1351627] [ENSMUST-00000111183] 
3.08 
Krtap20-2 A_55_P2092475 keratin associated protein 20-2 (Krtap20-2) 
[NM_001163615] 
3.07 
9130004C02Rik A_55_P2014174 septin 7 [AK046843] 3.06 
Ccdc30 A_51_P321600 coiled-coil domain containing 30 [MGI:1920582] 
[ENSMUST-00000170059] 
3.05 
C1ql4 A_55_P2069602 complement component 1, q subcomponent-like 4 
(C1ql4) [NM_001024702] 
3.05 
Cd300e A_51_P312035 CD300e antigen (Cd300e) [NM_172050] 3.05 
Gnrh1 A_55_P2095716 gonadotropin releasing hormone 1 [BC116897] 3.04 
ENSMUST-
00000093246 
A_55_P2056501 thymidine kinase 1 [MGI:98763] [ENSMUST-
00000129852] 
3.03 
Gapdhs A_55_P2124881 glyceraldehyde-3-phosphate dehydrogenase, 
spermatogenic [MGI:95653] [ENSMUST-
00000076658] 
3.03 
Fam83e A_51_P434758 family with sequence similarity 83, member E 
(Fam83e) [NM_001033170] 
3.03 
Rnf157 A_52_P106285 ring finger protein 157 (Rnf157) [NM_027258] 3.02 
Axin2 A_66_P134405 axin2 (Axin2) [NM_015732] 3.01 
Cybrd1 A_55_P1956472 cytochrome b reductase 1 (Cybrd1) [NM_028593] 3.01 
Kcnj13 A_55_P2066878 potassium inwardly-rectifying channel, subfamily J, 
member 13 (Kcnj13) [NM_001110227] 
3.00 
A.4 Downregulated genes in HSCs upon transient MIF 
stimulation at day 1 
Listed are downregulated genes in transiently MIF-stimulated cells at day 1 (sample IIC) 
compared to control (sample IIA). The list comprises genes that are downregulated with a 
mean fold change (FC) > 3 and a significant signal above background in the control 
sample. 
SeqName Seqcode Full name FC 
Zmat4 A_51_P422685 zinc finger, matrin type 4 (Zmat4) [NM_177086] -111.81 
Slc17a1 A_55_P1969506 solute carrier family 17 (sodium phosphate), member 1 
(Slc17a1), transcript variant 1 [NM_009198] 
-82.99 
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Vmn2r75 A_55_P1966634 vomeronasal 2, receptor 75 (Vmn2r75) 
[NM_001102578] 
-53.01 
Pira6 A_52_P18236 paired-Ig-like receptor A6 (Pira6), transcript variant 2 
[NM_011093] 
-29.28 
Orm1 A_51_P336325 orosomucoid 1 (Orm1) [NM_008768] -22.29 
ENSMUST-
00000080298 
A_51_P173484 IQ motif containing with AAA domain 
[MGI:1922168] [ENSMUST-00000164210] 
-21.06 
Myt1l A_55_P2001793 myelin transcription factor 1-like (Myt1l), transcript 
variant 1 [NM_001093775] 
-19.95 
Col19a1 A_55_P2019631 procollagen, type XIX, alpha 1 [AK149136] -19.62 
Ppp1r1a A_52_P144818 protein phosphatase 1, regulatory (inhibitor) subunit 
1A (Ppp1r1a) [NM_021391] 
-18.59 
Tmem190 A_51_P490337 transmembrane protein 190 (Tmem190) [NM_030028] -17.96 
Il12rb2 A_55_P1978416 interleukin 12 receptor, beta 2 (Il12rb2) [NM_008354] -17.00 
Adamts3 A_55_P2163541 a disintegrin-like and metallopeptidase (reprolysin 
type) with thrombospondin type 1 motif, 3 (Adamts3), 
transcript variant 1 [NM_177872] 
-16.56 
Slitrk3 A_52_P47781 SLIT and NTRK-like family, member 3 (Slitrk3) 
[NM_198864] 
-15.80 
Nlrc4 A_52_P655136 NLR family, CARD domain containing 4 (Nlrc4) 
[NM_001033367] 
-15.25 
Neurod1 A_55_P2004972 neurogenic differentiation 1 (Neurod1) [NM_010894] -13.83 
Olfr1387 A_55_P2162718 olfactory receptor 1387 (Olfr1387) [NM_146473] -13.72 
Gh A_51_P104687 growth hormone (Gh) [NM_008117] -13.69 
Eda A_55_P2030667 ectodysplasin-A (Eda), transcript variant 7 
[NM_001177942] 
-12.24 
Caps2 A_55_P2089091 calcyphosphine 2 (Caps2) [NM_178278] -12.17 
Gli1 A_55_P2080658 GLI-Kruppel family member GLI1 [MGI:95727] 
[ENSMUST-00000105252] 
-12.12 
Olfr1342 A_55_P2100000 olfactory receptor 1342 (Olfr1342) [NM_146713] -11.85 
Olfr1132 A_55_P2072671 olfactory receptor 1132 (Olfr1132) [NM_146836] -11.42 
Yipf7 A_52_P313102 Yip1 domain family, member 7 (Yipf7) [NM_023784] -11.30 
ENSMUST-
00000118205 
A_66_P120309 TRANSMEMBRANE PROTEIN VEZATIN homolog 
[Homo sapiens] [AK042540] 
-11.19 
ENSMUST-
00000112310 
A_51_P186487 phosphoinositide-3-kinase, class 2, beta polypeptide 
[MGI:2685045] [ENSMUST-00000124934] 
-9.93 
Cdh29 A_52_P120122 cadherin-like 29 (Cdh29) [NM_177090] -9.36 
Efcab5 A_55_P2138217 EF-hand calcium binding domain 5 (Efcab5) 
[NM_176965] 
-9.14 
Nlrp1b A_66_P106290 NLR family, pyrin domain containing 1B (Nlrp1b), 
transcript variant 1 [NM_001040696] 
-9.10 
Mmp28 A_55_P2150612 matrix metallopeptidase 28 (epilysin) (Mmp28), 
transcript variant 1 [NM_080453] 
-8.95 
Lrrc2 A_55_P2428967 leucine rich repeat containing 2 (Lrrc2) [NM_028838] -8.94 
Vmn1r61 A_55_P1972169 vomeronasal 1 receptor 61 (Vmn1r61) 
[NM_001166733] 
-8.51 
Cyp3a11 A_55_P2121225 cytochrome P450, family 3, subfamily a, polypeptide 
11 (Cyp3a11) [NM_007818] 
-8.36 
Olfr716 A_51_P211978 olfactory receptor 716 (Olfr716) [NM_146604] -7.79 
128 A Appendix 
SeqName Seqcode Full name FC 
Agxt2 A_55_P2186282 alanine-glyoxylate aminotransferase 2 (Agxt2) 
[NM_001031851] 
-7.38 
Gzmb A_51_P333274 granzyme B (Gzmb) [NM_013542] -7.31 
Mybpc2 A_55_P2013665 myosin binding protein C, fast-type (Mybpc2), 
transcript variant 2 [NM_146189] 
-7.26 
Mug1 A_55_P2105413 murinoglobulin 1 (Mug1) [NM_008645] -6.89 
Il5 A_55_P2138386 interleukin 5 (Il5) [NM_010558] -6.88 
Vwa5b1 A_55_P2081990 von Willebrand factor A domain containing 5B1 
(Vwa5b1) [NM_029401] 
-6.77 
Adad2 A_51_P140042 adenosine deaminase domain containing 2 (Adad2) 
[NM_029428] 
-6.40 
Slc25a21 A_55_P2033393 solute carrier family 25 (mitochondrial 
oxodicarboxylate carrier), member 21 (Slc25a21), 
transcript variant 1 [NM_172577] 
-6.23 
Hoxc12 A_55_P2169099 homeobox C12 (Hoxc12) [NM_010463] -6.22 
Ifltd1 A_55_P1954960 intermediate filament tail domain containing 1 (Ifltd1) 
[NM_028742] 
-5.53 
Meox1 A_55_P2034245 mesenchyme homeobox 1 (Meox1) [NM_010791] -5.41 
Stx8 A_55_P2176989 syntaxin 8 (Stx8) [NM_018768] -5.40 
Krt71 A_51_P364639 keratin 71 (Krt71) [NM_019956] -5.39 
Plxna4 A_52_P650037 plexin A4 (Plxna4) [NM_175750] -5.26 
Olfr462 A_55_P2086797 olfactory receptor 462 (Olfr462) [NM_146411] -5.23 
Tbx18 A_51_P438711 T-box18 (Tbx18) [NM_023814] -5.17 
Col9a3 A_66_P101732 collagen, type IX, alpha 3 (Col9a3) [NM_009936] -5.15 
Tdrd9 A_55_P1989369 tudor domain containing 9 (Tdrd9) [NM_029056] -5.08 
Ly6d A_51_P343517 lymphocyte antigen 6 complex, locus D (Ly6d) 
[NM_010742] 
-5.04 
Etv1 A_55_P1986321 ets variant gene 1 (Etv1), transcript variant 1 
[NM_007960] 
-4.85 
Lcn5 A_55_P1963727 lipocalin 5 (Lcn5), transcript variant 1 [NM_007947] -4.78 
Vmn1r183 A_55_P1978847 vomeronasal 1 receptor 183 (Vmn1r183) 
[NM_203489] 
-4.72 
Ms4a3 A_51_P364210 membrane-spanning 4-domains, subfamily A, member 
3 (Ms4a3) [NM_133246] 
-4.64 
Sprr2e A_55_P2109569 small proline-rich protein 2E (Sprr2e) [NM_011471] -4.61 
Trim61 A_65_P10737 tripartite motif-containing 61 (Trim61), transcript 
variant 1 [NM_153110] 
-4.60 
Ror1 A_52_P212025 receptor tyrosine kinase-like orphan receptor 1 
[MGI:1347520] [ENSMUST-00000039630] 
-4.58 
Cacna1g A_51_P466910 calcium channel, voltage-dependent, T type, alpha 1G 
subunit (Cacna1g), transcript variant 1 [NM_009783] 
-4.43 
Il22ra1 A_55_P2047431 interleukin 22 receptor, alpha 1 (Il22ra1) 
[NM_178257] 
-4.36 
Zc3hav1l A_51_P160042 zinc finger CCCH-type, antiviral 1-like (Zc3hav1l) 
[NM_172467] 
-4.34 
Vmn2r27 A_55_P2159969 vomeronasal 2, receptor27 (Vmn2r27) 
[NM_001104642] 
-4.33 
Tcfcp2l1 A_55_P2413458 transcription factor CP2-like 1 (Tcfcp2l1) 
[NM_023755] 
-4.31 
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Mbl2 A_51_P178828 mannose-binding lectin (protein C) 2 (Mbl2) 
[NM_010776] 
-4.28 
Vmn1r148 A_55_P2056450 vomeronasal 1 receptor 148 (Vmn1r148) 
[NM_030736] 
-4.27 
Tcam1 A_55_P2013475 testicular cell adhesion molecule 1 (Tcam1) 
[NM_029467] 
-4.25 
Car1 A_55_P2099952 carbonic anhydrase 1 (Car1), transcript variant 1 
[NM_009799] 
-4.23 
Prb1 A_52_P71756 proline-rich protein BstNI subfamily 1 (Prb1) 
[NM_198669] 
-4.22 
Ms4a5 A_55_P1958171 membrane-spanning 4-domains, subfamily A, member 
5 (Ms4a5) [NM_183190] 
-4.19 
Rhox3a A_66_P107583 reproductive homeobox 3A (Rhox3a) [NM_194063] -4.18 
Kcnip4 A_52_P319774 Kv channel interacting protein 4 (Kcnip4), transcript 
variant 4 [NM_030265] 
-4.17 
Fam70a A_52_P518270 family with sequence similarity 70, member A 
(Fam70a) [NM_172930] 
-4.17 
Steap2 A_51_P438584 six transmembrane epithelial antigen of prostate 2 
(Steap2), transcript variant 1 [NM_001103157] 
-4.17 
Cblc A_51_P484978 Casitas B-lineage lymphoma c (Cblc), transcript 
variant 1 [NM_023224] 
-4.16 
Tpbpb A_51_P130808 trophoblast specific protein beta (Tpbpb) 
[NM_026429] 
-4.09 
Crmp1 A_55_P2017600 collapsin response mediator protein 1 (Crmp1), 
transcript variant 2 [NM_007765] 
-4.09 
Igsf1 A_55_P2059864 immunoglobulin superfamily, member 1 (Igsf1), 
transcript variant 1 [NM_177591] 
-4.09 
Chd2 A_66_P101171 chromodomain helicase DNA binding protein 2 (Chd2) 
[NM_001081345] 
-4.08 
Mpped2 A_52_P408025 metallophosphoesterase domain containing 2 
(Mpped2), transcript variant 1 [NM_001143683] 
-4.06 
Afm A_52_P425734 afamin (Afm) [NM_145146] -4.00 
Apoc2 A_51_P334979 apolipoprotein C-II (Apoc2) [NM_009695] -4.00 
Slc5a9 A_55_P2015650 solute carrier family 5 (sodium/glucose cotransporter), 
member 9 (Slc5a9) [NM_145551] 
-3.98 
Wnt9b A_52_P15377 wingless-type MMTV integration site 9B (Wnt9b) 
[NM_011719] 
-3.98 
Pgm5 A_52_P229924 phosphoglucomutase 5 (Pgm5) [NM_175013] -3.97 
LOC435333 A_55_P2011950 immunoglobulin heavy variable 1-85 [MGI:3645723] 
[ENSMUST-00000103552] 
-3.96 
Six3 A_55_P2082408 sine oculis-related homeobox 3 homolog (Drosophila) 
[MGI:102764] [ENSMUST-00000043819] 
-3.96 
Cer1 A_55_P1970100 cerberus 1 homolog (Xenopus laevis) (Cer1) 
[NM_009887] 
-3.95 
ENSMUST-
00000101612 
A_55_P1978696 ATP-binding cassette, sub-family B (MDR/TAP), 
member 4 [MGI:97569] [ENSMUST-00000101612] 
-3.94 
Akr1c20 A_51_P382764 aldo-keto reductase family 1, member C20 
[BC021607] 
-3.94 
Col2a1 A_55_P2004179 collagen, type II, alpha 1 (Col2a1), transcript variant 2 
[NM_001113515] 
-3.87 
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Cyp2a4 A_55_P2007326 cytochrome P450, family 2, subfamily a, polypeptide 4 
(Cyp2a4) [NM_009997] 
-3.84 
Akr1c14 A_55_P2007155 aldo-keto reductase family 1, member C14 (Akr1c14) 
[NM_134072] 
-3.81 
Pla2g4d A_55_P1987775 phospholipase A2, group IVD (Pla2g4d) 
[NM_001024137] 
-3.81 
Hoxa1 A_55_P2066123 homeobox A1 (Hoxa1) [NM_010449] -3.80 
Sema3c A_52_P87839 sema domain, immunoglobulin domain (Ig), short 
basic domain, secreted, (semaphorin) 3C (Sema3c) 
[NM_013657] 
-3.79 
Wdfy3 A_55_P2161530 WD repeat and FYVE domain containing 3 (Wdfy3) 
[NM_172882] 
-3.77 
Olfr1232 A_51_P502492 olfactory receptor 1232 (Olfr1232) [NM_146323] -3.74 
Defa-rs2 A_55_P2018869 defensin, alpha, related sequence 2 (Defa-rs2) 
[NM_007847] 
-3.73 
Hsd17b2 A_51_P441914 hydroxysteroid (17-beta) dehydrogenase 2 (Hsd17b2) 
[NM_008290] 
-3.72 
Olfr1314 A_52_P629709 olfactory receptor 1314 (Olfr1314) [NM_146450] -3.71 
Trim71 A_55_P1962334 tripartite motif-containing 71 (Trim71) 
[NM_001042503] 
-3.68 
Mrgprb3 A_52_P320394 MAS-related GPR, member B3 (Mrgprb3) 
[NM_207537] 
-3.68 
Coq3 A_51_P378336 coenzyme Q3 homolog, methyltransferase (yeast) 
(Coq3) [NM_172687] 
-3.67 
Nrarp A_51_P504354 Notch-regulated ankyrin repeat protein (Nrarp) 
[NM_025980] 
-3.67 
Pik3r5 A_52_P1093529 phosphoinositide-3-kinase, regulatory subunit 5, p101 
(Pik3r5) [NM_177320] 
-3.61 
Eps8l2 A_52_P257426 EPS8-like 2 (Eps8l2) [NM_133191] -3.55 
Elavl4 A_55_P1990309 ELAV (embryonic lethal, abnormal vision, 
Drosophila)-like 4 (Hu antigen D) (Elavl4), transcript 
variant 1 [NM_010488] 
-3.54 
Acoxl A_55_P2160416 acyl-Coenzyme A oxidase-like (Acoxl) [NM_028765] -3.52 
Kif17 A_51_P442023 kinesin family member 17 (Kif17), transcript variant 1 
[NM_010623] 
-3.51 
Gal3st1 A_55_P2013823 galactose-3-O-sulfotransferase 1 (Gal3st1), transcript 
variant 1 [NM_016922] 
-3.50 
Rnf43 A_55_P2079619 ring finger protein 43 (Rnf43) [NM_172448] -3.50 
Pot1a A_66_P106584 protection of telomeres 1A [MGI:2141503] 
[ENSMUST-00000115329] 
-3.49 
Zfp57 A_55_P2172201 zinc finger protein 57 (Zfp57), transcript variant 3 
[NM_001168502] 
-3.47 
Ugt2b37 A_51_P302856 UDP glucuronosyltransferase 2 family, polypeptide 
B37 (Ugt2b37) [NM_053215] 
-3.44 
Vwa2 A_55_P2414159 von Willebrand factor A domain containing 2 (Vwa2) 
[NM_172840] 
-3.40 
Fgb A_51_P428483 fibrinogen, B beta polypeptide (Fgb) [NM_181849] -3.36 
Alb A_51_P160713 albumin (Alb) [NM_009654] -3.33 
Crtam A_51_P150302 cytotoxic and regulatory T cell molecule (Crtam) 
[NM_019465] 
-3.32 
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Olfr338 A_51_P252650 olfactory receptor 338 (Olfr338) [NM_146947] -3.28 
M35492 A_55_P1976297 T cell receptor alpha variable 6D-5 [MGI:3649416] 
[ENSMUST-00000103582] 
-3.27 
C4bp A_52_P60194 complement component 4 binding protein (C4bp) 
[NM_007576] 
-3.18 
S100b A_51_P468260 S100 protein, beta polypeptide, neural (S100b) 
[NM_009115] 
-3.16 
Sik1 A_55_P2061278 salt inducible kinase 1 (Sik1) [NM_010831] -3.16 
Ugt2b5 A_55_P1975080 UDP glucuronosyltransferase 2 family, polypeptide B5 
(Ugt2b5) [NM_009467] 
-3.16 
Hnf4a A_55_P1959633 hepatic nuclear factor 4, alpha (Hnf4a) [NM_008261] -3.13 
Htr1d A_55_P2019428 5-hydroxytryptamine (serotonin) receptor 1D (Htr1d) 
[NM_008309] 
-3.13 
ENSMUST-
00000098156 
A_55_P2120662 MOB1, Mps One Binder kinase activator-like 2B 
(yeast) [MGI:2664539] [ENSMUST-00000102975] 
-3.13 
Agrp A_55_P2049717 agouti related protein (Agrp) [NM_007427] -3.12 
Evi2a A_55_P2017759 ecotropic viral integration site 2a (Evi2a), transcript 
variant 1 [NM_001033711] 
-3.11 
Mfi2 A_51_P324351 antigen p97 (melanoma associated) identified by 
monoclonal antibodies 133.2 and 96.5 (Mfi2) 
[NM_013900] 
-3.09 
Olfr796 A_51_P136589 olfactory receptor 796 (Olfr796) [NM_146931] -3.08 
Dll3 A_51_P504494 delta-like 3 (Drosophila) (Dll3) [NM_007866] -3.07 
Utp6 A_52_P33927 UTP6, small subunit (SSU) processome component, 
homolog (yeast) [MGI:2445193] [ENSMUST-
00000108241] 
-3.07 
Duox2 A_55_P1974760 dual oxidase 2 (Duox2) [NM_177610] -3.05 
Nrn1 A_51_P308844 neuritin 1 (Nrn1) [NM_153529] -3.02 
A.5 Upregulated genes in HSCs upon transient MIF 
stimulation at day 5 
Listed are upregulated genes in transiently MIF-stimulated cells at day 5 (sample IID) 
compared to control (sample IIA). The list comprises genes that are upregulated with a 
mean fold change (FC) > 3 and a significant signal above background in the sample of 
transiently stimulated cells. 
SeqName Seqcode Full name FC 
Serpinb2 A_55_P2004867 serine (or cysteine) peptidase inhibitor, clade B, 
member 2 (Serpinb2), transcript variant 1 
[NM_011111] 
40.09 
Cabp5 A_55_P2055504 calcium binding protein 5 (Cabp5) [NM_013877] 21.03 
Krt25 A_51_P441898 keratin 25 (Krt25) [NM_133730] 20.08 
Krtap16-5 A_51_P345995 keratin associated protein 16-5 (Krtap16-5) 
[NM_130857] 
18.51 
Sprr2h A_66_P138462 small proline-rich protein 2H (Sprr2h) [NM_011474] 17.67 
Tmem163 A_55_P1973041 transmembrane protein 163 (Tmem163) [NM_028135] 16.11 
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ENSMUST-
00000098564 
A_55_P1976519 WD repeat domain 72 [MGI:3583957] [ENSMUST-
00000098564] 
13.11 
Olfr286 A_55_P2094314 olfactory receptor 286 (Olfr286) [NM_001011779] 13.08 
Gpr183 A_55_P2116385 G protein-coupled receptor 183 (Gpr183) 
[NM_183031] 
12.47 
Cxcl3 A_52_P232813 chemokine (C-X-C motif) ligand 3 (Cxcl3) 
[NM_203320] 
9.53 
Olfr1469 A_55_P2000756 olfactory receptor 1469 (Olfr1469) [NM_146695] 9.28 
Retnla A_51_P257951 resistin like alpha (Retnla) [NM_020509] 8.84 
ENSMUST-
00000110862 
A_55_P1963259 signal recognition particle 14 [MGI:107169] 
[ENSMUST-00000110862] 
8.71 
Prl A_55_P2160168 prolactin (Prl), transcript variant 1 [NM_011164] 8.58 
Gpr55 A_55_P2087850 G protein-coupled receptor 55 (Gpr55) 
[NM_001033290] 
8.15 
Sprr2e A_55_P2109569 small proline-rich protein 2E (Sprr2e) [NM_011471] 7.63 
Sprr2f A_51_P386870 small proline-rich protein 2F (Sprr2f) [NM_011472] 7.51 
Chrna1 A_55_P2130987 cholinergic receptor, nicotinic, alpha polypeptide 1 
(muscle) (Chrna1) [NM_007389] 
7.51 
ENSMUST-
00000118194 
A_55_P2029116 peroxisomal biogenesis factor 11c [AK165461] 6.95 
Dab1 A_52_P392216 disabled homolog 1 (Drosophila) (Dab1), transcript 
variant 2 [NM_177259] 
6.76 
Sh2d4b A_55_P2147260 SH2 domain containing 4B (Sh2d4b) [NM_177816] 6.61 
Tmem9b A_55_P1982767 TMEM9 domain family, member B (Tmem9b) 
[NM_020050] 
6.51 
Dbc1 A_55_P2124941 deleted in bladder cancer 1 (human) (Dbc1) 
[NM_019967] 
6.44 
ENSMUST-
00000023934 
A_55_P2108151 hemoglobin subunit beta-1-like (Beta-s) 
[NM_001201391] 
6.23 
Has2 A_51_P213359 hyaluronan synthase 2 (Has2) [NM_008216] 6.15 
Tmem90b A_66_P137501 transmembrane protein 90B (Tmem90b) 
[NM_001085521] 
6.09 
Mmp13 A_51_P184484 matrix metallopeptidase 13 (Mmp13) [NM_008607] 6.09 
Prl8a6 A_55_P2269459 prolactin family 8, subfamily a, member 6 (Prl8a6) 
[NM_011167] 
6.08 
Mcpt8 A_51_P413059 mast cell protease 8 (Mcpt8) [NM_008572] 6.07 
Chst5 A_55_P2054027 carbohydrate (N-acetylglucosamine 6-O) 
sulfotransferase 5 (Chst5) [NM_019950] 
6.02 
Sprr3 A_55_P2034195 small proline-rich protein 3 (Sprr3), transcript variant 
1 [NM_011478] 
5.97 
Tnk1 A_52_P167411 tyrosine kinase, non-receptor, 1 (Tnk1) [NM_031880] 5.93 
Plscr5 A_55_P2143551 phospholipid scramblase family, member 5 (Plscr5) 
[NM_001195693] 
5.92 
Casc5 A_55_P2027317 cancer susceptibility candidate 5 [MGI:1923714] 
[ENSMUST-00000028799] 
5.75 
Olfr32 A_55_P2094771 olfactory receptor 32 (Olfr32) [NM_010980] 5.71 
Trim50 A_55_P2131642 tripartite motif-containing 50 (Trim50) [NM_178240] 5.62 
Kcnj14 A_51_P250559 potassium inwardly-rectifying channel, subfamily J, 
member 14 (Kcnj14) [NM_145963] 
5.50 
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Efcab10 A_51_P467629 EF-hand calcium binding domain 10 (Efcab10) 
[NM_029152] 
5.48 
Fkbp6 A_55_P1952385 FK506 binding protein 6 (Fkbp6) [NM_033571] 5.37 
Tmem26 A_52_P126403 transmembrane protein 26 (Tmem26) [NM_177794] 5.32 
Gbx2 A_51_P179578 gastrulation brain homeobox 2 (Gbx2) [NM_010262] 5.32 
Ttc9 A_52_P21 tetratricopeptide repeat domain 9 (Ttc9) 
[NM_001033149] 
5.29 
Pi15 A_51_P240448 peptidase inhibitor 15 (Pi15) [NM_053191] 5.24 
Cyp2w1 A_52_P567228 cytochrome P450, family 2, subfamily w, polypeptide 
1 (Cyp2w1) [NM_001160265] 
5.24 
Pkp1 A_51_P151732 plakophilin 1 (Pkp1) [NM_019645] 5.20 
Triobp A_55_P1953353 TRIO and F-actin binding protein (Triobp), transcript 
variant 4 [NM_001039155] 
5.17 
Crlf1 A_52_P304720 cytokine receptor-like factor 1 (Crlf1) [NM_018827] 5.16 
Plcd4 A_52_P327588 phospholipase C, delta 4 (Plcd4), transcript variant 2 
[NM_148937] 
5.10 
St6galnac3 A_55_P2055647 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-
1,3)-N-acetylgalactosaminide alpha-2,6-
sialyltransferase 3 (St6galnac3) [NM_011372] 
5.07 
Fam83e A_51_P434758 family with sequence similarity 83, member E 
(Fam83e) [NM_001033170] 
5.03 
Spint1 A_51_P341108 serine protease inhibitor, Kunitz type 1 (Spint1) 
[NM_016907] 
5.01 
Kbtbd12 A_55_P2091116 kelch repeat and BTB (POZ) domain containing 12 
(Kbtbd12), transcript variant 1 [NM_001142724] 
4.96 
Caskin1 A_55_P2057469 CASK interacting protein 1 (Caskin1) [NM_027937] 4.95 
Tbx4 A_55_P2112445 T-box 4 (Tbx4), transcript variant 1 [NM_011536] 4.92 
Ntsr2 A_55_P1974527 neurotensin receptor 2 (Ntsr2) [NM_008747] 4.89 
ENSMUST-
00000071972 
A_55_P1977787 WD repeat domain 65 [MGI:2686209] [ENSMUST-
00000071972] 
4.86 
Nanog A_55_P2007708 Nanog homeobox [MGI:1919200] [ENSMUST-
00000012540] 
4.84 
Spp1 A_55_P2085142 secreted phosphoprotein 1 (Spp1), transcript variant 5 
[NM_001204233] 
4.79 
Fam198a A_51_P205326 family with sequence similarity 198, member A 
(Fam198a), transcript variant 1 [NM_177743] 
4.77 
Col15a1 A_55_P2060386 collagen, type XV, alpha 1 (Col15a1) [NM_009928] 4.76 
Usp26 A_55_P2067161 ubiquitin specific peptidase 26 (Usp26) [NM_031388] 4.70 
Fst A_55_P2394308 follistatin (Fst) [NM_008046] 4.69 
C5ar1 A_55_P2017681 complement component 5a receptor 1 (C5ar1), 
transcript variant 2 [NM_001173550] 
4.67 
Gabbr2 A_52_P612928 gamma-aminobutyric acid (GABA) B receptor, 2 
(Gabbr2) [NM_001081141] 
4.54 
Iqcj A_52_P256955 IQ motif containing J (Iqcj) [NM_177585] 4.44 
Lce1f A_52_P547456 late cornified envelope 1F (Lce1f) [NM_026394] 4.43 
Grem1 A_52_P481957 gremlin 1 (Grem1) [NM_011824] 4.43 
Nudt18 A_51_P210814 nudix (nucleoside diphosphate linked moiety X)-type 
motif 18 (Nudt18) [NM_153136] 
4.32 
Mmp1a A_55_P1984546 matrix metallopeptidase 1a (interstitial collagenase) 
(Mmp1a) [NM_032006] 
4.30 
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Tm7sf3 A_55_P2045109 transmembrane 7 superfamily member 3 (Tm7sf3) 
[NM_026281] 
4.30 
Gdf3 A_66_P107818 growth differentiation factor 3 (Gdf3) [NM_008108] 4.30 
Wdr63 A_55_P1975989 WD repeat domain 63 (Wdr63) [NM_172864] 4.27 
Nlrp2 A_55_P2042247 NLR family, pyrin domain containing 2 (Nlrp2) 
[NM_177690] 
4.25 
Epb4.1l5 A_66_P111035 erythrocyte protein band 4.1-like 5 (Epb4.1l5), 
transcript variant 2 [NM_001113416] 
4.16 
Flrt1 A_55_P2110915 fibronectin leucine rich transmembrane protein 1 
(Flrt1) [NM_201411] 
4.15 
Sprr1a A_51_P139678 small proline-rich protein 1A (Sprr1a) [NM_009264] 4.14 
Tmem59l A_51_P215038 transmembrane protein 59-like (Tmem59l) 
[NM_182991] 
4.13 
Foxn1 A_55_P1953172 forkhead box N1 (Foxn1) [NM_008238] 4.12 
Spag8 A_66_P115187 sperm associated antigen 8 (Spag8) [NM_001007463] 4.09 
ENSMUST-
00000049946 
A_52_P584753 protein kinase, cAMP dependent regulatory, type II 
alpha [MGI:108025] [ENSMUST-00000049946] 
4.05 
Il18 A_66_P105046 interleukin 18 (Il18) [NM_008360] 4.04 
Sh3kbp1 A_55_P1970002 SH3-domain kinase binding protein 1 (Sh3kbp1), 
transcript variant 1 [NM_001135727] 
4.04 
Vmn1r40 A_51_P271136 vomeronasal 1 receptor 40 (Vmn1r40) [NM_053228] 4.03 
Npnt A_51_P289889 nephronectin (Npnt), transcript variant 1 
[NM_033525] 
4.02 
Asb12 A_55_P2100360 ankyrin repeat and SOCS box-containing 12 (Asb12) 
[NM_080858] 
3.99 
Defb47 A_55_P2105239 defensin beta 47 (Defb47) [NM_001039125] 3.98 
Pik3ap1 A_52_P642239 phosphoinositide-3-kinase adaptor protein 1 (Pik3ap1) 
[NM_031376] 
3.98 
Pkd1l1 A_55_P1966024 polycystic kidney disease 1 like 1 [MGI:2156538] 
[ENSMUST-00000154153] 
3.96 
Glyctk A_55_P2096973 glycerate kinase (Glyctk), transcript variant 1 
[NM_174846] 
3.95 
Bcl2l15 A_55_P1975873 BCLl2-like 15 (Bcl2l15), transcript variant 1 
[NM_001142959] 
3.95 
Zp2 A_52_P331981 zona pellucida glycoprotein 2 (Zp2) [NM_011775] 3.94 
Ampd1 A_52_P880457 adenosine monophosphate deaminase 1 (Ampd1) 
[NM_001033303] 
3.94 
Cyp3a59 A_55_P2028046 cytochrome P450, subfamily 3A, polypeptide 59 
(Cyp3a59) [NM_001105160] 
3.94 
4930434E21Rik A_55_P2010366 WD40 repeat domain 95 (Wdr95) [NM_029440] 3.93 
Sprr2k A_55_P1955372 small proline-rich protein 2K (Sprr2k) [NM_011477] 3.93 
Fxc1 A_55_P2166698 fractured callus expressed transcript 1 [MGI:1315196] 
[ENSMUST-00000058333] 
3.92 
ENSMUST-
00000111183 
A_55_P2115181 pyruvate dehydrogenase complex, component X 
[MGI:1351627] [ENSMUST-00000111183] 
3.87 
Adam22 A_55_P2028465 a disintegrin and metallopeptidase domain 22 
(Adam22), transcript variant 1 [NM_001007220] 
3.86 
Ap3b2 A_51_P486681 adaptor-related protein complex 3, beta 2 subunit 
(Ap3b2) [NM_021492] 
3.86 
Tecta A_51_P499288 tectorin alpha (Tecta) [NM_009347] 3.81 
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Crlf1 A_55_P2052240 cytokine receptor-like factor 1 (Crlf1) [NM_018827] 3.76 
Ifnab A_55_P2030076 interferon alpha B (Ifnab) [NM_008336] 3.74 
F2rl3 A_51_P431636 coagulation factor II (thrombin) receptor-like 3 (F2rl3) 
[NM_007975] 
3.73 
Ppbp A_51_P428372 pro-platelet basic protein (Ppbp) [NM_023785] 3.73 
Ccl3 A_51_P140710 chemokine (C-C motif) ligand 3 (Ccl3) [NM_011337] 3.72 
ENSMUST-
00000098876 
A_55_P2103541 mitochondrial ribosomal protein L9 [AK146237] 3.71 
Synpo2 A_52_P223127 synaptopodin 2 (Synpo2) [NM_080451] 3.70 
Ptpn22 A_51_P483324 protein tyrosine phosphatase, non-receptor type 22 
(lymphoid) (Ptpn22) [NM_008979] 
3.70 
Cck A_55_P1977431 cholecystokinin (Cck) [NM_031161] 3.69 
Slc38a1 A_52_P232648 solute carrier family 38, member 1 (Slc38a1), 
transcript variant 1 [NM_134086] 
3.69 
Bcl2l14 A_51_P341336 BCL2-like 14 (apoptosis facilitator) (Bcl2l14) 
[NM_025778] 
3.67 
Cdh15 A_51_P481930 cadherin 15 (Cdh15) [NM_007662] 3.66 
Rgs16 A_51_P249286 regulator of G-protein signaling 16 (Rgs16) 
[NM_011267] 
3.64 
Nox3 A_52_P412457 NADPH oxidase 3 (Nox3) [NM_198958] 3.63 
Ch25h A_55_P2008987 cholesterol 25-hydroxylase (Ch25h) [NM_009890] 3.62 
Slpi A_52_P472324 secretory leukocyte peptidase inhibitor (Slpi) 
[NM_011414] 
3.61 
Igsf11 A_52_P433643 immunoglobulin superfamily, member 11 (Igsf11) 
[NM_170599] 
3.61 
Cdh11 A_52_P437795 cadherin 11 (Cdh11) [NM_009866] 3.60 
Pgk2 A_55_P2051444 phosphoglycerate kinase 2 (Pgk2) [NM_031190] 3.59 
Gli1 A_55_P2183587 GLI-Kruppel family member GLI1 (Gli1) 
[NM_010296] 
3.56 
Mtmr15 A_55_P2030229 FANCD2/FANCI-associated nuclease 1 (Fan1) 
[NM_177893] 
3.52 
Murc A_55_P1954331 muscle-related coiled-coil protein (Murc) 
[NM_026509] 
3.50 
Gsdma3 A_55_P2180536 gasdermin A3 (Gsdma3) [NM_001007461] 3.50 
Rnf157 A_52_P106285 ring finger protein 157 (Rnf157) [NM_027258] 3.49 
Ccl17 A_51_P114462 chemokine (C-C motif) ligand 17 (Ccl17) 
[NM_011332] 
3.49 
Gpr132 A_55_P2051229 G protein-coupled receptor 132 (Gpr132) 
[NM_019925] 
3.46 
Trpv6 A_55_P2111444 transient receptor potential cation channel, subfamily 
V, member 6 (Trpv6) [NM_022413] 
3.46 
Ahrr A_55_P2128388 aryl-hydrocarbon receptor repressor (Ahrr) 
[NM_009644] 
3.45 
Fkbp11 A_51_P130727 FK506 binding protein 11 (Fkbp11) [NM_024169] 3.45 
Hsd3b6 A_52_P253567 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and 
steroid delta-isomerase 6 (Hsd3b6) [NM_013821] 
3.45 
Ivl A_51_P475748 involucrin (Ivl) [NM_008412] 3.44 
Mapk13 A_51_P239203 mitogen-activated protein kinase 13 (Mapk13) 
[NM_011950] 
3.44 
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Pot1a A_55_P2115452 POT1-like telomere end-binding protein (S. pombe) 
[AK135346] 
3.43 
Nhsl2 A_55_P2173506 NHS-like 2 [MGI:3645090] [ENSMUST-
00000125115] 
3.43 
Vat1l A_52_P577533 vesicle amine transport protein 1 homolog-like (T. 
californica) (Vat1l) [NM_173016] 
3.37 
Ptgs2 A_51_P254855 prostaglandin-endoperoxide synthase 2 (Ptgs2) 
[NM_011198] 
3.36 
ENSMUST-
00000106078 
A_55_P2063033 polyhomeotic-like 2 (Drosophila) [MGI:1860454] 
[ENSMUST-00000133439] 
3.34 
Ivl A_55_P2053439 involucrin (Ivl) [NM_008412] 3.33 
Fam110c A_52_P476731 family with sequence similarity 110, member C 
(Fam110c) [NM_027828] 
3.30 
ENSMUST-
00000101095 
A_55_P2152069 cytidine 5'-triphosphate synthase 2 [AK161564] 3.30 
Elane A_66_P137219 elastase, neutrophil expressed (Elane) [NM_015779] 3.28 
Parvb A_51_P169415 parvin, beta (Parvb) [NM_133167] 3.28 
Galnt3 A_51_P380005 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 3 (Galnt3) 
[NM_015736] 
3.25 
Hhipl1 A_66_P106711 hedgehog interacting protein-like 1 (Hhipl1) 
[NM_001044380] 
3.22 
Serpinb1c A_52_P493477 serine (or cysteine) peptidase inhibitor, clade B, 
member 1c (Serpinb1c) [NM_173051] 
3.21 
Foxq1 A_55_P2046877 forkhead box Q1 (Foxq1) [NM_008239] 3.19 
Baiap2l1 A_51_P195374 BAI1-associated protein 2-like 1 (Baiap2l1) 
[NM_025833] 
3.19 
Prkg2 A_51_P273433 protein kinase, cGMP-dependent, type II (Prkg2) 
[NM_008926] 
3.17 
Tmem200a A_51_P515532 transmembrane protein 200A (Tmem200a) 
[NM_029881] 
3.16 
Gas1 A_55_P2070510 growth arrest specific 1 (Gas1) [NM_008086] 3.13 
Ccdc96 A_52_P390913 coiled-coil domain containing 96 (Ccdc96) 
[NM_025725] 
3.12 
Gal3st4 A_52_P1174 galactose-3-O-sulfotransferase 4 (Gal3st4) 
[NM_001033416] 
3.10 
Galntl1 A_52_P94830 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase-like 1 (Galntl1) 
[NM_001081421] 
3.09 
Ints10 A_55_P2152862 integrator complex subunit 10 [MGI:1918135] 
[ENSMUST-00000167982] 
3.08 
Ptpn4 A_55_P2419961 protein tyrosine phosphatase, non-receptor type 4 
(Ptpn4) [NM_019933] 
3.07 
Lilra6 A_55_P2043171 leukocyte immunoglobulin-like receptor, subfamily A 
(with TM domain), member 6 (Lilra6), transcript 
variant 1 [NM_011090] 
3.07 
Olfr700 A_55_P2021953 olfactory receptor 700 (Olfr700) [NM_146600] 3.07 
Txnrd2 A_55_P2019349 thioredoxin reductase 2 [MGI:1347023] [ENSMUST-
00000115604] 
3.06 
Sox11 A_52_P160955 SRY-box containing gene 11 (Sox11) [NM_009234] 3.01 
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A.6 Downregulated genes in HSCs upon transient MIF 
stimulation at day 5 
Listed are downregulated genes in transiently MIF-stimulated cells at day 5 (sample IID) 
compared to control (sample IIA). The list comprises genes that are downregulated with a 
mean fold change (FC) > 3 and a significant signal above background in the control 
sample. 
SeqName Seqcode Full name FC 
Zmat4 A_51_P422685 zinc finger, matrin type 4 (Zmat4) [NM_177086] -107.38 
Slc17a1 A_55_P1969506 solute carrier family 17 (sodium phosphate), member 
1 (Slc17a1), transcript variant 1 [NM_009198] 
-57.35 
Vmn2r75 A_55_P1966634 vomeronasal 2, receptor 75 (Vmn2r75) 
[NM_001102578] 
-50.81 
Pira6 A_52_P18236 paired-Ig-like receptor A6 (Pira6), transcript variant 2 
[NM_011093] 
-24.78 
Nlrc4 A_52_P655136 NLR family, CARD domain containing 4 (Nlrc4) 
[NM_001033367] 
-24.58 
Col19a1 A_55_P2019631 procollagen, type XIX, alpha 1 [AK149136] -23.70 
Orm1 A_51_P336325 orosomucoid 1 (Orm1) [NM_008768] -21.47 
Myt1l A_55_P2001793 myelin transcription factor 1-like (Myt1l), transcript 
variant 1 [NM_001093775] 
-19.16 
Ppp1r1a A_52_P144818 protein phosphatase 1, regulatory (inhibitor) subunit 
1A (Ppp1r1a) [NM_021391] 
-17.88 
Il12rb2 A_55_P1978416 interleukin 12 receptor, beta 2 (Il12rb2) [NM_008354] -16.45 
Adamts3 A_55_P2163541 a disintegrin-like and metallopeptidase (reprolysin 
type) with thrombospondin type 1 motif, 3 (Adamts3), 
transcript variant 1 [NM_177872] 
-15.30 
Agxt2 A_55_P2186282 alanine-glyoxylate aminotransferase 2 (Agxt2) 
[NM_001031851] 
-14.60 
Gh A_51_P104687 growth hormone (Gh) [NM_008117] -13.56 
Neurod1 A_55_P2004972 neurogenic differentiation 1 (Neurod1) [NM_010894] -13.56 
Olfr1387 A_55_P2162718 olfactory receptor 1387 (Olfr1387) [NM_146473] -13.21 
Caps2 A_55_P2089091 calcyphosphine 2 (Caps2) [NM_178278] -11.78 
Olfr1342 A_55_P2100000 olfactory receptor 1342 (Olfr1342) [NM_146713] -11.49 
Yipf7 A_52_P313102 Yip1 domain family, member 7 (Yipf7) [NM_023784] -11.07 
Olfr1132 A_55_P2072671 olfactory receptor 1132 (Olfr1132) [NM_146836] -11.01 
ENSMUST--
00000118205 
A_66_P120309 TRANSMEMBRANE PROTEIN VEZATIN homolog 
[Homo sapiens] [AK042540] 
-10.82 
Cdh29 A_52_P120122 cadherin-like 29 (Cdh29) [NM_177090] -10.46 
Gli1 A_55_P2080658 GLI-Kruppel family member GLI1 [MGI:95727] 
[ENSMUST-00000105252] 
-10.27 
Tmem190 A_51_P490337 transmembrane protein 190 (Tmem190) 
[NM_030028] 
-10.06 
Olfr716 A_51_P211978 olfactory receptor 716 (Olfr716) [NM_146604] -9.25 
Acvr1c A_55_P1975140 activin A receptor, type IC (Acvr1c), transcript variant 
1 [NM_001111030] 
-9.05 
Nlrp1b A_66_P106290 NLR family, pyrin domain containing 1B (Nlrp1b), 
transcript variant 1 [NM_001040696] 
-8.90 
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Slitrk3 A_52_P47781 SLIT and NTRK-like family, member 3 (Slitrk3) 
[NM_198864] 
-8.73 
Vmn1r61 A_55_P1972169 vomeronasal 1 receptor 61 (Vmn1r61) 
[NM_001166733] 
-8.43 
Ugt2b5 A_55_P1975080 UDP glucuronosyltransferase 2 family, polypeptide 
B5 (Ugt2b5) [NM_009467] 
-8.13 
Rhox10 A_66_P138201 reproductive homeobox 10 (Rhox10) 
[NM_001024850] 
-7.77 
Cyp2a4 A_55_P2007326 cytochrome P450, family 2, subfamily a, polypeptide 
4 (Cyp2a4) [NM_009997] 
-7.56 
Il5 A_55_P2138386 interleukin 5 (Il5) [NM_010558] -7.48 
Lcn5 A_55_P1963727 lipocalin 5 (Lcn5), transcript variant 1 [NM_007947] -7.39 
Nr1h5 A_55_P2128606 nuclear receptor subfamily 1, group H, member 5 
(Nr1h5), transcript variant 1 [NM_198658] 
-7.29 
Ptprq A_51_P377995 protein tyrosine phosphatase, receptor type, Q (Ptprq) 
[NM_001081432] 
-7.16 
9430014F16Rik A_55_P2229239 Selenoprotein homolog [Mus musculus] [AK135264] -7.08 
Mybpc2 A_55_P2013665 myosin binding protein C, fast-type (Mybpc2), 
transcript variant 2 [NM_146189] 
-7.05 
Eda A_55_P2030667 ectodysplasin-A (Eda), transcript variant 7 
[NM_001177942] 
-7.04 
Tmprss5 A_51_P516741 transmembrane protease, serine 5 (spinesin) (Tmprss5) 
[NM_030709] 
-6.92 
Skor1 A_55_P2000434 SKI family transcriptional corepressor 1 (Skor1), 
transcript variant 1 [NM_172446] 
-6.81 
Snhg11 A_55_P2047809 small nucleolar RNA host gene 11 (Snhg11) 
[NM_175692] 
-6.74 
Vwa5b1 A_55_P2081990 von Willebrand factor A domain containing 5B1 
(Vwa5b1) [NM_029401] 
-6.72 
Adad2 A_51_P140042 adenosine deaminase domain containing 2 (Adad2) 
[NM_029428] 
-6.41 
Grin2c A_55_P1970090 glutamate receptor, ionotropic, NMDA2C (epsilon 3) 
(Grin2c) [NM_010350] 
-6.29 
Slc25a21 A_55_P2033393 solute carrier family 25 (mitochondrial 
oxodicarboxylate carrier), member 21 (Slc25a21), 
transcript variant 1 [NM_172577] 
-6.13 
Gprc6a A_55_P2097645 G protein-coupled receptor, family C, group 6, 
member A (Gprc6a) [NM_153071] 
-6.07 
Rabgap1l A_55_P2002815 RAB GTPase activating protein 1-like [MGI:1352507] 
[ENSMUST-00000028048] 
-6.01 
Gzmb A_51_P333274 granzyme B (Gzmb) [NM_013542] -5.92 
Hoxc12 A_55_P2169099 homeobox C12 (Hoxc12) [NM_010463] -5.87 
Tmem100 A_52_P368306 transmembrane protein 100 (Tmem100) 
[NM_026433] 
-5.85 
Acvr1c A_55_P2064203 activin A receptor, type IC (Acvr1c), transcript variant 
1 [NM_001111030] 
-5.79 
Efcab5 A_55_P2138217 EF-hand calcium binding domain 5 (Efcab5) 
[NM_176965] 
-5.66 
Col9a3 A_66_P101732 collagen, type IX, alpha 3 (Col9a3) [NM_009936] -5.52 
A.6 Downregulated genes in HSCs upon transient MIF stimulation at day 5 139 
SeqName Seqcode Full name FC 
Skor1 A_55_P2106504 SKI family transcriptional corepressor 1 (Skor1), 
transcript variant 1 [NM_172446] 
-5.48 
Cyp2c67 A_55_P1977144 cytochrome P450, family 2, subfamily c, polypeptide 
67 (Cyp2c67) [NM_001024719] 
-5.47 
Ifltd1 A_55_P1954960 intermediate filament tail domain containing 1 (Ifltd1) 
[NM_028742] 
-5.46 
Krt71 A_51_P364639 keratin 71 (Krt71) [NM_019956] -5.36 
Stx8 A_55_P2176989 syntaxin 8 (Stx8) [NM_018768] -5.36 
Olfr462 A_55_P2086797 olfactory receptor 462 (Olfr462) [NM_146411] -5.23 
Atp10b A_55_P2011425 ATPase, class V, type 10B (Atp10b) [NM_176999] -5.19 
Kctd18 A_55_P1952634 potassium channel tetramerisation domain containing 
18 [MGI:3603813] [ENSMUST-00000068000] 
-5.17 
Cyp3a11 A_55_P2121225 cytochrome P450, family 3, subfamily a, polypeptide 
11 (Cyp3a11) [NM_007818] 
-5.14 
Adh1 A_52_P629895 alcohol dehydrogenase 1 (class I) (Adh1) 
[NM_007409] 
-5.09 
Myo1f A_55_P2124273 myosin IF (Myo1f) [NM_053214] -5.01 
Wnt9b A_52_P15377 wingless-type MMTV integration site 9B (Wnt9b) 
[NM_011719] 
-4.96 
Fbxw14 A_55_P2035379 F-box and WD-40 domain protein 14 (Fbxw14) 
[NM_015793] 
-4.94 
ENSMUST--
00000120654 
A_55_P2017911 colony stimulating factor 1 (macrophage) 
[MGI:1339753] [ENSMUST-00000120654] 
-4.89 
Tdrd9 A_55_P1989369 tudor domain containing 9 (Tdrd9) [NM_029056] -4.89 
Ap4e1 A_66_P134822 adaptor-related protein complex AP-4, epsilon 1 
[MGI:1336993] [ENSMUST-00000110394] 
-4.87 
Tbc1d8 A_51_P448005 TBC1 domain family, member 8 (Tbc1d8) 
[NM_018775] 
-4.87 
Scgb1c1 A_52_P156775 secretoglobin, family 1C, member 1 (Scgb1c1) 
[NM_001099742] 
-4.85 
Fbxw24 A_52_P152030 F-box and WD-40 domain protein 24 (Fbxw24) 
[NM_001013776] 
-4.84 
Nfam1 A_55_P1974577 Nfat activating molecule with ITAM motif 1 (Nfam1) 
[NM_028728] 
-4.79 
Hs3st3b1 A_55_P2167893 heparan sulfate (glucosamine) 3-O-sulfotransferase 
3B1 (Hs3st3b1) [NM_018805] 
-4.76 
Olfr432 A_55_P2127100 olfactory receptor 432 (Olfr432) [NM_146716] -4.74 
Ror1 A_52_P212025 receptor tyrosine kinase-like orphan receptor 1 
[MGI:1347520] [ENSMUST-00000039630] 
-4.73 
Vmn1r183 A_55_P1978847 vomeronasal 1 receptor 183 (Vmn1r183) 
[NM_203489] 
-4.72 
Vmn2r27 A_55_P2159969 vomeronasal 2, receptor27 (Vmn2r27) 
[NM_001104642] 
-4.71 
Fgd4 A_55_P2099267 FYVE, RhoGEF and PH domain containing 4 
[MGI:2183747] [ENSMUST-00000162542] 
-4.70 
Scn11a A_55_P2109392 sodium channel, voltage-gated, type XI, alpha 
(Scn11a) [NM_011887] 
-4.66 
Tmem71 A_55_P2129207 transmembrane protein 71 (Tmem71) [NM_172514] -4.65 
Aldob A_51_P337269 aldolase B, fructose-bisphosphate (Aldob) 
[NM_144903] 
-4.62 
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Pot1a A_66_P106584 protection of telomeres 1A [MGI:2141503] 
[ENSMUST-00000115329] 
-4.61 
Trim61 A_65_P10737 tripartite motif-containing 61 (Trim61), transcript 
variant 1 [NM_153110] 
-4.60 
Ms4a3 A_51_P364210 membrane-spanning 4-domains, subfamily A, member 
3 (Ms4a3) [NM_133246] 
-4.49 
Crygs A_55_P1975315 crystallin, gamma S (Crygs) [NM_009967] -4.44 
Aldh1a7 A_51_P383399 aldehyde dehydrogenase family 1, subfamily A7 
(Aldh1a7) [NM_011921] 
-4.41 
Vipr2 A_55_P2033676 vasoactive intestinal peptide receptor 2 (Vipr2) 
[NM_009511] 
-4.40 
Abcc6 A_55_P1969904 ATP-binding cassette, sub-family C (CFTR/MRP), 
member 6 (Abcc6) [NM_018795] 
-4.37 
Pik3r5 A_52_P1093529 phosphoinositide-3-kinase, regulatory subunit 5, p101 
(Pik3r5) [NM_177320] 
-4.36 
Abca4 A_55_P2146034 ATP-binding cassette, sub-family A (ABC1), member 
4 (Abca4) [NM_007378] 
-4.33 
Olfr791 A_51_P310741 olfactory receptor 791 (Olfr791) [NM_146930] -4.32 
Cacna1g A_51_P466910 calcium channel, voltage-dependent, T type, alpha 1G 
subunit (Cacna1g), transcript variant 1 [NM_009783] 
-4.30 
Traf6 A_55_P2151689 TNF receptor-associated factor 6 [MGI:108072] 
[ENSMUST-00000143341] 
-4.26 
Ptpn7 A_51_P167360 protein tyrosine phosphatase, non-receptor type 7 
(Ptpn7) [NM_177081] 
-4.26 
Vmn1r148 A_55_P2056450 vomeronasal 1 receptor 148 (Vmn1r148) 
[NM_030736] 
-4.24 
Ripk4 A_55_P2035400 receptor-interacting serine-threonine kinase 4 (Ripk4) 
[NM_023663] 
-4.23 
Ptcra A_55_P2122884 pre T-cell antigen receptor alpha (Ptcra) 
[NM_011195] 
-4.22 
Car1 A_55_P2099952 carbonic anhydrase 1 (Car1), transcript variant 1 
[NM_009799] 
-4.21 
Duox2 A_55_P1974760 dual oxidase 2 (Duox2) [NM_177610] -4.20 
Prb1 A_52_P71756 proline-rich protein BstNI subfamily 1 (Prb1) 
[NM_198669] 
-4.19 
Fam70a A_52_P518270 family with sequence similarity 70, member A 
(Fam70a) [NM_172930] 
-4.16 
Kcnip4 A_52_P319774 Kv channel interacting protein 4 (Kcnip4), transcript 
variant 4 [NM_030265] 
-4.16 
Fam180a A_51_P207706 family with sequence similarity 180, member A 
(Fam180a) [NM_173375] 
-4.14 
4930573O21Rik A_55_P2256586 gamma-aminobutyric acid (GABA-B) receptor, 1 
[AK016293] 
-4.11 
Lrba A_55_P2040200 LPS-responsive beige-like anchor (Lrba), transcript 
variant 1 [NM_030695] 
-4.11 
Bzrap1 A_55_P1982916 benzodiazepine receptor associated protein 1 (Bzrap1) 
[NM_172449] 
-4.10 
Mmp28 A_55_P2150612 matrix metallopeptidase 28 (epilysin) (Mmp28), 
transcript variant 1 [NM_080453] 
-4.04 
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Vipr2 A_51_P342773 vasoactive intestinal peptide receptor 2 (Vipr2) 
[NM_009511] 
-4.02 
Ptprd A_55_P2227321 protein tyrosine phosphatase, receptor type, D (Ptprd), 
transcript variant b [NM_011211] 
-4.01 
Angptl6 A_51_P259571 angiopoietin-like 6 (Angptl6) [NM_145154] -4.00 
Afm A_52_P425734 afamin (Afm) [NM_145146] -3.99 
Tpbpb A_51_P130808 trophoblast specific protein beta (Tpbpb) 
[NM_026429] 
-3.95 
Mmel1 A_55_P2001078 membrane metallo-endopeptidase-like 1 (Mmel1) 
[NM_013783] 
-3.95 
Tcfcp2l1 A_55_P2413458 transcription factor CP2-like 1 (Tcfcp2l1) 
[NM_023755] 
-3.95 
Six3 A_55_P2082408 sine oculis-related homeobox 3 homolog (Drosophila) 
[MGI:102764] [ENSMUST-00000043819] 
-3.92 
Efcab1 A_55_P1967470 EF hand calcium binding domain 1 (Efcab1) 
[NM_025769] 
-3.91 
Prl2a1 A_51_P145511 prolactin family 2, subfamily a, member 1 (Prl2a1) 
[NM_019991] 
-3.89 
Pnpla3 A_51_P389265 patatin-like phospholipase domain containing 3 
(Pnpla3) [NM_054088] 
-3.89 
Rbm20 A_55_P2102444 RNA binding motif protein 20 (Rbm20) 
[NM_001170847] 
-3.88 
Dnahc2 A_55_P2106180 dynein, axonemal, heavy chain 2 (Dnahc2) 
[NM_001081330] 
-3.88 
Zfp57 A_55_P2172201 zinc finger protein 57 (Zfp57), transcript variant 3 
[NM_001168502] 
-3.84 
Nmur2 A_55_P2179582 neuromedin U receptor 2 (Nmur2) [NM_153079] -3.84 
ENSMUST--
00000122330 
A_55_P1987822 ubiquitin-fold modifier 1 [MGI:1915140] 
[ENSMUST-00000122330] 
-3.84 
Col2a1 A_55_P2004179 collagen, type II, alpha 1 (Col2a1), transcript variant 2 
[NM_001113515] 
-3.83 
Slc17a2 A_66_P118430 solute carrier family 17 (sodium phosphate), member 
2 [MGI:2443098] [ENSMUST-00000006786] 
-3.80 
Ankrd58 A_55_P1994447 ankyrin repeat domain 58 (Ankrd58) [NM_173779] -3.80 
Hoxa1 A_55_P2066123 homeobox A1 (Hoxa1) [NM_010449] -3.80 
Smad1 A_55_P2029289 MAD homolog 1 (Drosophila) [AK084505] -3.80 
Olfr424 A_55_P2017377 olfactory receptor 424 (Olfr424) [NM_146721] -3.79 
LOC435333 A_55_P2011950 immunoglobulin heavy variable 1-85 [MGI:3645723] 
[ENSMUST-00000103552] 
-3.77 
Nhlrc4 A_66_P139052 NHL repeat containing 4 (Nhlrc4) [NM_001039038] -3.77 
Adamts17 A_66_P124114 a disintegrin-like and metallopeptidase (reprolysin 
type) with thrombospondin type 1 motif, 17 
(Adamts17) [NM_001033877] 
-3.77 
Pla2g4d A_55_P1987775 phospholipase A2, group IVD (Pla2g4d) 
[NM_001024137] 
-3.77 
Rnf43 A_55_P2079619 ring finger protein 43 (Rnf43) [NM_172448] -3.72 
Dnajc21 A_55_P2007165 DnaJ (Hsp40) homolog, subfamily C, member 21 
[MGI:1925371] [ENSMUST-00000147224] 
-3.71 
Olfr1232 A_51_P502492 olfactory receptor 1232 (Olfr1232) [NM_146323] -3.69 
Olfr1314 A_52_P629709 olfactory receptor 1314 (Olfr1314) [NM_146450] -3.68 
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Wnt8b A_55_P2140913 wingless related MMTV integration site 8b (Wnt8b) 
[NM_011720] 
-3.68 
Clmn A_51_P200667 calmin (Clmn), transcript variant 1 [NM_053155] -3.65 
Wdfy3 A_55_P2161530 WD repeat and FYVE domain containing 3 (Wdfy3) 
[NM_172882] 
-3.64 
Agrp A_55_P2049717 agouti related protein (Agrp) [NM_007427] -3.63 
Ly86 A_51_P465350 lymphocyte antigen 86 (Ly86) [NM_010745] -3.63 
Vipr2 A_51_P473205 vasoactive intestinal peptide receptor 2 (Vipr2) 
[NM_009511] 
-3.61 
Mrgprb3 A_52_P320394 MAS-related GPR, member B3 (Mrgprb3) 
[NM_207537] 
-3.59 
Dad1 A_55_P2047912 defender against cell death 1 (Dad1), transcript variant 
2 [NM_010015] 
-3.58 
Omd A_51_P342926 osteomodulin (Omd) [NM_012050] -3.57 
Hnf4a A_55_P1959633 hepatic nuclear factor 4, alpha (Hnf4a) [NM_008261] -3.55 
Trim63 A_52_P517224 tripartite motif-containing 63 (Trim63) 
[NM_001039048] 
-3.55 
Emr4 A_51_P286357 EGF-like module containing, mucin-like, hormone 
receptor-like sequence 4 (Emr4) [NM_139138] 
-3.55 
Loxhd1 A_51_P238009 lipoxygenase homology domains 1 [MGI:1914609] 
[ENSMUST-00000035501] 
-3.55 
Olfr1052 A_55_P1982643 olfactory receptor 1052 (Olfr1052) [NM_147010] -3.55 
Kif17 A_51_P442023 kinesin family member 17 (Kif17), transcript variant 1 
[NM_010623] 
-3.50 
Olfr455 A_55_P2061681 olfactory receptor 455 (Olfr455) [NM_001081301] -3.50 
Mest A_51_P124535 mesoderm specific transcript (Mest) [NM_008590] -3.49 
Cyp2d10 A_55_P2037912 cytochrome P450, family 2, subfamily d, polypeptide 
10 (Cyp2d10) [NM_010005] 
-3.49 
F2 A_55_P1960683 coagulation factor II (F2) [NM_010168] -3.47 
Acoxl A_55_P2160416 acyl-Coenzyme A oxidase-like (Acoxl) [NM_028765] -3.47 
Ttr A_65_P19832 transthyretin (Ttr) [NM_013697] -3.43 
Pou2f2 A_51_P166728 POU domain, class 2, transcription factor 2 (Pou2f2), 
transcript variant 2 [NM_011138] 
-3.41 
Mug1 A_55_P2105413 murinoglobulin 1 (Mug1) [NM_008645] -3.40 
Lrriq3 A_52_P173580 leucine-rich repeats and IQ motif containing 3 (Lrriq3) 
[NM_028938] 
-3.36 
Plk5 A_55_P1972297 polo-like kinase 5 (Drosophila) (Plk5) [NM_183152] -3.36 
Chst8 A_51_P277006 carbohydrate (N-acetylgalactosamine 4-0) 
sulfotransferase 8 (Chst8) [NM_175140] 
-3.35 
Mpp7 A_55_P1971892 membrane protein, palmitoylated 7 (MAGUK p55 
subfamily member 7) (Mpp7), transcript variant 1 
[NM_001081287] 
-3.35 
Ly6g6d A_55_P2052145 lymphocyte antigen 6 complex, locus G6D (Ly6g6d) 
[NM_033478] 
-3.35 
Grik2 A_55_P2039992 glutamate receptor, ionotropic, kainate 2 (beta 2) 
(Grik2), transcript variant 1 [NM_001111268] 
-3.34 
Btc A_52_P672689 betacellulin, epidermal growth factor family member 
(Btc) [NM_007568] 
-3.33 
S100a14 A_51_P419226 S100 calcium binding protein A14 (S100a14), 
transcript variant 2 [NM_025393] 
-3.33 
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Igfbp5 A_52_P281702 insulin-like growth factor binding protein 5 (Igfbp5) 
[NM_010518] 
-3.33 
Crmp1 A_55_P2017600 collapsin response mediator protein 1 (Crmp1), 
transcript variant 2 [NM_007765] 
-3.32 
Gucy2e A_55_P2176275 guanylate cyclase 2e (Gucy2e) [NM_008192] -3.30 
Dact2 A_51_P308347 dapper homolog 2, antagonist of beta-catenin 
(xenopus) (Dact2) [NM_172826] 
-3.29 
Slc38a5 A_55_P2010641 solute carrier family 38, member 5 (Slc38a5) 
[NM_172479] 
-3.29 
Kcnn2 A_51_P309854 potassium intermediate/small conductance calcium-
activated channel, subfamily N, member 2 (Kcnn2) 
[NM_080465] 
-3.28 
Mest A_55_P2151868 mesoderm specific transcript (Mest) [NM_008590] -3.27 
ENSMUST--
00000105497 
A_55_P2169909 osteopetrosis associated transmembrane protein 1 
[MGI:2655574] [ENSMUST-00000147899] 
-3.26 
Myo1g A_55_P1955015 myosin IG (Myo1g) [NM_178440] -3.25 
Mest A_55_P2090025 mesoderm specific transcript (Mest) [NM_008590] -3.25 
Elavl4 A_55_P1990309 ELAV (embryonic lethal, abnormal vision, 
Drosophila)-like 4 (Hu antigen D) (Elavl4), transcript 
variant 1 [NM_010488] 
-3.24 
Tbx18 A_51_P438711 T-box18 (Tbx18) [NM_023814] -3.23 
Fam189a2 A_52_P369123 family with sequence similarity 189, member A2 
(Fam189a2) [NM_001114174] 
-3.21 
ENSMUST--
00000101612 
A_55_P1978696 ATP-binding cassette, sub-family B (MDR/TAP), 
member 4 [MGI:97569] [ENSMUST-00000101612] 
-3.18 
Ugt2b36 A_51_P102438 UDP glucuronosyltransferase 2 family, polypeptide 
B36 (Ugt2b36) [NM_001029867] 
-3.18 
Ccl6 A_51_P460954 chemokine (C-C motif) ligand 6 (Ccl6) [NM_009139] -3.16 
Lrrc2 A_55_P2428967 leucine rich repeat containing 2 (Lrrc2) [NM_028838] -3.16 
Pnma1 A_55_P2139984 paraneoplastic antigen MA1 (Pnma1) [NM_027438] -3.16 
Retn A_55_P2428514 resistin (Retn), transcript variant 2 [NM_001204959] -3.13 
Gramd2 A_55_P1970901 GRAM domain containing 2 (Gramd2) 
[NM_001033498] 
-3.13 
Ankrd5 A_55_P2073572 ankyrin repeat domain 5 (Ankrd5) [NM_175667] -3.12 
Bcl11a A_55_P1958275 B-cell CLL/lymphoma 11A (zinc finger protein) 
(Bcl11a), transcript variant 1 [NM_016707] 
-3.11 
Ugt2b38 A_66_P131389 UDP glucuronosyltransferase 2 family, polypeptide 
B38 (Ugt2b38) [NM_133894] 
-3.09 
Muc5b A_55_P2007457 mucin 5, subtype B, tracheobronchial (Muc5b) 
[NM_028801] 
-3.03 
Sncaip A_52_P59264 synuclein, alpha interacting protein (synphilin) 
(Sncaip), transcript variant 2 [NM_026408] 
-3.00 
Evx2 A_55_P2145582 even skipped homeotic gene 2 homolog (Evx2) 
[NM_007967] 
-3.00 
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